学术周报 · IF≥10 或专科旗舰刊
眼科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| American journal of ophthalmology | 39 | IF 4.7 |
| Ophthalmology | 13 | IF 10.9 |
| Investigative ophthalmology & visual science | 9 | IF 5.5 |
| Bioactive materials | 4 | IF 23.6 |
| JAMA ophthalmology | 3 | IF 10.5 |
| Biomaterials | 3 | IF 13.6 |
| Science advances | 2 | IF 13.9 |
| Nature biomedical engineering | 1 | IF 26.3 |
| Chemical Society reviews | 1 | IF 48.3 |
| Journal of extracellular vesicles | 1 | IF 21.7 |
1视网膜疾病 (25篇)
临床研究 (22篇)
The pathophysiology of central serous chorioretinopathy (CSC) remains incompletely understood, and there is ongoing debate regarding the origin of primary dysfunction. To elucidate the genetic architecture of CSC and map susceptibility loci to specific ocular cell types and molecular pathways. This genetic association study was a genome-wide association study (GWAS) meta-analysis aggregating data from 5 large biobank cohorts and included 2584 patients with CSC and 1 044 455 control participants of European ancestry. Cohort data were from July 1, 2010, to October 31, 2023; data analysis was performed from Febuary 2024 to January 2026. Post-GWAS functional mapping was performed using mendelian randomization, bayesian colocalization, and single-cell disease relevance scoring across human ocular tissue atlases. The relevance of the genetic findings was demonstrated by building a CSC genetic risk score and applying it to the UK Biobank (UKB). Identification of risk loci reaching the genome-wide threshold, prioritized putative causal genes, enrichment of genetic risk within specific ocular tissues and cell types, and performance of a GRS in the independent UKB dataset. The meta-analysis identified 10 risk loci reaching the genome-wide threshold (P < 5 × 10-8), including 3 novel loci (TGFB1, LINC00551, and LOC105375630) and 7 replicated loci (CFH, GATA5, PREX1, CD46, NOTCH4, PTPRB, and TNFRSF10A). Integrative post-GWAS analysis prioritized 10 genes, including TGFB1, TNFRSF10A, and CFH, as likely causal effectors. Single-cell enrichment mapping revealed that CSC genetic risk is concentrated in scleral tissue (P < .001) and vascular endothelial cells (P < .001). Mendelian randomization pointed to circulating TGFB1 and TNFRSF10A levels as associated with CSC risk. A CSC genetic risk score applied in UKB revealed a higher frequency of CSC-relevant abnormalities on macular optical coherence tomography in participants in the top 1% of polygenic risk (18/109 [16.5%] vs 8/134 [6.0%]; difference, 10.5 percentage points; 95% CI, 2.6-19.1; adjusted odds ratio, 4.05; 95% CI, 1.65-10.87; P = .002). Convergent genetic evidence supports CSC as a primary disorder of the sclera and choroidal vasculature with retinal pigment epithelium changes likely representing a downstream consequence. Integrative post-GWAS analysis pointed to complement regulation (CFH, CD46), vascular integrity and endothelial cell signaling (PTPRB, TNFRSF10A, NOTCH4, PREX1), and scleral extracellular matrix biology (TGFB1) as important in CSC.
中文摘要:中心性浆液性脉络膜视网膜病变(CSC)的病理生理机制尚未完全阐明,关于原发功能障碍的来源仍有争论。为阐明CSC的遗传结构,并把易感位点定位到特定眼部细胞类型与分子通路,本遗传关联研究汇集5个大型生物样本库队列的数据,纳入2584例欧洲血统CSC患者和1 044 455名对照参与者,开展全基因组关联研究(GWAS)荟萃分析。队列数据覆盖2010年7月1日至2023年10月31日;数据分析于2024年2月至2026年1月完成。GWAS后的功能定位采用孟德尔随机化、贝叶斯共定位以及跨人类眼组织图谱的单细胞疾病相关性评分。通过构建CSC遗传风险评分并应用于英国生物样本库(UKB),验证了遗传发现的相关性。研究结局包括识别达到全基因组显著性阈值的风险位点、筛选可能的因果基因、遗传风险在特定眼组织与细胞类型中的富集,以及在独立UKB数据集中遗传风险评分的表现。荟萃分析识别出10个达到全基因组阈值(P < 5 × 10-8)的风险位点,含3个新位点(TGFB1、LINC00551、LOC105375630)和7个重复验证位点(CFH、GATA5、PREX1、CD46、NOTCH4、PTPRB、TNFRSF10A)。整合性GWAS后分析优先列出10个基因,包括TGFB1、TNFRSF10A和CFH,作为可能的因果效应基因。单细胞富集定位显示,CSC遗传风险集中于巩膜组织(P < .001)和血管内皮细胞(P < .001)。孟德尔随机化提示循环TGFB1与TNFRSF10A水平与CSC风险相关。将CSC遗传风险评分用于UKB显示,多基因风险最高1%的参与者在黄斑光学相干断层扫描中出现CSC相关异常的比例更高(18/109 [16.5%] 对 8/134 [6.0%];差值10.5个百分点;95% CI 2.6-19.1;校正比值比4.05;95% CI 1.65-10.87;P = .002)。一致的遗传学证据支持CSC是巩膜与脉络膜血管的原发性疾病,视网膜色素上皮改变可能为下游结果。整合性GWAS后分析提示补体调节(CFH、CD46)、血管完整性与内皮细胞信号(PTPRB、TNFRSF10A、NOTCH4、PREX1)以及巩膜细胞外基质生物学(TGFB1)在CSC中具有重要作用。
The purpose of this study was to evaluate the association of metabolomic signatures reflecting adherence and metabolic response to dietary patterns with prevalence and structural severity of age-related macular degeneration (AMD). In this cross-sectional study of 1008 eyes from 504 participants, metabolomic profiles in plasma and urine were measured by liquid chromatography-tandem mass spectrometry. Previously derived signatures for eight dietary patterns-including the Alternate Mediterranean diet (AMED), Dietary Approaches to Stop Hypertension (DASH), plant-based diet indices (PDIs), and two mechanism-based diets including Empirical Dietary Inflammatory Pattern (EDIP) and Empirical Dietary Index for Hyperinsulinemia (EDIH)-were evaluated for association with AMD using linear mixed models and Mendelian randomization (MR). Each signature (38-66 metabolites) correlated with its dietary pattern score (Pearson r = 0.16-0.30). Per SD increase in plasma signatures of four healthy dietary patterns (AMED, DASH, PDI, and healthy PDI [hPDI]) were associated with 12% to 16% lower odds of AMD and reduced severity, whereas the unhealthy PDI (uPDI) signature was associated with 13% higher odds and greater severity (false discovery rate [FDR] < 0.05). DASH showed the strongest inverse association with AMD and with atrophy, hyper-reflective foci, and ellipsoid-zone disruption (β = -0.808 to -0.613). Further MR analyses found that genetically instrumented signatures of DASH and Alternate Health Eating Index (AHEI)-2010 were inversely associated with AMD, whereas the EDIP signature was positively associated. Metabolomic signatures of healthy dietary patterns are associated with lower odds and reduced structural severity of AMD. Further longitudinal studies are warranted to validate these findings.
中文摘要:该研究旨在评估反映膳食模式依从性及代谢反应的代谢组学特征与年龄相关性黄斑变性(AMD)患病率及结构严重程度之间的关联。这项横断面研究纳入504名参与者的1008只眼,采用液相色谱-串联质谱测定血浆和尿液代谢组谱。研究评估了既往构建的八种膳食模式特征与AMD的关联,包括替代地中海饮食(AMED)、终止高血压膳食疗法(DASH)、植物性饮食指数(PDIs),以及两种基于机制的饮食模式——经验性膳食炎症模式(EDIP)和经验性高胰岛素血症膳食指数(EDIH),分析采用线性混合模型和孟德尔随机化(MR)。每种特征(38-66种代谢物)与其膳食模式评分相关(Pearson r=0.16-0.30)。四种健康膳食模式(AMED、DASH、PDI和健康PDI[hPDI])的血浆特征每增加1个标准差,AMD风险降低12%至16%,严重程度降低;不健康PDI(uPDI)特征则与AMD风险升高13%及更严重程度相关(错误发现率[FDR]<0.05)。DASH与AMD以及萎缩、高反射灶和椭圆体带破坏的负相关最强(β=-0.808至-0.613)。进一步的MR分析发现,经遗传工具化的DASH和2010年替代健康饮食指数(AHEI-2010)特征与AMD呈负相关,而EDIP特征呈正相关。健康膳食模式的代谢组学特征与较低的AMD风险及较低的结构严重程度相关。仍需进一步纵向研究验证这些发现。
To evaluate the efficacy of home-based visual perceptual learning (VPL) on visual function and explore the residual visual plasticity in diabetic retinopathy (DR). Thirty-six DR patients following routine therapies were randomized (1:1). Twenty-eight completed the study (VPL, n = 12; control, n = 16) after excluding eight for poor adherence or incomplete follow-up. The VPL group underwent 3-month home-based grating detection training at individual cutoff spatial frequencies. Best-corrected visual acuity (BCVA), grating acuity (GA), contrast sensitivity to first-order motion stimuli (1stM), optical coherence tomography angiography (OCTA), and Low Vision Quality-of-Life (LVQOL) questionnaire were assessed at baseline, 1 month, and 3 months for the VPL group and at baseline and 3 months for the control group. BCVA improved from 0.36 to 0.26 logMAR (P = 0.003), GA improved from 12.42 to 17.47 cycles per degree (2.96 dB) and 1stM increased from 64.26 to 83.42 (2.27 dB) in the VPL group. A significant group × time interaction was found for GA (F1, 26 = 63.595, P < 0.001, \( \eta_{p}^2 \) = 0.710), 1stM (F1, 26 = 32.663, P < 0.001, \( \eta_{p}^2 \) = 0.557), and BCVA (F1, 26 = 10.872, P = 0.003, \( \eta_{p}^2 \) = 0.295). The LVQOL score increased (+4.33; P < 0.001) and correlated with ΔGA (r = 0.671, P = 0.017). OCTA parameters remained stable in both groups. The results reveal significant plasticity in the visual system in DR and suggest that contrast detection training may extend to motion perception tasks. Our study provides additional support for VPL as a potential treatment for DR.
中文摘要:评估家庭视觉知觉学习(VPL)对糖尿病视网膜病变(DR)患者视觉功能的效果,并探讨其残余视觉可塑性。36例接受常规治疗的DR患者按1:1随机分组。排除8例依从性差或随访不完整者后,28例完成研究(VPL组12例,对照组16例)。VPL组接受3个月家庭光栅检测训练,训练空间频率取个体截止空间频率。VPL组在基线、1个月和3个月评估最佳矫正视力(BCVA)、光栅视力(GA)、一阶运动刺激对比敏感度(1stM)、光学相干断层扫描血管成像(OCTA)和低视力生活质量问卷(LVQOL);对照组在基线和3个月评估。VPL组BCVA由0.36 logMAR改善至0.26 logMAR(P=0.003),GA由12.42周期/度提高至17.47周期/度(2.96 dB),1stM由64.26提高至83.42(2.27 dB)。GA(F1,26=63.595,P<0.001,ηp²=0.710)、1stM(F1,26=32.663,P<0.001,ηp²=0.557)和BCVA(F1,26=10.872,P=0.003,ηp²=0.295)均存在显著的组×时间交互作用。LVQOL评分升高(+4.33;P<0.001),并与ΔGA相关(r=0.671,P=0.017)。两组OCTA参数保持稳定。结果提示DR患者视觉系统存在显著可塑性,对比度检测训练可能迁移至运动知觉任务。该研究为VPL作为DR潜在治疗提供了额外支持。
To quantify flicker-induced changes in capillary flow and red blood cell (RBC) distribution in the human retina. Capillary blood flow in the parafoveal region of five healthy subjects was imaged using high-speed flood-illumination adaptive optics at 300 fps. Measurements were obtained before and after 30 seconds of 10-Hz flicker stimulation (≥5 repeats). Changes in capillary diameter, RBC velocity, hematocrit, and transit time were quantified. Flicker stimulation increased mean RBC velocity by 11% (P < 0.001) but reduced pulsatility by 7.1% (P < 0.001). Mean capillary diameter increased by 3.5% (P < 0.01). Average transit time for individual capillary segments was reduced by 10.0% (P < 0.001), as was the standard deviation (SD) across segments (12.5%; P < 0.001), such that the coefficient of variation (CV) was preserved (P > 0.05). Average RBC flow increased (21.6%; P < 0.001), as did SD across segments (17.1%; P < 0.05), with no significant change in CV (P > 0.05). Despite variability in capillary diameter and RBC flow responses, no clear baseline-dependent relationship was observed for either parameter, and fractional RBC flow distribution at branches was preserved (P > 0.05). A subset of segments lacked RBC perfusion at both baseline and following stimulation. Within the sampled post-stimulation window, the flicker-evoked retinal capillary flow response was characterized primarily by broadly distributed, approximately proportional scaling across segments, with no evidence of homogenization. Some segments consistently lacked measurable flow, and their physiological role remains unclear.
中文摘要:量化人视网膜中闪烁光刺激引起的毛细血管血流与红细胞分布变化。采用300帧/秒的高速泛光照明自适应光学系统,对5名健康受试者旁中心凹区域毛细血管血流成像。在30秒10 Hz闪烁光刺激前后进行测量,重复至少5次。量化毛细血管直径、红细胞速度、血细胞比容和通过时间的变化。闪烁刺激使平均红细胞速度增加11%(P < 0.001),搏动性降低7.1%(P < 0.001)。平均毛细血管直径增加3.5%(P < 0.01)。单个毛细血管段的平均通过时间缩短10.0%(P < 0.001),各段间标准差也降低12.5%(P < 0.001),变异系数保持不变(P > 0.05)。平均红细胞流量增加21.6%(P < 0.001),各段间标准差增加17.1%(P < 0.05),变异系数无显著变化(P > 0.05)。毛细血管直径和红细胞流量反应存在变异,但两者均未观察到明确的基线依赖关系,分支处红细胞流量分数分布保持不变(P > 0.05)。一部分毛细血管段在基线和刺激后均缺乏红细胞灌注。在所采样的刺激后窗口内,闪烁光诱发的视网膜毛细血管血流反应主要表现为各段间广泛分布、近似成比例的整体放大,未见均一化证据。部分毛细血管段持续缺乏可测血流,其生理作用仍不清楚。
Increasing age is the strongest risk factor in developing AMD. Growing evidence suggests that systemic immunosenescence is implicated in its pathogenesis. This study aims to characterize age-related T-cell differentiation in late-stage AMD by comparing patients with geographic atrophy (GA) and neovascular AMD (nAMD) to a shared healthy control group. Patients with GA or nAMD were recruited from an outpatient AMD-clinic. Individuals with immunological disease, cancer or use of immune-modulating medication were excluded. Blood samples from all participants were stained with monoclonal antibodies and analyzed with flow cytometry to assess T-cell subsets (naive, central memory [CM], effector memory [EM], and effector memory with CD45ra+ [EMRA]) and expression of the age-associated costimulatory markers (CD27, CD28, and CD56). One hundred twenty-eight patients were included in this study. Patients with GA demonstrated significantly higher levels of CD8+CD28-EM T cells (P = 0.038) and significantly lower levels of CD4+CD56+CM T cells (P = 0.021) compared with healthy controls. Patients with nAMD showed significantly higher levels of naive CD4+CD56+ and CD4+CD56+CM T cells (P = 0.008 and P = 0.008) compared to patients with GA. Patients with GA demonstrated an increased proportion of CD8+CD28- EM T cells, a finding similar to other infectious, autoimmune, and neurodegenerative disorders. The increased expression of CD56+ T cells in patients with nAMD supports CD56 having a potential role in angiogenic regulation. Contrarily, we suggest the reduced CD56 expression in patients with GA might contribute to GA pathogenesis.
中文摘要:年龄增长是发生AMD最强的危险因素。越来越多证据提示全身性免疫衰老参与其发病机制。本研究旨在通过比较地图样萎缩(GA)和新生血管性AMD(nAMD)患者与同一健康对照组,描述晚期AMD中与年龄相关的T细胞分化特征。GA或nAMD患者从AMD门诊招募。排除患有免疫性疾病、癌症或使用免疫调节药物者。所有参与者血样经单克隆抗体染色并用流式细胞术分析,以评估T细胞亚群(初始、中央记忆[CM]、效应记忆[EM]及CD45RA+效应记忆[EMRA])和年龄相关共刺激标志物(CD27、CD28、CD56)表达。共纳入128例患者。与健康对照相比,GA患者CD8+CD28-EM T细胞水平显著升高(P=0.038),CD4+CD56+CM T细胞水平显著降低(P=0.021)。与GA患者相比,nAMD患者初始CD4+CD56+和CD4+CD56+CM T细胞水平显著升高(P=0.008和P=0.008)。GA患者CD8+CD28-EM T细胞比例增加,这一表现与其他感染性、自身免疫性和神经退行性疾病相似。nAMD患者CD56+ T细胞表达增加支持CD56可能在血管生成调节中发挥作用。相反,我们认为GA患者CD56表达降低可能参与GA发病机制。
Persistent fluid despite intravitreal anti-vascular endothelial growth factor (VEGF) treatment remains common in neovascular age-related macular degeneration (nAMD). Regulatory T cell-derived exosomes (TregExo) have preclinical immunomodulatory activity. To evaluate the safety and maximum tolerated dose (MTD) of intravitreal autologous TregExo plus ranibizumab in refractory nAMD. Design, Setting, and Participants: Single-centre, prospective, open-label phase 1a trial using a 3+3 dose-escalation design at Hebei General Hospital. Four participants with persistent intraretinal or subretinal fluid despite at least 3 consecutive monthly intravitreal anti-VEGF injections were treated. One intravitreal injection of autologous TregExo (planned doses, 0.05, 0.5, or 1.5 mg) coformulated with ranibizumab, 0.5 mg. The primary outcome was safety and MTD determination. Dose-limiting toxicity (DLT) was prespecified as severe sterile intraocular inflammation, sustained intraocular pressure greater than 30 mm Hg, loss of more than 15 ETDRS points, or another serious ocular adverse event within 30 days. Exploratory visual and anatomic outcomes were assessed through day 90. Four participants were treated: 3 at 0.05 mg and 1 at 0.5 mg. No DLT or intraocular inflammation occurred in the 0.05-mg cohort, and intraocular pressure remained stable. Two low-dose participants improved from ETDRS scores of 3 and 9 at baseline to 35 at day 90; Patient 1 had a macular thickness reduction from 318.2 to 253.9 µm. The 0.5-mg participant developed sterile intraocular inflammation with vision loss and a large intraretinal cyst, which resolved after local corticosteroid therapy. Dose escalation was stopped, and 0.05 mg was the protocol-defined MTD. Intravitreal autologous TregExo plus ranibizumab had an identifiable dose ceiling: 0.05 mg was tolerated, whereas 0.5 mg was associated with DLT. Further controlled evaluation of lower-dose TregExo-based adjunctive therapy in refractory nAMD is warranted. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2500095798.
中文摘要:新生血管性年龄相关性黄斑变性(nAMD)患者接受玻璃体腔抗血管内皮生长因子(VEGF)治疗后持续积液仍较常见。调节性T细胞来源外泌体(TregExo)在临床前研究中具有免疫调节活性。评估玻璃体腔注射自体TregExo联合雷珠单抗治疗难治性nAMD的安全性和最大耐受剂量(MTD)。设计、场所和参与者:在河北省人民医院开展单中心、前瞻性、开放标签1a期试验,采用3+3剂量递增设计。4例连续每月接受至少3次玻璃体腔抗VEGF注射后仍存在持续视网膜内或视网膜下积液的患者接受治疗。给予1次玻璃体腔注射自体TregExo(计划剂量0.05、0.5或1.5 mg)与雷珠单抗0.5 mg共同配制。主要结局为安全性和MTD确定。剂量限制性毒性(DLT)预设为30天内出现严重无菌性眼内炎症、持续眼内压高于30毫米汞柱、ETDRS评分下降超过15个字母或其他严重眼部不良事件。探索性视觉和解剖结局评估至第90天。共治疗4例参与者:3例接受0.05 mg,1例接受0.5 mg。0.05 mg队列未发生DLT或眼内炎症,眼内压保持稳定。2例低剂量参与者的ETDRS评分从基线的3分和9分提高至第90天的35分;患者1的黄斑厚度从318.2微米降至253.9微米。0.5 mg参与者出现无菌性眼内炎症,伴视力下降和较大的视网膜内囊肿,经局部糖皮质激素治疗后消退。剂量递增停止,0.05 mg为方案定义的MTD。玻璃体腔注射自体TregExo联合雷珠单抗存在可识别的剂量上限:0.05 mg可耐受,0.5 mg与DLT相关。有必要在难治性nAMD中进一步对照评估低剂量TregExo辅助治疗。试验注册:中国临床试验注册中心注册号ChiCTR2500095798。
Public guidance often treats screen time as a uniform exposure, yet associations with health may vary by outcome and use definition. We conducted a prospectively registered umbrella review of 59 meta-analyses published from July 1, 2015 to May 15, 2026; post-registration amendments were reported transparently. Methodological quality was assessed with AMSTAR-2, and representative effects were summarized using native-metric contrasts. General screen exposure showed small-to-moderate associations with myopia and overweight/obesity, whereas problematic or high-intensity indicators did not consistently amplify these outcomes. Sleep showed an intermediate contrast (descriptive OR ratio = 1.95; approximate interval [1.45, 2.64]). Mental health showed the largest selected within-metric contrast: time spent using social networking sites was weakly associated with depression symptoms (r = 0.11), whereas problematic use showed a larger association (r = 0.29); no correlation ratio was calculated. Neck pain was numerically higher under smartphone-overuse definitions (descriptive OR ratio = 1.72; approximate interval [0.97, 3.06]), but the interval included 1 under the independence assumption. Primary-study overlap was generally low, heterogeneity was high, and 56 of 59 reviews were rated critically low by AMSTAR-2. Publication-bias-restricted paired contrasts were available only for myopia, mental health, and sleep, precluding claims of complete cross-domain robustness. These findings motivate the Outcome-Differentiated Amplification Framework (ODAF), a hypothesis-generating account in which cumulative exposure, behavioral-postural disruption, and dysregulated engagement may matter differently across outcomes; ODAF is not a confirmed causal mechanism.
中文摘要:公共指南常将屏幕时间视为统一暴露,但其与健康的关联可能随结局和使用定义而变化。我们开展了一项前瞻性注册的伞状综述,纳入2015年7月1日至2026年5月15日发表的59篇荟萃分析;注册后修订已透明报告。方法学质量采用AMSTAR-2评估,代表性效应以原始度量对比进行总结。一般屏幕暴露与近视及超重/肥胖呈小到中等关联,而问题性使用或高强度指标并未一致放大这些结局。睡眠呈现中间对比(描述性OR比值=1.95;近似区间[1.45, 2.64])。心理健康在选定的同一度量内对比最大:使用社交网站的时间与抑郁症状呈弱关联(r=0.11),问题性使用的关联更大(r=0.29);未计算相关性比值。智能手机过度使用定义下颈痛在数值上更高(描述性OR比值=1.72;近似区间[0.97, 3.06]),但在独立性假设下该区间包含1。原始研究重叠总体较低,异质性较高,59篇综述中有56篇被AMSTAR-2评为极低。限制发表偏倚的配对对比仅可用于近视、心理健康和睡眠,因此无法声称跨领域完全稳健。这些发现促成结局分化放大框架(ODAF),这是一种生成假设的解释:累积暴露、行为-姿势扰乱和失调性参与在不同结局中可能具有不同重要性;ODAF并非已确认的因果机制。
To evaluate the cost-effectiveness of photobiomodulation (PBM) for intermediate dry age-related macular degeneration (AMD) from the US healthcare payer perspective, using 24-month LIGHTSITE III trial data. Model-based cost-effectiveness analysis using a 5-state Markov model with 6-month cycles over a 10-year horizon, discounting costs and outcomes at 3% annually. Modeled cohort of adults with bilateral intermediate dry AMD and best-corrected visual acuity (BCVA) 20/32-20/100, consistent with LIGHTSITE III eligibility. Transition probabilities were derived from LIGHTSITE III 24-month outcomes and AREDS natural history data. Costs were derived from 2025 Medicare Physician Fee Schedule and published claims-based sources. One-way and probabilistic sensitivity analyses, a societal perspective, a 2-year limited treatment scenario, and a 5-year national budget impact analysis were conducted. Quality-adjusted life-years (QALYs) derived from published visual acuity-to-utility mapping and VFQ-25-to-EQ-5D conversion of LIGHTSITE III quality-of-life data; incremental cost-effectiveness ratio (ICER) as cost per QALY; 5-year national budget impact. PBM yielded 5.244 discounted QALYs at an incremental cost of $29,556 over 10 years, producing a base-case ICER of $73,910 per QALY, below both the $100,000 and $150,000 US willingness-to-pay thresholds. The ICER ranged from $36,700 ($1,000/course) to $117,694 per QALY (30% geographic atrophy [GA] reduction) across clinically realistic scenarios. Only the $5,000/course scenario exceeded both thresholds. The 5-year cumulative national budget impact was $25.0 billion at 20% uptake. PBM is cost-effective at conventional US willingness-to-pay thresholds, driven primarily by a 71.7% relative reduction in incident GA at 24 months. These findings support coverage consideration of PBM for intermediate dry AMD, pending independent replication of the GA reduction and prospective EQ-5D data collection.
中文摘要:从美国医疗支付方视角评估光生物调节(PBM)治疗中间型干性年龄相关性黄斑变性(AMD)的成本效果,采用LIGHTSITE III试验24个月数据。研究为基于模型的经济学评价,构建5状态Markov模型,周期6个月,时限10年,成本和结局按每年3%贴现。模型队列为双眼中间型干性AMD且最佳矫正视力(BCVA)20/32-20/100的成人,与LIGHTSITE III入组标准一致。转移概率来自LIGHTSITE III 24个月结局和AREDS自然史数据。成本来自2025年美国医疗保险医师费用表及已发表索赔来源。分析包括单因素敏感性分析、概率敏感性分析、社会视角、2年有限治疗情景和5年全国预算影响分析。质量调整生命年(QALY)由已发表视力至效用映射以及LIGHTSITE III生活质量数据的VFQ-25至EQ-5D转换得出;增量成本效果比(ICER)为每QALY成本;并计算5年全国预算影响。PBM在10年内产生5.244个贴现QALY,增量成本29,556美元,基础情形ICER为每QALY 73,910美元,低于美国100,000美元和150,000美元支付意愿阈值。在临床现实情景中,ICER范围从每QALY 36,700美元(每疗程1,000美元)至117,694美元(地理萎缩[GA]减少30%)。仅每疗程5,000美元情景超过两个阈值。在20%使用率下,5年累计全国预算影响为250亿美元。PBM在常规美国支付意愿阈值下具有成本效果,主要驱动因素为24个月时新发GA相对减少71.7%。这些发现支持考虑将PBM纳入中间型干性AMD的覆盖范围,但仍需独立重复GA减少结果并前瞻性收集EQ-5D数据。
This US-based large-scale retrospective study evaluates whether demographic differences influence the likelihood of surgical intervention after a diagnosis of rhegmatogenous retinal detachment (RRD). Retrospective cohort study. Patients with International Classification of Diseases-Tenth revision encounter diagnosis codes for RRD. Through a de-identified electronic health record platform, patients with RRD were separated into sex, race, ethnicity, and socioeconomic/psychosocial (SES) cohorts. Pair-wise comparisons were made after 1:1 propensity score matching on age, ocular conditions, SES conditions, and systemic and lifestyle comorbidities. The likelihood of patients to have a common procedural terminology code for RRD repair surgery at 4 time points (within 1 day, 1 week, 1 month, 3 months) following RRD was assessed. Risk ratios (RRs) and 95% CIs were reported with a significance threshold of <0.9 or >1.1. Following propensity score matching, there were 21,756 patients in the male vs female analysis, 5071 in the White vs Black, 1903 in the White vs Asian, 3279 in the Hispanic vs non-Hispanic, and 2194 in the SES analysis. Males were more likely to receive surgery within 1 day (RR = 1.20, 95% CI: 1.15, 1.24) up to 3 months after RRD (RR = 1.19, 95% CI: 1.15, 1.23). Compared with Black patients, White patients were more likely to receive surgery within 1 day (RR = 1.47, 95% CI: 1.35, 1.61) up to 3 months (RR = 1.36, 95% CI: 1.26, 1.46) after RRD. Both White vs Asian patients and non-Hispanic/Latinos vs Hispanic/Latinos did not have significant differences in time to surgery. Patients without SES conditions were more likely to receive surgery at 1 day (RR = 3.35, 95% CI: 2.73, 4.10) up to 3 months (RR = 2.83, 95% CI: 2.41, 3.34) after RRD. A sensitivity analysis performed between female patients ± SES and Black patients ± SES yielded increased differences. Comparison between patients with reported and unreported race and ethnicity also demonstrated differences up to 3 months. Males are more likely to receive surgical intervention for RRD. Significant racial disparities exist in the timely repair of RRD for Black patients and patients with SES conditions. This study highlights continued disparities that exist in the management of RRD.
中文摘要:这项基于美国的大规模回顾性研究评估人口学差异是否影响孔源性视网膜脱离(RRD)诊断后接受手术干预的可能性。研究为回顾性队列研究,纳入具有RRD的ICD-10就诊诊断代码的患者。通过去标识化电子健康记录平台,将RRD患者按性别、种族、族裔和社会经济/心理社会(SES)因素分组。在年龄、眼部疾病、SES相关状况以及全身和生活方式共病方面进行1:1倾向评分匹配后,开展两两比较。评估患者在RRD后4个时间点(1天内、1周内、1个月内、3个月内)具有RRD修复手术的CPT代码的可能性。报告风险比(RR)和95%CI,显著性阈值设为<0.9或>1.1。倾向评分匹配后,男性与女性分析有21756例患者,白人与黑人分析有5071例,白人与亚裔分析有1903例,西班牙裔与非西班牙裔分析有3279例,SES分析有2194例。男性在RRD后1天内接受手术的可能性更高(RR=1.20,95%CI:1.15,1.24),这一差异持续至3个月(RR=1.19,95%CI:1.15,1.23)。与黑人患者相比,白人患者在RRD后1天内接受手术的可能性更高(RR=1.47,95%CI:1.35,1.61),并持续至3个月(RR=1.36,95%CI:1.26,1.46)。白人与亚裔患者之间、非西班牙裔/拉丁裔与西班牙裔/拉丁裔患者之间在手术时间上均无显著差异。无SES相关状况的患者在RRD后1天接受手术的可能性更高(RR=3.35,95%CI:2.73,4.10),并持续至3个月(RR=2.83,95%CI:2.41,3.34)。在女性患者±SES与黑人患者±SES之间进行的敏感性分析显示差异增大。报告与未报告种族和族裔的患者之间的比较也显示差异持续至3个月。男性更可能接受RRD手术干预。黑人患者和具有SES相关状况的患者在RRD及时修复方面存在显著种族差异。该研究凸显RRD管理中持续存在的差异。
To estimate progression rates in sickle cell retinopathy (SCR) and identify risk factors associated with progression. Retrospective Cohort Study. Patients with SCR (317 patients; 620 eyes) seen at the Retina Division of the Wilmer Eye Institute at least once between July 1, 2013 and June 30, 2023. Demographics and clinical history were retrospectively extracted from electronic medical records. Goldberg staging of SCR was performed using fluorescein angiography or ultra-widefield fundus photography. Cox-proportional hazards models were used to evaluate factors associated with progression. Progression from baseline nonproliferative sickle retinopathy (NPSR) to proliferative sickle retinopathy (PSR), and from baseline PSR to more advanced PSR. Progression occurred in 10.7% of baseline NPSR eyes and 17.0% of at-risk baseline PSR eyes (median follow-up, 7.8 and 11.1 years, respectively). Active smoking at PSR diagnosis was significantly associated with progression to more advanced PSR (hazard ratio [95% confidence interval], 2.78 [1.50-5.16]). Age at diagnosis, sex, genotype, hydroxyurea use, blood transfusions, chronic red cell exchanges, bone marrow transplantation, and lifetime smoking history were not associated with SCR progression. Qualitative assessment of macular optical coherence tomography findings did not correlate with baseline peripheral vascular stage and were not associated with SCR progression. The higher progression rate within the baseline PSR cohort supports early referral and longitudinal ophthalmic surveillance for these patients. The strong association between active smoking at PSR diagnosis and subsequent progression supports recommendations for smoking cessation and closer monitoring with timely intervention among active smokers with PSR.
中文摘要:估计镰状细胞视网膜病变(SCR)的进展率并识别与进展相关的危险因素。回顾性队列研究。纳入2013年7月1日至2023年6月30日期间在Wilmer眼科研究所视网膜科至少就诊一次的SCR患者317例(620眼)。从电子病历中回顾性提取人口学资料与临床病史。采用荧光素血管造影或超广角眼底照相进行SCR的Goldberg分期。使用Cox比例风险模型评估与进展相关的因素。结局为从基线非增殖性镰状细胞视网膜病变(NPSR)进展为增殖性镰状细胞视网膜病变(PSR),以及从基线PSR进展为更晚期PSR。基线NPSR眼中10.7%发生进展,基线PSR高危眼中17.0%发生进展(中位随访分别为7.8年和11.1年)。PSR诊断时当前吸烟与进展至更晚期PSR显著相关(风险比[95%置信区间]为2.78[1.50-5.16])。诊断时年龄、性别、基因型、羟基脲使用、输血、慢性红细胞置换、骨髓移植及终生吸烟史均与SCR进展无关。黄斑光学相干断层扫描表现的定性评估与基线周边血管分期不相关,也与SCR进展无关。基线PSR队列内部较高的进展率支持对这类患者早期转诊并开展纵向眼科监测。PSR诊断时当前吸烟与后续进展之间的强关联支持建议戒烟,并对活动性吸烟的PSR患者进行更密切监测与及时干预。
To evaluate the incidence of endophthalmitis after intravitreal injections using a large, national ophthalmic registry. Retrospective clinical cohort study. Patients in the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) who received intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, fluocinolone acetonide (Iluvien, Yutiq), avacincaptad pegol (Izervay), pegcetacoplan (Syfovre), or dexamethasone (Ozurdex) were included in this analysis. Data from pediatric and adult patients in the IRIS Registry who were diagnosed with acute endophthalmitis within 30 days after intravitreal injections from 2016 to 2024 were collected. The overall incidence of endophthalmitis in adults was 3.5 per 10,000 cases with rates of 3.3 per 10,000 after anti-VEGF, 4.9 per 10,000 after avacincaptad pegol, 6.6 per 10,000 after pegcetacoplan, 10 per 10,000 and 8 per 10,000 after fluocinolone acetonide (Iluvien and Yutiq, respectively), and 12 per 10,000 after dexamethasone implant. The rate of endophthalmitis was significantly higher for corticosteroid implants and pegcetacoplan compared to anti-VEGF injections. Over the past years, there were statistically significant yet small fluctuations in endophthalmitis incidence for anti-VEGF injections ranging from 2.4 per 10,000 in 2021 to 4 per 10,000 in 2020. The incidence of post-injection endophthalmitis is greater with corticosteroid implants and anticomplement therapies. Heightened aseptic vigilance may be warranted with injections that necessitate larger gauge needles, modulate the immune response and/or are prepared from a vial.
中文摘要:评估玻璃体内注射后眼内炎发生率,采用大型全国眼科登记系统。回顾性临床队列研究。纳入美国眼科学会IRIS登记系统(Intelligent Research in Sight)中接受抗血管内皮生长因子(VEGF)药物、氟轻松玻璃体内植入剂(Iluvien、Yutiq)、avacincaptad pegol(Izervay)、pegcetacoplan(Syfovre)或地塞米松(Ozurdex)玻璃体内注射的患者。收集2016至2024年IRIS登记系统中玻璃体内注射后30天内诊断为急性眼内炎的儿童和成人患者数据。成人眼内炎总发生率为每1万例3.5例,抗VEGF后为每1万例3.3例,avacincaptad pegol后为每1万例4.9例,pegcetacoplan后为每1万例6.6例,氟轻松(Iluvien和Yutiq分别为每1万例10例和8例)后为每1万例10例和8例,地塞米松植入剂后为每1万例12例。与抗VEGF注射相比,皮质类固醇植入剂和pegcetacoplan的眼内炎发生率显著更高。过去数年中,抗VEGF注射后眼内炎发生率存在统计学显著但幅度较小的波动,从2021年每1万例2.4例到2020年每1万例4例。皮质类固醇植入剂和抗补体治疗后的注射后眼内炎发生率更高。对于需要使用较大口径针头、调节免疫反应和/或由药瓶制备的注射,可能需要提高无菌操作警惕性。
To describe the frequency and prevalence of macular features in X-linked retinoschisis (XLRS) patients using optical coherence tomography (OCT) and fundus photography, with attention to inter-eye asymmetry. Retrospective consecutive case series. Thirty-three male patients (66 eyes) with genetically confirmed XLRS evaluated at a tertiary pediatric retina clinic between 2013 and 2024. Fundus photography and macular OCT images were graded independently by 2 masked reviewers for macular schisis, cystoid spaces (with layer localization), macular atrophy, spoke-wheel patterns, retinal folds, vitreous veils, and chorioretinal atrophy. Intergrader reliability was assessed using percent agreement and Cohen's kappa. Frequency and prevalence of OCT and fundus photography features, including unilateral versus bilateral involvement. Cystoid spaces were present in 100% of gradable eyes and macular schisis in 87.5%. Cystoid changes most frequently involved the inner nuclear and outer plexiform layers. Macular atrophy was identified in 20.8% of eyes, with unilateral involvement in 8.3% of assessable patients. On fundus photography, retinal folds were present in 57.9% of eyes, spoke-wheel patterns in 54.5%, vitreous veils in 10.5%, and chorioretinal atrophy in 5.3%. Unilateral manifestations were observed across multiple imaging features. Intergrader agreement was excellent for macular schisis (κ = 0.91) and moderate for spoke-wheel patterns. Macular abnormalities in XLRS demonstrate phenotypic and interpretative variability, including clinically relevant unilateral findings. Systematic characterization of OCT and fundus features may improve phenotypic recognition of asymmetric disease and may help identify patients who warrant genetic testing or further retinal evaluation.
中文摘要:描述X连锁视网膜劈裂症(XLRS)患者中使用OCT和眼底照相所见的黄斑特征频率与患病率,并关注双眼不对称性。回顾性连续病例系列。33名经基因确诊的男性XLRS患者(66眼)于2013年至2024年在三级儿童视网膜门诊接受评估。眼底照相和黄斑OCT图像由2名设盲阅片者独立分级,评估黄斑劈裂、囊样腔隙(并定位所在层次)、黄斑萎缩、辐轮状模式、视网膜皱褶、玻璃体纱膜和脉络膜视网膜萎缩。采用一致率和Cohen kappa评估阅片者间可靠性。统计OCT和眼底照相特征的频率与患病率,包括单侧与双侧受累。囊样腔隙见于100%可分级眼,黄斑劈裂见于87.5%。囊样改变最常累及内核层和外丛状层。黄斑萎缩见于20.8%的眼,在可评估患者中单侧受累为8.3%。眼底照相中,视网膜皱褶见于57.9%的眼,辐轮状模式为54.5%,玻璃体纱膜为10.5%,脉络膜视网膜萎缩为5.3%。多种影像特征均可见单侧表现。阅片者间一致性对黄斑劈裂极好(κ=0.91),对辐轮状模式为中等。XLRS的黄斑异常表现出表型和判读上的变异性,包括具有临床意义的单侧发现。系统描述OCT和眼底特征可能提高对不对称疾病的表型识别,并有助于识别需要基因检测或进一步视网膜评估的患者。
To evaluate access to diabetic retinopathy (DR) care by quantifying the geographic distribution of therapeutic and diagnostic procedures for DR across the United States. Retrospective cohort study. Using the IRIS® Registry (Intelligent Research in Sight), we identified patients with 2 or more International Classification of Diseases codes for DR between January 1, 2013, and December 31, 2024. Care was classified as therapeutic (intravitreal injections [IVIs], panretinal photocoagulation [PRP], focal laser photocoagulation, and pars plana vitrectomy) or diagnostic (OCT, fundus photography, and fluorescein angiography) by Current Procedural Terminology codes. Urban versus nonurban practice locations were defined using the United States Department of Agriculture Rural-Urban Commuting Area codes. Procedure volume, population-adjusted and disease-adjusted rates, and physician subspecialty distributions were compared across settings. A subanalysis examined disease burden, DR care adherence, and diabetic macular edema management among nonurban residents stratified by treating practice urbanization and sociodemographic factors. Likelihood of each diagnostic and therapeutic procedure occurring in urban areas. We identified 11 254 015 therapeutic and 35 892 574 diagnostic procedures undergone by 1 142 505 patients with DR. Urban practices performed 67% to 80% of all procedures after adjusting for population differences, and 65% to 90% after adjusting for disease burden, with nonurban sites contributing only 1% to 35% across categories. In nonurban practices, comprehensive ophthalmologists performed more than 35% of IVI and PRP procedures, whereas in urban practices, they performed roughly 5% to 7% of these procedures. More than 93% of nonurban residents and more than 97% of urban residents received therapeutic procedures in urban practices. Nonurban residents showed a higher PDR prevalence (18.21% vs. 16.02%) and higher rates of all therapeutic procedures. Of those receiving care at urban practices, 47.7% had a more than 1-year OCT gap versus 44.1% at nonurban practices; this increase in discontinuity was disproportionately larger among older patients, Black patients, and those with lower household incomes. Diabetic retinopathy-related diagnostic and therapeutic services were concentrated in urban practice locations, even after adjustment for population differences and disease burden. This finding supports the need for strategies to improve access in nonurban communities. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:评估美国糖尿病视网膜病变(DR)诊疗服务的可及性,通过量化DR治疗性和诊断性操作在全美的地理分布。回顾性队列研究。利用IRIS® Registry(Intelligent Research in Sight),识别2013年1月1日至2024年12月31日期间至少2次国际疾病分类DR代码的患者。根据当前操作术语代码将诊疗分为治疗性(玻璃体腔内注射[IVI]、全视网膜光凝[PRP]、局灶激光光凝和经平坦部玻璃体切割术)或诊断性(OCT、眼底照相和荧光素血管造影)。使用美国农业部城乡通勤区代码定义城市与非城市执业地点。比较不同设置下的操作量、人口校正率和疾病校正率以及医师亚专科分布。亚组分析考察非城市居民中的疾病负担、DR诊疗依从性和糖尿病黄斑水肿管理,按就诊执业地点城市化程度和社会人口学因素分层。分析各项诊断和治疗操作发生于城市地区的可能性。共识别1 142 505例DR患者接受的11 254 015次治疗性操作和35 892 574次诊断性操作。校正人口差异后,城市执业地点完成全部操作的67%至80%;校正疾病负担后完成65%至90%;非城市地点在各分类中仅贡献1%至35%。在非城市执业地点,综合眼科医师完成超过35%的IVI和PRP操作,而城市执业地点约为5%至7%。超过93%的非城市居民和超过97%的城市居民在城市执业地点接受治疗性操作。非城市居民的PDR患病率更高(18.21% vs. 16.02%),并且所有治疗性操作的发生率更高。在城市执业地点接受诊疗者中,47.7%存在超过1年的OCT间隔,非城市执业地点为44.1%;这种诊疗不连续性的增加在老年患者、黑人患者和家庭收入较低者中更大。即使校正人口差异和疾病负担后,DR相关诊断和治疗服务仍集中于城市执业地点。该发现支持需要制定策略改善非城市社区的可及性。专有或商业披露见本文末尾脚注和披露部分。
To investigate Bruch's membrane (BrM) morphology in angioid streak (AS)-associated macular neovascularization (MNV) and neovascular age-related macular degeneration (nAMD) using multimodal imaging. Retrospective clinical cohort study. Treatment-naïve eyes with MNV secondary to AS or nAMD that achieved a dry macula after 3 loading intravitreal antivascular endothelial growth factor (VEGF) injections. Baseline indocyanine green angiography (ICGA) images obtained before antiVEGF treatment were used to measure axial length-corrected MNV area and identify late-phase speckled hypofluorescent areas (SHA). Optical coherence tomography (OCT) images after dry macula achievement were used to assess central foveal thickness (CFT), subfoveal choroidal thickness (SCT), fibrovascular pigment epithelial detachment (PED) thickness, BrM undulation, and a newly defined BrM reflectivity index (BRI) calculated from intensity-normalized images. Group comparisons assessed BrM-related biomarker differences, and receiver operating characteristic (ROC) analyses evaluated their diagnostic performance. Differences in ICGA- and OCT-derived findings between AS-associated MNV and nAMD, including SHA, BrM undulation, and BRI, and the diagnostic performance of BRI and BrM undulation in differentiating AS-associated MNV from nAMD. Twenty-five eyes with AS and 32 eyes with nAMD were analyzed. Among eyes with available ICGA, MNV area was larger in AS than in nAMD (5.34 ± 3.29 mm2 vs 3.45 ± 1.22 mm2, P = .005), and late-phase SHA was more frequent in AS (86.4% vs 18.8%, P < .001). CFT and fibrovascular PED thickness did not differ significantly, whereas SCT was lower in AS-associated MNV than in nAMD (166.0 ± 67.1 µm vs 217.2 ± 112.0 µm; P = .049). BrM undulation was more common in the AS group (24.0% vs 3.1%, P = .036). BRI was higher in AS than in nAMD (0.905 ± 0.148 vs 0.663 ± 0.169, P < .001). The ROC curve for BRI showed an area under the curve of 0.850 (95% confidence interval, 0.754-0.946) with an optimal cutoff of 0.749, yielding 0.880 sensitivity and 0.656 specificity. Compared with nAMD, AS-associated MNV showed distinct ICGA and OCT features, including larger MNV area, more frequent late-phase SHA and BrM undulation, and higher BRI after antiVEGF loading. These findings may reflect BrM alterations associated with calcification and mechanical instability. BrM-derived ICGA and OCT biomarkers may help characterize AS pathophysiology and differentiate AS-associated MNV from nAMD.
中文摘要:探讨使用多模式影像研究血管样条纹(AS)相关黄斑新生血管(MNV)与新生血管性年龄相关性黄斑变性(nAMD)中Bruch膜(BrM)形态。回顾性临床队列研究。纳入AS或nAMD继发MNV、接受3次负荷剂量玻璃体腔抗血管内皮生长因子(VEGF)注射后达到黄斑干燥的治疗初治眼。使用抗VEGF治疗前基线吲哚菁绿血管造影(ICGA)图像测量经眼轴校正的MNV面积并识别晚期斑点状低荧光区(SHA)。达到黄斑干燥后的光学相干断层扫描(OCT)图像评估中心凹厚度(CFT)、黄斑下脉络膜厚度(SCT)、纤维血管性色素上皮脱离(PED)厚度、BrM起伏,以及新定义的BrM反射指数(BRI),BRI由强度归一化图像计算。比较组间BrM相关生物标志物差异,采用受试者工作特征(ROC)分析评估其诊断性能。比较AS相关MNV与nAMD在ICGA和OCT表现上的差异,包括SHA、BrM起伏和BRI,以及BRI和BrM起伏区分二者的诊断性能。分析25只AS眼和32只nAMD眼。有ICGA的眼,AS的MNV面积大于nAMD(5.34 ± 3.29 mm2 对 3.45 ± 1.22 mm2,P = .005),晚期SHA在AS更常见(86.4% 对 18.8%,P < .001)。CFT和纤维血管性PED厚度无显著差异,AS相关MNV的SCT低于nAMD(166.0 ± 67.1 µm 对 217.2 ± 112.0 µm;P = .049)。BrM起伏在AS组更常见(24.0% 对 3.1%,P = .036)。AS的BRI高于nAMD(0.905 ± 0.148 对 0.663 ± 0.169,P < .001)。BRI的ROC曲线下面积为0.850(95%可信区间0.754-0.946),最佳截断值0.749,敏感度0.880,特异度0.656。与nAMD相比,AS相关MNV具有不同的ICGA和OCT特征,包括更大的MNV面积、更常见的晚期SHA和BrM起伏,以及抗VEGF负荷后更高的BRI。这些发现可能反映与钙化和机械不稳定相关的BrM改变。BrM来源的ICGA和OCT生物标志物有助于刻画AS病理生理并区分AS相关MNV与nAMD。
To evaluate whether hyperreflective lesions on en face optical coherence tomography of the middle retinal layers, which we label as hyperreflective abnormal areas (HAAs), improve the distinction of referable and vision-threatening diabetic retinopathy (DR), beyond established clinical factors. Accuracy analysis of revised treatment referral criteria. Two hundred seventy-five eyes from 185 patients with diabetes without center-involving diabetic macular edema, encompassing a broad range of DR severity. HAAs were manually quantified on averaged en face optical coherence tomography of a middle-retina slab, segmented from 10 µm above the inner plexiform layer to 10 µm below the outer plexiform layer, and quantified as percentage HAA of the analyzable retinal area. Generalized estimating equation logistic regression models were constructed to distinguish referable and vision-threatening DR. A base model included clinical parameters of age, sex, duration of diabetes, hemoglobin A1c, and hypertension, while a full model additionally incorporated HAAs. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), internal cross-validation, and calibration. Model discrimination and effect size of HAAs for distinguishing referable and vision-threatening DR. For referable DR, the full model showed significantly improved discrimination compared with the base model (AUC 0.969 vs 0.865; ΔAUC 0.104, P = .002). HAAs were independently associated with referable DR, with an odds ratio of 3.42 per 0.1-percentage point increase (95% CI, 2.37-7.97). Internal cross-validation supported the robustness of the improved discrimination for referable DR. For vision-threatening DR, the full model showed higher discrimination (AUC 0.865 vs 0.778), but did not reach significance (P = .126). HAAs were positively associated with vision-threatening DR, with an odds ratio of 1.23. Middle retinal layer HAAs identified eyes with referable DR beyond established clinical factors. The association of HAAs with vision-threatening DR was directionally consistent but did not improve model discrimination beyond clinical factors. Because HAAs may capture lesion-agnostic structural signatures of microvascular pathology in the middle retina, they may serve as a promising biomarker for diagnostic discrimination of high-risk diabetic eyes in the absence of center-involving diabetic macular edema.
中文摘要:评估中层视网膜en face光相干断层扫描上的高反射病灶(称为高反射异常区,HAA)能否在既有临床因素之外提高对需转诊糖尿病视网膜病变(DR)和威胁视力DR的区分能力。对修订后的治疗转诊标准进行准确性分析。纳入185例无中心受累糖尿病黄斑水肿的糖尿病患者共275眼,覆盖较宽的DR严重程度范围。HAA在中层视网膜层的平均en face光相干断层扫描图像上手动定量,该层从内丛状层上10 µm至外丛状层下10 µm分割,并以HAA占可分析视网膜面积的百分比表示。构建广义估计方程logistic回归模型区分需转诊DR与威胁视力DR。基础模型纳入年龄、性别、糖尿病病程、血红蛋白A1c和高血压等临床参数,完整模型额外纳入HAA。采用受试者工作特征曲线下面积(AUC)、内部交叉验证和校准评估模型性能。评估模型判别能力及HAA区分需转诊DR和威胁视力DR的效应量。对需转诊DR,完整模型较基础模型判别能力显著提高(AUC 0.969 vs 0.865;ΔAUC 0.104,P = .002)。HAA与需转诊DR独立相关,每增加0.1个百分点比值比为3.42(95% CI 2.37-7.97)。内部交叉验证支持需转诊DR判别能力提升的稳健性。对威胁视力DR,完整模型判别能力较高(AUC 0.865 vs 0.778),但未达统计学显著性(P = .126)。HAA与威胁视力DR呈正相关,比值比1.23。中层视网膜HAA可在既有临床因素之外识别需转诊DR眼。HAA与威胁视力DR的关联方向一致,但未能在临床因素之外改善模型判别能力。由于HAA可能反映中层视网膜微血管病变的非病灶特异性结构特征,在无中心受累糖尿病黄斑水肿时,其有望作为诊断区分高风险糖尿病眼的生物标志物。
To evaluate whether baseline foveal tomographic lesions are associated with foveal-first versus extrafoveal-first onset of complete retinal pigment epithelial and outer retinal atrophy (cRORA) in intermediate age-related macular degeneration (iAMD). Retrospective cohort study. A total of 129 eyes of 89 patients with iAMD developing cRORA. Consecutive eyes with iAMD progressing to cRORA were identified through back-tracking grading on spectral-domain optical coherence tomography. Eligible eyes had at least 3 years of follow-up before cRORA onset, with no pre-cRORA inter-visit gap exceeding 6 months. The foveal region was operationally defined as the 1-mm Early Treatment Diabetic Retinopathy Study central subfield. Baseline foveal lesions included soft drusen, subretinal drusenoid deposits (SDD), drusenoid pigment epithelial detachment (dPED), acquired vitelliform lesions (AVL), and incomplete retinal pigment epithelium and outer retinal atrophy (iRORA). Hyperreflective foci (HRF) were recorded as present/absent. Foveal-first versus extrafoveal-first cRORA onset; interval-censored time from extrafoveal cRORA onset to foveal involvement. Over a mean follow-up of 10.4 ± 3.4 years, 108 eyes (83.7%) developed foveal cRORA. cRORA onset was foveal-first in 60 eyes (46.5%) and extrafoveal-first in 69 eyes (53.5%). Onset pattern differed across baseline lesions (P < .001). SDD and soft drusen were more frequently associated with extrafoveal-first onset (20/22 [91%] and 25/40 [63%]), whereas AVL, iRORA, and dPED were more frequently associated with foveal-first onset (16/23 [70%], 7/10 [70%], and 20/34 [59%]). Among 48 extrafoveal-first eyes that reached the fovea, time to foveal involvement was similar across lesion types (median, 1.5-1.8 years; P = .97). Compared with soft drusen, the time to foveal cRORA was shorter for iRORA, dPED, and AVL (time ratios: 0.12, 0.40, and 0.50; 95% CIs: 0.06-0.23, 0.30-0.55, and 0.35-0.71). Foveal HRF independently predicted faster progression (time ratio, 0.66; 95% CI, 0.51-0.85; P = .001). In iAMD eyes progressing to cRORA, distinct tomographic lesions at the fovea were associated with a different propensity to foveal-first versus extrafoveal-first atrophic onset. Once extrafoveal cRORA was established, time to foveal involvement did not differ across tomographic lesions. These findings may inform lesion-specific risk stratification for emerging dry AMD therapies.
中文摘要:评估中间型年龄相关性黄斑变性(iAMD)患者基线中心凹断层扫描病灶是否与完全性视网膜色素上皮和光感受器外段萎缩(cRORA)以中心凹先累及或中心凹外先累及的方式起病相关。回顾性队列研究。共纳入129眼(89例)iAMD并进展为cRORA的患者。通过谱域光学相干断层扫描回溯分级,连续识别由iAMD进展为cRORA的眼。纳入眼在cRORA起病前至少随访3年,cRORA发生前各次随访间隔均不超过6个月。中心凹区域操作定义为早期治疗糖尿病视网膜病变研究1 mm中央子域。基线中心凹病灶包括软性玻璃膜疣、视网膜下玻璃膜疣样沉积(SDD)、玻璃膜疣样色素上皮脱离(dPED)、获得性卵黄样病变(AVL)及不完全性视网膜色素上皮和光感受器外段萎缩(iRORA)。高反射灶(HRF)按有或无记录。观察指标为中心凹先发与中心凹外先发cRORA起病,以及从中心凹外cRORA起病至中心凹受累的区间删失时间。平均随访10.4±3.4年,108眼(83.7%)出现中心凹cRORA。cRORA起病为中心凹先发60眼(46.5%),中心凹外先发69眼(53.5%)。起病模式在不同基线病灶间存在差异(P<.001)。SDD和软性玻璃膜疣更多与中心凹外先发相关(20/22[91%]和25/40[63%]),AVL、iRORA和dPED更多与中心凹先发相关(16/23[70%]、7/10[70%]和20/34[59%])。在48只中心凹外先发且最终累及中心凹的眼中,不同病灶类型到达中心凹受累的时间相近(中位1.5~1.8年;P=.97)。与软性玻璃膜疣相比,iRORA、dPED和AVL到达中心凹cRORA的时间更短(时间比:0.12、0.40和0.50;95%CI:0.06~0.23、0.30~0.55和0.35~0.71)。中心凹HRF独立预测更快的进展(时间比0.66;95%CI 0.51~0.85;P=.001)。在由iAMD进展为cRORA的眼中,中心凹处不同的断层扫描病灶与中心凹先发或中心凹外先发起病的倾向不同相关。一旦中心凹外cRORA形成,到达中心凹受累的时间在不同断层扫描病灶间无差异。这些结果可为新兴干性AMD治疗的病灶特异性风险分层提供参考。
To investigate how exposure to GABAergic medications affects diabetic retinopathy (DR) development, progression, and complications. Retrospective clinical cohort study using multi-institutional electronic health record data (TriNetX, US Collaborative Network). Adults aged ≥ 18 years with type 2 diabetes mellitus with ophthalmology follow-up. Study cohorts had GABAergic prescription records for 6-months, 1-year, 3-years, or 5-years; control cohorts had no GABAergic prescriptions ever. Cohorts were propensity-score matched (PSM) on demographics, systemic comorbidities, common indications for GABAergic medications, and ophthalmic confounders. Outcomes included incident DR, progression from mild/moderate nonproliferative DR to severe nonproliferative DR, proliferative DR, or interventions required in advanced DR, and incident DR complications. Hazard ratio (HR) and 95% confidence intervals (CI); significance threshold < 0.9 or > 1.1. After successful PSM, there were 110 495 (6-months), 99 187 (1-year), 63 194 (3-years), and 40 810 (5-years) DR-naive study patients with the respective GABAergic prescription durations of interest. Compared to 109 603 DR-naive control patients, study patients demonstrated a significantly reduced HR for DR development at all time points from 6-months (HR 0.61, 95% CI 0.57-0.65) to 5-years (HR 0.81, 95% CI 0.77-0.85). Study patients (n = 14 644) with baseline mild/moderate nonproliferative DR had a significantly reduced hazard of progressing to severe nonproliferative DR, proliferative DR, or DR interventions with 6-months (HR 0.75, 95% CI 0.68-0.82) and 1-year (HR 0.69, 95% CI 0.73, 0.86) GABAergic exposure. Prescription for 6-months (HR 0.74, 95% CI 0.68-0.80) to 3-years (HR 0.80, 95% CI 0.84-0.86) was associated with a significantly reduced hazard for DR complications. Stratification by 4 specific medication indications consistently showed a reduced hazard for DR development with a 6-month prescription duration. GABAergic medication use, particularly short-term exposure, is associated with a reduced hazard of DR development, progression, and complications. These exploratory findings support a potential role of GABAergic modulation in diabetic retinal disease.
中文摘要:探讨GABA能药物暴露如何影响糖尿病视网膜病变(DR)的发生、进展和并发症。采用多机构电子健康记录数据(TriNetX美国协作网络)进行回顾性临床队列研究。纳入年龄≥18岁、接受眼科随访的2型糖尿病患者。研究队列分别有6个月、1年、3年或5年的GABA能药物处方记录;对照队列从未有GABA能药物处方。队列按人口学特征、全身合并症、GABA能药物常见适应证及眼科混杂因素进行倾向评分匹配(PSM)。结局包括新发DR、从轻/中度非增殖型DR进展为重度非增殖型DR、增殖型DR或晚期DR所需干预,以及新发DR并发症。采用风险比(HR)和95%置信区间(CI);显著性阈值为<0.9或>1.1。成功PSM后,分别有110495例(6个月)、99187例(1年)、63194例(3年)和40810例(5年)无DR研究患者具有相应关注时长的GABA能药物处方。与109603例无DR对照患者相比,研究患者在6个月(HR 0.61,95% CI 0.57-0.65)至5年(HR 0.81,95% CI 0.77-0.85)所有时间点均显示DR发生HR显著降低。基线为轻/中度非增殖型DR的研究患者(n=14644)在6个月(HR 0.75,95% CI 0.68-0.82)和1年(HR 0.69,95% CI 0.73-0.86)GABA能药物暴露下,进展为重度非增殖型DR、增殖型DR或需DR干预的风险显著降低。6个月(HR 0.74,95% CI 0.68-0.80)至3年(HR 0.80,95% CI 0.84-0.86)处方与DR并发症风险显著降低相关。按4种具体用药指征分层后,6个月处方时长均一致显示DR发生风险降低。GABA能药物使用,尤其短期暴露,与DR发生、进展和并发症风险降低相关。这些探索性结果支持GABA能调节在糖尿病视网膜疾病中的潜在作用。
To investigate the association between hyporeflective core drusen (hypoRCD) and the formation of large choroidal hypertransmission defects (hyperTDs) in eyes with intermediate age-related macular degeneration, we used swept-source optical coherence tomography (SS-OCT) imaging and a novel algorithm to detect and quantify hypoRCD before the onset of hyperTDs. Posthoc subgroup analysis of a prospective cohort study. Eyes with intermediate age-related macular degeneration enrolled in a prospective SS-OCT imaging study were retrospectively reviewed. SS-OCT angiography scans were obtained at baseline and follow-up. En face images derived from a retinal pigment epithelium (RPE) to Bruch's membrane slab identified hyporeflective cores (hypoRCs) within drusen as dark spots. A sub-RPE slab located 64 to 400 µm beneath Bruch's membrane was used to identify calcified drusen (CaD) based on their characteristic choroidal hypotransmission defects. hypoRCs associated with CaD (hypoRC-CaD) were identified. HypoRCs not associated with CaD were labeled as noncalcified hypoRCD and quantified separately. Large hyperTDs, defined as bright lesions with a greatest linear dimension ≥250 µm on the sub-RPE slab, were graded. A semiautomated algorithm measured the areas of hypoRC-CaD and noncalcified hypoRCD within a 5 mm circle centered on the fovea, and their association with hyperTD formation was analyzed. The risk attributed to CaD with and without hypoRCs was evaluated. The study included 171 eyes from 121 patients with a median follow-up of 59.1 months (95% CI: 52.0-67.8). Eighty-two eyes developed at least one large hyperTD during follow-up. The total hypoRCD area at the time of hyperTD onset was 0.026 mm² (range: 0-0.349 mm²), compared to 0.015 mm² (range: 0-0.532 mm²) at the final visit in eyes that did not develop hyperTDs. When drusen volume, hyperreflective foci area, CaD area, and total hypoRCD area were studied as risk factors, the hypoRCD area was not a significant predictor of hyperTD onset in the univariable (P = .36) or multivariable (P = .60) Cox regression models. HypoRCD alone was not predictive of progression to atrophy, but the risk of progression was found to be associated with CaD with or without hyporeflective cores.
中文摘要:为探讨中期年龄相关性黄斑变性眼中低反射核心玻璃膜疣(hypoRCD)与大脉络膜高透射缺陷(hyperTD)形成之间的关联,我们使用扫频源光学相干断层扫描(SS-OCT)成像和一种新算法,在hyperTD出现前检测并量化hypoRCD。这是前瞻性队列研究的亚组事后分析。研究回顾性审查了参加一项前瞻性SS-OCT成像研究的中期年龄相关性黄斑变性眼。基线和随访时获取SS-OCT血管成像扫描。由视网膜色素上皮至Bruch膜层段生成的眼正面图像将玻璃膜疣内的低反射核心识别为暗点。位于Bruch膜下64至400微米的视网膜下RPE层段用于根据钙化玻璃膜疣(CaD)特征性的脉络膜低透射缺陷识别CaD。与CaD相关的低反射核心被识别为hypoRC-CaD。未与CaD相关的低反射核心标记为非钙化hypoRCD并单独量化。大hyperTD定义为视网膜下RPE层段上最大线性尺寸≥250微米的亮病灶,并对其进行分级。半自动算法测量以黄斑中心凹为中心5 mm圆内hypoRC-CaD和非钙化hypoRCD的面积,并分析其与hyperTD形成的关联。评估伴或不伴低反射核心的CaD所对应的风险。研究纳入121例患者的171只眼,中位随访59.1个月(95% CI:52.0-67.8)。82只眼在随访期间出现至少一个大hyperTD。出现hyperTD时总hypoRCD面积为0.026 mm²(范围:0-0.349 mm²),未出现hyperTD眼在末次随访时为0.015 mm²(范围:0-0.532 mm²)。将玻璃膜疣体积、高反射灶面积、CaD面积和总hypoRCD面积作为危险因素分析时,hypoRCD面积在单变量(P = .36)或多变量(P = .60)Cox回归模型中均不是hyperTD出现的显著预测因素。单独的hypoRCD不能预测向萎缩进展,但进展风险与伴或不伴低反射核心的CaD相关。
To compare the site-specific optical coherence tomography (OCT) biomarkers that appear before the formation of large hypertransmission defects (hyperTDs) with the eye-level OCT biomarkers that have been found to predict disease progression in eyes with intermediate age-related macular degeneration (iAMD). Retrospective subgroup analysis of a prospective cohort study. A prospectively enrolled cohort of eyes with iAMD imaged with swept-source OCT (SS-OCT) was retrospectively reviewed to identify eyes that developed large hyperTDs. Large hyperTDs were defined as bright lesions with a greatest linear dimension of ≥250 µm on an en face sub-retinal pigment epithelium slab image created using segmentation boundaries positioned 64 to 400 µm below the Bruch's membrane. All visits before the formation of the large hyperTDs were retrospectively reviewed to identify the OCT biomarker at the retinal location where the initial large hyperTD formed. Of 171 eyes, 82 (48%) with iAMD developed at least 1 large hyperTD. At the first visits when the large hyperTD developed, a total of 119 large hyperTDs were detected. Hyperreflective foci (HRF) were the most frequent OCT biomarker at the sites before the formation of hyperTDs (88/119, 74%). Soft drusenoid lesions were the second most frequent biomarker (77/119, 65%); however, 67 of these lesions occurred in conjunction with HRF. Calcified drusen (CaD) were present at 19 of the 119 sites (16%). Of these 19 CaD lesions, 7 contained hyporeflective cores and 11 were associated with HRF. Non-calcified hyporeflective core drusen were present at 16 of the 119 sites (13%), with 3 associated with HRF. Basal laminar deposits were present at 2 of the 119 sites (2%), both of which were associated with HRF. Single cases of a vitelliform lesion and a small hyperTD were also identified before the large hyperTDs. Site-specific analysis revealed that HRF were the most frequent OCT biomarker at the sites before the formation of large hyperTDs. Soft drusenoid lesions and HRF were frequently observed together, consistent with our previous eye-level multivariable analysis, which revealed that drusen volume was not independently predictive of the future formation of large hyperTDs.
中文摘要:比较大面积高透射缺陷(hyperTDs)形成前出现的位点特异性OCT生物标志物与已发现可预测中期年龄相关性黄斑变性(iAMD)眼病进展的眼水平OCT生物标志物。本研究为前瞻性队列研究的回顾性子组分析。回顾性审查前瞻性入组并经扫频源OCT(SS-OCT)成像的iAMD眼,识别发生大面积hyperTDs的眼。大面积hyperTDs定义为:在使用位于Bruch膜下64至400 µm的分割边界生成的视网膜色素上皮下en face slab图像上,最大线性尺寸≥250 µm的亮病灶。回顾大面积hyperTDs形成前的所有随访,识别初始大面积hyperTD形成视网膜位置的OCT生物标志物。171眼中82眼(48%)发生至少1个大面积hyperTD。首次发现大面积hyperTD时共检出119个大面积hyperTD。高反射灶(HRF)是hyperTDs形成前位点最常见的OCT生物标志物(88/119,74%)。软性玻璃膜疣样病灶为第二常见标志物(77/119,65%),其中67个病灶与HRF同时出现。钙化玻璃膜疣(CaD)见于19/119个位点(16%),其中7个含低反射核,11个与HRF相关。非钙化低反射核玻璃膜疣见于16/119个位点(13%),其中3个与HRF相关。基底板层沉积见于2/119个位点(2%),均与HRF相关。另识别出1例卵黄样病灶和1个小hyperTD发生于大面积hyperTDs之前。位点特异性分析显示,HRF是大面积hyperTDs形成前位点最常见的OCT生物标志物。软性玻璃膜疣样病灶与HRF常同时出现,这与既往眼水平多变量分析一致,该分析显示玻璃膜疣体积并不能独立预测未来大面积hyperTDs的形成。
While inherited genetics strongly influence AMD risk, clonal hematopoiesis of indeterminate potential (CHIP), an age-related condition driven by somatic mutations and inflammation, is a novel, biologically plausible risk factor. Prospective evidence exploring their interplay with AMD incidence is lacking. Prospective cohort study. We conducted a prospective cohort study among 395 505 participants from the UK Biobank. CHIP was defined by somatic mutations (variant allele fraction ≥ 2%) in leukemia-associated driver genes from blood-derived exome sequencing. A polygenic risk score (PRS) for AMD was calculated using established genetic variants. We used Cox proportional hazards models to assess the independent and joint associations of CHIP and PRS with incident AMD. Age-related macular degeneration. During a median follow-up of 15.5 years, we documented 7178 incident AMD cases. CHIP was associated with a 14% higher risk of incident AMD (HR: 1.14; 95% CI: 1.03, 1.26; P = .009). Gene-specific analyses showed significant associations for mutations in DNMT3A (HR: 1.20; 95% CI: 1.06, 1.36; P = .005), spliceosome genes (HR: 1.72; 95% CI: 1.02, 2.97; P = .042), and DNA damage repair genes (HR: 1.68; 95% CI: 1.06, 2.67; P = .028). A high AMD PRS was also associated with AMD risk. Participants with both any CHIP and a high PRS had a 3.26-fold higher risk (95% CI: 2.75, 3.86; P < .001) compared to those with neither, with evidence of additive interaction (relative excess risk due to interaction [RERI] = 0.60; 95% CI: 0.07, 1.20). The joint effect was also strongest for DNMT3A mutation carriers with high PRS (HR: 3.69; 95% CI: 2.58, 3.96; P < .001; RERI = 0.34; 95% CI: 0.04, 1.12). These synergistic effects were more pronounced in older adults. CHIP was an independent risk factor for incident AMD. The risk is amplified in individuals with high genetic susceptibility, suggesting a synergistic interplay between inherited genetic risk and somatic clonal expansion in AMD pathogenesis, with the strongest effects observed in older adults. These findings provide a rationale for future efforts to integrate somatic mutation status into risk stratification paradigms for AMD, especially among the elderly.
中文摘要:尽管遗传因素强烈影响AMD风险,意义未明的克隆性造血(CHIP)是一种由体细胞突变和炎症驱动的年龄相关状态,是新的、生物学上合理的风险因素。探讨其与AMD发病相互作用的前瞻性证据缺乏。前瞻性队列研究。我们在英国生物银行395505名参与者中开展前瞻性队列研究。CHIP定义为血液外显子测序中白血病相关驱动基因的体细胞突变(变异等位基因分数≥2%)。AMD多基因风险评分(PRS)使用已确定的遗传变异计算。我们使用Cox比例风险模型评估CHIP和PRS与AMD发病的独立及联合关联。年龄相关性黄斑变性。中位随访15.5年期间,记录7178例AMD发病。CHIP与AMD发病风险升高14%相关(HR:1.14;95% CI:1.03,1.26;P=.009)。基因特异性分析显示DNMT3A突变(HR:1.20;95% CI:1.06,1.36;P=.005)、剪接体基因(HR:1.72;95% CI:1.02,2.97;P=.042)和DNA损伤修复基因(HR:1.68;95% CI:1.06,2.67;P=.028)的突变存在显著关联。高AMD PRS也与AMD风险相关。同时具有任何CHIP和高PRS的参与者相比两者均无者风险高3.26倍(95% CI:2.75,3.86;P<.001),并有相加交互证据(交互作用相对超额风险[RERI]=0.60;95% CI:0.07,1.20)。联合效应在携带DNMT3A突变且高PRS者中最强(HR:3.69;95% CI:2.58,3.96;P<.001;RERI=0.34;95% CI:0.04,1.12)。这些协同效应在老年人中更明显。CHIP是AMD发病的独立风险因素。遗传易感性高者风险放大,提示AMD发病机制中遗传风险与体细胞克隆扩增存在协同相互作用,老年人中效应最强。这些发现为未来将体细胞突变状态纳入AMD风险分层提供依据,尤其在老年人中。
Ellipsoid zone (EZ) integrity is a key biomarker and surrogate for photoreceptor health, including in age-related macular degeneration. The objectives of this study were to determine (1) the association of baseline EZ measures with geographic atrophy (GA) progression and photoreceptor loss and (2) the impact of avacincaptad pegol (ACP), a complement inhibitor, on EZ integrity over the first year of treatment. Post hoc analysis of the phase II/III GATHER 1 and phase III GATHER 2 trials. Patients 50 years of age and older with non-center point-involving GA in the study eye. Spectral-domain OCT images were evaluated using advanced multilayer segmentation with certified reader validation for EZ integrity, measuring total EZ attenuation or loss (EZ to retinal pigment epithelium [RPE] thickness of 0 μm, i.e., total loss of EZ) and partial EZ attenuation or degradation (EZ-RPE thickness of ≤ 20 μm). Geographic atrophy lesion growth was assessed through fundus autofluorescence. A natural history assessment of progression of GA and total EZ attenuation in sham-treated eyes based on quartiles of baseline EZ measures and the impact of ACP versus sham on progression of total and partial EZ attenuation over 12 months were evaluated. This study included 292 eyes receiving ACP 2 mg and 332 eyes receiving sham therapy. In sham-treated eyes, mean GA growth and progression of total EZ attenuation were substantially greater in higher quartiles of baseline total EZ attenuation and partial EZ attenuation measures over 12 months. ACP 2 mg significantly reduced mean growth in total EZ attenuation by 19.5% (P = .0009) and mean growth in percentage of partial EZ attenuation by 55.3% (P < .0001) versus sham over 12 months. Greater baseline total and partial EZ attenuation were associated with higher rates of GA growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. ACP reduced EZ loss and degradation over 12 months versus sham. Ellipsoid zone measures may enhance identification of patients at high risk of disease progression who would benefit from early therapeutic intervention. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:椭圆体带(EZ)完整性是光感受器健康的关键生物标志物和替代指标,在年龄相关性黄斑变性中亦然。本研究旨在确定(1)基线EZ指标与地图样萎缩(GA)进展及光感受器丢失的关联;(2)补体抑制剂avacincaptad pegol(ACP)治疗第一年内对EZ完整性的影响。研究为II/III期GATHER 1试验和III期GATHER 2试验的事后分析。纳入研究眼为非中心点累及GA、年龄50岁及以上的患者。使用经认证阅片者验证的先进多层分割评估谱域OCT图像中的EZ完整性,测量总EZ衰减或丢失(EZ至视网膜色素上皮[RPE]厚度为0 μm,即EZ完全丢失)和部分EZ衰减或退化(EZ-RPE厚度≤20 μm)。通过眼底自发荧光评估GA病灶增长。评估基于基线EZ指标四分位数的假治疗眼GA进展和总EZ衰减的自然史,以及ACP与假治疗相比12个月内对总EZ衰减和部分EZ衰减进展的影响。研究纳入292只接受ACP 2 mg治疗的眼和332只接受假治疗的眼。在假治疗眼中,基线总EZ衰减和部分EZ衰减指标较高四分位者的12个月内平均GA增长和总EZ衰减进展明显更大。与假治疗相比,ACP 2 mg在12个月内使总EZ衰减的平均增长显著降低19.5%(P = .0009),使部分EZ衰减百分比的平均增长显著降低55.3%(P < .0001)。较高的基线总EZ衰减和部分EZ衰减与更高的GA增长率和随时间进展的EZ丢失相关,表明这些EZ指标是未来GA增长和光感受器丢失的重要预测因素。ACP在12个月内较假治疗减少了EZ丢失和退化。EZ指标可能有助于识别疾病进展高风险、可从早期治疗干预中获益的患者。专有或商业披露见文末脚注和披露部分。
To investigate intravitreal anti-VEGF drug use among Medicare Fee-For-Service (FFS) and Medicare Advantage (MA) beneficiaries. Retrospective, cross-sectional analysis of de-identified health care data from the American Academy of Ophthalmology's IRIS® Registry (Intelligent Research in Sight) for patient encounters between January 2017 and December 2022. Medicare beneficiaries 65 years of age and older with FFS or MA coverage with continuous insurance enrollment for at least 12 months. Unique FFS and MA beneficiaries receiving intravitreal anti-VEGF therapy were included. Patients were considered to be treated with a particular drug if more than 50% of the injections for at least 12 months were with that drug. For each anti-VEGF drug, we compared proportions of patients treated (> 50% of the injections) with that drug between FFS and MA groups and calculated the difference in use between the 2 Medicare health care programs. Differences in anti-VEGF drug use between FFS and MA groups. Nine hundred thirty thousand four hundred and eleven beneficiaries underwent 12 942 057 intravitreal injections. In the FFS group, aflibercept 2 mg was used most frequently (43.8%; n = 4 271 050), followed by bevacizumab (34.7%; n = 3 382 439), ranibizumab (20.6%; n = 2 008 791), brolucizumab (0.6%; n = 56 728), and faricimab (0.4%; n = 40 729). In the MA group, bevacizumab was used most frequently (45.1%; n = 1 436 151), followed by aflibercept 2 mg (37.8%; n = 1 201 311), ranibizumab (16.5%; n = 524 758), brolucizumab (0.4%; n = 13 406), and faricimab (0.2%; n = 6694). Repackaged bevacizumab (lower cost) was more common in the MA group compared with the FFS group (60.0% vs. 47.0%; difference, 13.0%; 95% confidence interval [CI], 12.8%-13.3%; P < 0.001). Higher-cost drugs were used significantly less often among those with MA compared with FFS coverage, respectively (aflibercept 2 mg, 28.9% vs. 36.6%; difference, -7.7%; 95% CI, -7.9% to -7.4%; P < 0.001), ranibizumab (11.9% vs. 16.8%; difference, -4.9%; 95% CI, -5.0% to -4.7%; P < 0.001), faricimab (0.06% vs. 0.24%; difference, -0.1%; 95% CI, -0.19% to -0.16%); P < 0.001), and brolucizumab (0.12% vs. 0.19%; difference, -0.01%; 95% CI, -0.09% to -0.05%; P < 0.001). Beneficiaries enrolled in MA were less likely to receive higher-cost anti-VEGF drugs, raising concerns about reduced beneficiary access to newer, more expensive anti-VEGF drugs among those with MA coverage. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:旨在探讨Medicare按服务付费(FFS)与Medicare Advantage(MA)受益者中玻璃体腔内抗VEGF药物的使用情况。研究为回顾性横断面分析,数据来自美国眼科学会IRIS®登记库(Intelligent Research in Sight)2017年1月至2022年12月间去标识化医疗数据。纳入65岁及以上、具有FFS或MA覆盖且连续参保至少12个月的Medicare受益者。纳入接受玻璃体腔内抗VEGF治疗的唯一FFS和MA受益者。若至少12个月内超过50%的注射使用某一药物,则认为患者接受该药治疗。针对每种抗VEGF药物,比较FFS组与MA组中接受该药治疗(超过50%的注射)的患者比例,并计算两种Medicare医疗计划之间使用差异。主要观察FFS组与MA组抗VEGF药物使用差异。共930411名受益者接受12942057次玻璃体腔内注射。FFS组中阿柏西普2 mg使用最多(43.8%;n=4271050),其次为贝伐珠单抗(34.7%;n=3382439)、雷珠单抗(20.6%;n=2008791)、布罗鲁珠单抗(0.6%;n=56728)和法瑞西单抗(0.4%;n=40729)。MA组中贝伐珠单抗使用最多(45.1%;n=1436151),其次为阿柏西普2 mg(37.8%;n=1201311)、雷珠单抗(16.5%;n=524758)、布罗鲁珠单抗(0.4%;n=13406)和法瑞西单抗(0.2%;n=6694)。与FFS组相比,MA组更常使用重新包装的贝伐珠单抗(成本较低)(60.0% vs. 47.0%;差异13.0%;95%置信区间12.8%-13.3%;P<0.001)。MA覆盖者中使用较高成本药物的比例显著低于FFS覆盖者,分别为阿柏西普2 mg(28.9% vs. 36.6%;差异-7.7%;95%置信区间-7.9%至-7.4%;P<0.001)、雷珠单抗(11.9% vs. 16.8%;差异-4.9%;95%置信区间-5.0%至-4.7%;P<0.001)、法瑞西单抗(0.06% vs. 0.24%;差异-0.1%;95%置信区间-0.19%至-0.16%;P<0.001)和布罗鲁珠单抗(0.12% vs. 0.19%;差异-0.01%;95%置信区间-0.09%至-0.05%;P<0.001)。参加MA的受益者接受较高成本抗VEGF药物的可能性较低,这引发了对MA覆盖者获取更新、更昂贵抗VEGF药物机会减少的担忧。本文脚注和文末披露部分可找到专有或商业披露。
基础研究 (3篇)
Drugs with glucagon-like peptide-1 (GLP-1) agonistic effects are beneficial for the treatment of diabetes and overweight but may be accompanied by an increased risk of vascular complications in the retina and the optic disc. The purpose of the present study was to investigate whether GLP-1 agonists can have vasoactive effects on retinal resistance vessels at different branching levels ex vivo and whether these effects depend on nitric oxide (NO). The diameters of retinal arterioles, precapillary arterioles, and capillaries were studied in perfused porcine hemiretinas ex vivo after intravascular administration of the GLP-1 agonists exendin-4, liraglutide, and semaglutide, alone and in the presence of the NO synthase inhibitor L-NAME. Exendin-4 had no significant effect on the diameter of retinal arterioles, precapillary arterioles, and capillaries (P > 0.77 for all comparisons). However, liraglutide and semaglutide induced a significant contraction of arterioles and a significant dilatation of precapillary arterioles and capillaries (P < 0.03 for all comparisons). These vasoactive effects disappeared in the presence of the NO synthase inhibitor L-NAME (P > 0.08 for all comparisons). GLP-1 agonists modified to reduce degradation and facilitate binding to plasma proteins can constrict larger and dilate smaller porcine retinal resistance vessels ex vivo. NO synthesis inhibition abolishes the effects, but the specific NO synthase isoform involved, the downstream signaling pathway, and the cellular source of NO remain to be determined. The observed vascular effects may contribute to mediating the adverse effects of GLP-1 agonists on the retina and the optic disc in clinical practice.
中文摘要:具有胰高血糖素样肽-1(GLP-1)激动作用的药物有利于糖尿病和超重治疗,但可能伴随视网膜和视盘血管并发症风险增加。本研究旨在体外观察GLP-1激动剂对不同分支级别视网膜阻力血管是否具有血管活性作用,以及这些作用是否依赖一氧化氮(NO)。在灌注的猪半视网膜体外标本中,经血管内给予GLP-1激动剂exendin-4、利拉鲁肽和司美格鲁肽,单独或与NO合酶抑制剂L-NAME共同存在,检测视网膜小动脉、毛细血管前小动脉和毛细血管直径。Exendin-4对视网膜小动脉、毛细血管前小动脉和毛细血管直径无显著影响(所有比较P > 0.77)。利拉鲁肽和司美格鲁肽引起小动脉显著收缩,并引起毛细血管前小动脉和毛细血管显著扩张(所有比较P < 0.03)。在NO合酶抑制剂L-NAME存在时,这些血管活性作用消失(所有比较P > 0.08)。经修饰以减少降解并促进与血浆蛋白结合的GLP-1激动剂可在体外使较大的猪视网膜阻力血管收缩,使较小的阻力血管扩张。抑制NO合成可消除这些作用,但涉及的具体NO合酶亚型、下游信号通路及NO的细胞来源仍有待确定。观察到的血管效应可能参与介导临床实践中GLP-1激动剂对视网膜和视盘的不良影响。
Age-related macular degeneration (AMD) remains a leading cause of irreversible blindness worldwide, characterized by the progressive breakdown of the outer blood-retinal barrier, accumulation of protein and lipid deposits in the subretinal space, and the consequential degeneration of macular photoreceptors. Geographic atrophy (GA) is one of the blinding end points of AMD. While current pharmaceutical interventions can slow lesion expansion or counter choroidal neovascularization, they fail to address the most significant clinical unmet need: regeneration of damaged retinal tissue to restore vision. Regenerative medicine via stem cell transplantation offers a definitive curative approach by replacing the structural and immune framework of the outer retina. This review synthesizes current advancements in human embryonic and pluripotent stem cells platforms engineered for outer retinal reconstruction. We evaluate the differentiation, culturing, and quality validation required to generate clinical-grade, polarized RPE monolayers and homeostatic microglia-like cells. Structurally, single-cell suspensions are contrasted against bioengineered patches, scaffold-free cell sheets, and advanced cell strips, analyzing how graft configuration dictates post-transplantation integration and visual recovery while balancing procedural adverse events like cell reflux and epiretinal membrane formation. Furthermore, this review addresses the microenvironmental challenges of transplanting allogeneic constructs into an inflamed, senescent host niche. We examine CRISPR-Cas9 genome editing paradigms, including cytosine base and prime editing, designed to rectify cell-intrinsic genetic vulnerabilities such as the complement factor H (CFH) risk variant. We highlight translational applications, such as knocking out the Class II transactivator to eliminate major histocompatibility complex class II (MHC-II) expression, which successfully circumvents host T-cell immune surveillance and prevents graft rejection in non-human primates. Additionally, we analyze how engineering an inhibitor-resistant colony-stimulating factor 1 receptor (CSF1R) point mutation enables exogenously administered microglia to robustly outcompete and replace maladaptive, pro-inflammatory host microglia under selective small-molecule pressure. Finally, we discuss future directions, emphasizing multi-lineage bilayered co-transplantation models that combine genome-edited RPE patches with homeostatic microglia or retinal organoids to achieve durable synaptic repair, alongside automated artificial intelligence manufacturing pipelines. Together, these combined structural, molecular, and immune-modulating strategies represent the next clinical frontier in restoring clear central vision and achieving permanent neurovascular rescue in advanced macular degeneration.
中文摘要:年龄相关性黄斑变性(AMD)仍是全球不可逆盲的主要原因,其特征为外层血-视网膜屏障进行性破坏、蛋白质和脂质沉积物在视网膜下间隙积聚,以及随之发生黄斑区光感受器变性。地图样萎缩(GA)是AMD致盲终点之一。现有药物干预可减缓病灶扩大或抑制脉络膜新生血管,但未能解决最突出的临床未满足需求:再生受损视网膜组织以恢复视力。通过干细胞移植开展的再生医学,有望替换外层视网膜的结构与免疫框架,从而实现确定性治愈。本综述汇总用于外层视网膜重建的人胚胎干细胞和多能干细胞平台进展,评估生成临床级极化RPE单层和稳态小胶质细胞样细胞所需的定向分化、培养与质量验证。结构方面,将单细胞悬液与生物工程补片、无支架细胞片和先进细胞条带进行对比,分析移植构型如何决定移植后整合与视力恢复,同时权衡细胞反流和视网膜前膜形成等操作相关不良事件。综述还讨论将同种异体构建物移植到炎症化、衰老宿主微环境所面临的微环境挑战。综述审视CRISPR-Cas9基因组编辑范式,包括胞嘧啶碱基编辑和先导编辑,旨在纠正补体因子H(CFH)风险变异等细胞内在遗传易感因素。转化应用包括敲除II类反式激活因子以消除主要组织相容性复合体II类(MHC-II)表达,从而在非人灵长类中成功规避宿主T细胞免疫监视并防止移植物排斥。综述还分析工程化抗抑制剂的集落刺激因子1受体(CSF1R)点突变如何使外源给予的小胶质细胞在选择性小分子压力下强效竞争并替换适应不良、促炎的宿主小胶质细胞。未来方向强调多谱系双层共移植模型,将基因组编辑RPE补片与稳态小胶质细胞或视网膜类器官结合,以实现持久突触修复,并配合自动化人工智能制造流程。这些结构、分子和免疫调节策略共同构成恢复清晰中心视力、在晚期黄斑变性中实现永久神经血管挽救的下一个临床前沿。
Diabetic retinopathy (DR) is one of the leading causes of vision loss worldwide, making early and accurate DR grading critical for timely intervention. Recent clinical practices leverage multi-view fundus images for DR detection with a wide coverage of the field of view (FOV), motivating deep learning methods to explore the potential of multi-view learning for DR grading. However, existing methods often overlook the inter-view correlations when fusing multi-view fundus images, failing to fully exploit the inherent consistency across views originating from the same patient. In this work, we present MVGFDR, an end-to-end Multi-View Graph Fusion framework for DR grading. Different from existing methods that directly fuse visual features from multiple views, MVGFDR is equipped with a novel Multi-View Graph Fusion (MVGF) module to explicitly disentangle the shared and view-specific visual features. Specifically, MVGF comprises three key components: ① Multi-view Graph Initialization, which constructs visual graphs via residual-guided connections and employs Discrete Cosine Transform (DCT) coefficients as frequency-domain anchors; ② Multi-view Graph Fusion, which integrates selective nodes across multi-view graphs based on frequency-domain relevance to capture complementary view-specific information; and ③ Masked Cross-view Reconstruction, which leverages masked reconstruction of shared information across views to facilitate view-invariant representation learning. Extensive experimental results on MFIDDR, by far the largest multi-view fundus image dataset, demonstrate that the proposed approach achieves state-of-the-art overall performance for diabetic retinopathy grading. Code is available at https://github.com/HaoranLi525/MVGFDR.
中文摘要:糖尿病视网膜病变(DR)是全球视力丧失的主要原因之一,早期、准确的DR分级对及时干预至关重要。近期临床实践利用宽视野的多视角眼底图像进行DR检测,推动深度学习方法探索多视角学习在DR分级中的潜力。现有方法在融合多视角眼底图像时常常忽略视角间的相关性,未能充分利用同一患者不同视角之间固有的一致性。本研究提出MVGFDR,一个用于DR分级的端到端多视角图融合框架。与直接融合多个视角视觉特征的现有方法不同,MVGFDR配备新颖的多视角图融合(MVGF)模块,以显式解耦共享视觉特征与视角特有视觉特征。具体而言,MVGF包含三个关键部分:①多视角图初始化,通过残差引导连接构建视觉图,并采用离散余弦变换(DCT)系数作为频域锚点;②多视角图融合,基于频域相关性整合多视角图中的选择性节点,以捕获互补的视角特有信息;③掩蔽跨视角重建,利用跨视角共享信息的掩蔽重建促进视角不变表示学习。在迄今最大的多视角眼底图像数据集MFIDDR上的大量实验结果表明,所提方法在DR分级上取得最先进的整体性能。代码可在https://github.com/HaoranLi525/MVGFDR获取。
2青光眼 (15篇)
临床研究 (11篇)
Glaucoma, a leading cause of irreversible blindness, involves progressive retinal ganglion cell loss. Early detection of this neurodegeneration is critical, yet current clinical methods often identify disease only after substantial damage has occurred. This preliminary study used high-resolution adaptive optics-optical coherence tomography (AO-OCT) to track individual retinal ganglion cells in patients and healthy volunteers over 3 to 5 years. Results revealed higher neurodegeneration in glaucoma compared to normal aging. We observed 4.16 to 6.86% annual decrease in cell density in glaucoma, far exceeding the 0.27% cell loss rate observed in the healthy volunteer group. Critically, AO-OCT detected progression significantly earlier, identifying cell loss 0.74 years before conventional OCT and 1.49 years before visual field testing. These findings demonstrate AO-OCT as a more sensitive tool capable of monitoring glaucomatous damage with superior precision, potentially representing a major advancement over current clinical imaging.
中文摘要:青光眼是不可逆性盲的主要原因之一,以视网膜神经节细胞进行性丢失为特征。早期发现这种神经变性至关重要,但目前的临床方法往往在损害已相当明显后才识别出疾病。这项初步研究采用高分辨率自适应光学相干断层扫描(AO-OCT),对患者与健康志愿者进行为期3至5年的个体视网膜神经节细胞追踪。结果显示,青光眼患者的神经变性程度高于正常衰老。我们观察到青光眼患者细胞密度每年下降4.16%至6.86%,远高于健康志愿者组0.27%的细胞丢失率。关键在于,AO-OCT能显著更早地检出进展,比常规OCT提前0.74年、比视野检查提前1.49年发现细胞丢失。这些结果说明AO-OCT是一种更敏感的工具,能以更高精度监测青光眼性损害,可能代表对现有临床成像手段的重要提升。
To determine whether trabeculotomy is noninferior to combined trabeculotomy-trabeculectomy (CTT) for primary congenital glaucoma (PCG) with a horizontal corneal diameter (HCD) of 12-14 mm. Prospective, randomized, controlled noninferiority trial. Children from birth through 3 years of age with PCG, a HCD of 12 to 14 mm, and no previous intraocular or laser surgery were eligible. Two hundred and forty-eight children were enrolled from January 2015 through April 2021, and the final follow-up was completed in April 2024. One eligible eye per child was randomly assigned in a 1:1 ratio to trabeculotomy or CTT. The primary outcome was qualified surgical success at 36 months, defined as an intraocular pressure (IOP) of 5 to 21 mmHg with or without glaucoma medications, without vision-threatening complications or additional glaucoma surgery. The noninferiority margin was -15 percentage points. Exploratory secondary outcomes included changes in IOP, ocular morphometric and functional outcomes, and adverse events. Overall, 124 children were assigned to trabeculotomy (mean age, 9.8 months; 76.6% male) and 124 to CTT (mean age, 9.9 months; 68.5% male). In the intention-to-treat population, qualified success at 36 months was achieved in 102 of 124 eyes (82.3%) in the trabeculotomy group and 105 of 124 eyes (84.7%) in the CTT group (risk difference: -2.4%; 95%CI, -11.7 to 6.9; Pnoninferiority= 0.004). Corresponding rates in the per-protocol population were 90.3% and 92.9%, respectively (risk difference -2.6%; 95%CI -10.3 to 4.9; Pnoninferiority< 0.001). Mean IOP reduction was -12.1 mm Hg (95%CI, -12.9 to -11.4) and -13.2 mm Hg (95%CI, -14.0 to -12.4) in the trabeculotomy and CTT groups, respectively (P=0.067). No statistically significant between-group differences were observed in other secondary outcomes. Adverse events occurred in 56 children (45.2%) in the trabeculotomy group and 67 (54.0%) in the CTT group (P = 0.162). Hyphema was the most common adverse event in both groups, and most cases resolved spontaneously. Trabeculotomy was noninferior to CTT for qualified surgical success at 36 months in PCG patients with a HCD of 12-14 mm. These findings suggest that trabeculotomy may be an alternative to CTT in this population.
中文摘要:确定对于水平角膜直径(HCD)12-14 mm 的原发性先天性青光眼(PCG),小梁切开术是否不劣于小梁切开联合小梁切除术(CTT)。前瞻性、随机、对照非劣效性试验。出生至3岁、PCG、HCD 12至14 mm、既往无眼内或激光手术的儿童符合条件。2015年1月至2021年4月纳入248名儿童,最终随访于2024年4月完成。每名儿童一只符合条件眼按1:1随机分配至小梁切开术或CTT。主要结局为36个月时的合格手术成功,定义为眼压5至21 mmHg,使用或不使用青光眼药物,无威胁视力并发症或额外青光眼手术。非劣效界值为-15个百分点。探索性次要结局包括眼压变化、眼部形态测量与功能结局及不良事件。总体124名儿童分配至小梁切开术(平均年龄9.8个月;76.6%男性),124名至CTT(平均年龄9.9个月;68.5%男性)。意向治疗人群中,36个月合格成功在小梁切开术组为102/124眼(82.3%),CTT组为105/124眼(84.7%)(风险差-2.4%;95%CI -11.7至6.9;非劣效性P=0.004)。符合方案人群相应成功率分别为90.3%和92.9%(风险差-2.6%;95%CI -10.3至4.9;非劣效性P<0.001)。平均眼压降幅在小梁切开术组和CTT组分别为-12.1 mmHg(95%CI -12.9至-11.4)和-13.2 mmHg(95%CI -14.0至-12.4)(P=0.067)。其他次要结局未观察到统计学显著组间差异。不良事件在小梁切开术组发生56名儿童(45.2%),CTT组67名(54.0%)(P=0.162)。前房积血是两组最常见不良事件,多数自行缓解。对于HCD 12-14 mm的PCG患者,小梁切开术在36个月合格手术成功方面不劣于CTT。这些发现提示在该人群中小梁切开术可作为CTT的替代选择。
To determine whether baseline macular ganglion cell-inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thickness add prognostic value for glaucomatous visual field (VF) damage in patients with ocular hypertension. Retrospective clinical cohort study. 330 eyes of 235 patients with ocular hypertension, defined by intraocular pressure of 22 mmHg or higher or an International Classification of Diseases coded diagnosis, without repeatable glaucomatous VF damage at baseline. Eyes came from both the African Descent and Glaucoma Evaluation Study and a clinical cohort at the Shiley Eye Institute. Baseline GCIPL and cpRNFL thickness were measured from the first good-quality Cirrus optical coherence tomography (OCT) macular and optic-disc cubes. Clinical predictors were assessed with the Ocular Hypertension Treatment Study (OHTS)-European Glaucoma Prevention Study (EGPS) Risk Calculator. Repeatable glaucomatous VF damage required a Glaucoma Hemifield Test outside normal limits or a pattern standard deviation at the 5% level or worse on three consecutive reliable Humphrey 24-2 examinations. Hazard ratios per 1 standard deviation (SD) of thinner global and sectoral GCIPL or cpRNFL, and the change in the Harrell concordance (C) index (ΔC) after adding each measure to the Risk Calculator. Glaucomatous VF damage developed in 47 of 330 eyes (14%) over a median 4.4 years. Adjusted for the Risk Calculator, thinner macular GCIPL was associated with conversion (hazard ratio [HR] 1.89 per 1-SD thinner; 95% confidence interval [CI], 1.50 to 2.37; P < .001), and every macular sector was significant (HR 1.71 to 2.02). The Risk Calculator alone showed modest discrimination (Harrell C-index, 0.57). Adding macular GCIPL improved discrimination (ΔC +0.101; 95% CI, +0.022 to +0.220). Global cpRNFL thickness did not improve discrimination (ΔC +0.004; 95% CI, -0.021 to +0.133); among cpRNFL quadrants, only the inferior quadrant was associated with conversion (HR 1.50; 95% CI, 1.02 to 2.22). In patients with ocular hypertension, thinner baseline macular GCIPL was associated with glaucomatous VF damage and improved the discrimination of the OHTS-EGPS Risk Calculator, whereas global cpRNFL thickness did not.
中文摘要:评估基线黄斑区神经节细胞-内丛状层(GCIPL)及视盘周围视网膜神经纤维层(cpRNFL)厚度是否能为高眼压症患者发生青光眼性视野(VF)损害提供额外预后价值。回顾性临床队列研究。纳入235例高眼压症患者的330只眼,高眼压症定义为眼压≥22 mmHg或具有国际疾病分类编码诊断,且基线无可重复的青光眼性VF损害。眼别来自African Descent and Glaucoma Evaluation Study及Shiley Eye Institute临床队列。基线GCIPL和cpRNFL厚度取首次高质量Cirrus光学相干断层扫描(OCT)黄斑及视盘扫描立方体测量。临床预测因素采用Ocular Hypertension Treatment Study(OHTS)-European Glaucoma Prevention Study(EGPS)风险计算器评估。可重复的青光眼性VF损害要求连续三次可靠Humphrey 24-2检查中青光眼半视野检测超出正常范围或模式标准差处于5%水平或更差。指标为整体及分区GCIPL或cpRNFL每薄1个标准差(SD)的风险比,以及将各测量加入风险计算器后Harrell一致性(C)指数的变化(ΔC)。中位4.4年内,330只眼中47只眼(14%)发生青光眼性VF损害。校正风险计算器后,较薄黄斑GCIPL与转化相关(风险比[HR] 1.89/每薄1-SD;95%置信区间[CI] 1.50至2.37;P < .001),各黄斑分区均有统计学意义(HR 1.71至2.02)。单用风险计算器区分度有限(Harrell C指数0.57)。加入黄斑GCIPL改善区分度(ΔC +0.101;95% CI +0.022至+0.220)。整体cpRNFL厚度未改善区分度(ΔC +0.004;95% CI -0.021至+0.133);cpRNFL各象限中仅下方象限与转化相关(HR 1.50;95% CI 1.02至2.22)。在高眼压症患者中,基线较薄黄斑GCIPL与青光眼性VF损害相关,并改善OHTS-EGPS风险计算器的区分度,而整体cpRNFL厚度未见此作用。
To externally validate a deep-learning (DL) algorithm detecting perimetric glaucoma on color fundus photographs (CFPs) in a population-based cohort. External validation in a prospective population-based cohort. Participants aged 50-80 years from three Rotterdam Study cohorts. We applied the winning Artificial Intelligence for Robust Glaucoma Screening (AIROGS) challenge algorithm, trained on 101,442 macula-centered CFPs to detect referable presumed perimetric glaucoma. Performance was assessed at eye and participant level, with participant-level cluster bootstrap confidence intervals. Misclassified cases underwent qualitative review. Longitudinal detection was evaluated by Kaplan-Meier analysis. Additionally, paired analyses compared macula- with disc-centered CFPs. A post-hoc analysis examined the effect of image quality on positive predictive value (PPV). Sensitivity at 95% specificity, area under the receiver operating characteristic curve (ROC-AUC), partial AUC (pAUC) for 90-100% specificity, PPV, and precision-recall AUC (PR-AUC). Among 19,088 eyes (9,837 participants), 201 eyes (1.1%) had perimetric glaucoma. At eye level, sensitivity at 95% specificity was 70.6% (95% CI: 63.8-76.8), with an ROC-AUC of 0.911 (95% CI: 0.887-0.934) and a PR-AUC of 0.343 (95% CI: 0.274-0.427). At participant level, sensitivity was 68.8% (95% CI: 61.8-75.9) and ROC-AUC 0.909 (95% CI: 0.882-0.934). Overall, this resulted in 5.1 referrals per detected glaucoma case. True positives showed more advanced visual field damage than false negatives (median mean deviation -10.8 vs -5.8 dB; P < 0.001). Among true positives with prior imaging, 33 of 61 (54%) were flagged before conversion, typically 4-7 years before diagnosis. Discrimination in the 90-100% specificity range was higher for disc- than macula-centered CFPs (pAUC 0.860 vs 0.802; P = 0.003). PPV improved substantially after excluding CFPs with incomplete optic nerve head (ONH) visibility. The DL-algorithm achieved meaningful discrimination for perimetric glaucoma in an external population-based dataset. Correctly identified cases were frequently flagged at an earlier examination, years before the perimetric diagnosis. Despite having been trained exclusively on macula-centered CFPs, the DL-algorithm showed no loss of discriminative performance on disc-centered CFPs. Incomplete ONH visibility was an important source of false positives. These findings support CFP-based deep learning as a scalable triage tool for glaucoma screening and highlight image acquisition standards for implementation.
中文摘要:在基于人群的队列中对一种在彩色眼底照片(CFP)上检测视野性青光眼的深度学习(DL)算法进行外部验证。研究为前瞻性基于人群队列中的外部验证。参与者为来自三个鹿特丹研究队列、年龄50—80岁的人群。我们应用人工智能稳健青光眼筛查(AIROGS)挑战赛获胜算法,该算法在101,442张以黄斑为中心的CFP上训练,用于检测可转诊的疑似视野性青光眼。分别在眼水平和参与者水平评估性能,参与者水平采用聚类自助法置信区间。对误分类病例进行定性复核。用Kaplan-Meier分析评估纵向检测。另做配对分析比较以黄斑为中心与以视盘为中心的CFP。事后分析考察图像质量对阳性预测值(PPV)的影响。指标包括95%特异度下的敏感度、受试者工作特征曲线下面积(ROC-AUC)、90—100%特异度范围的部分AUC(pAUC)、PPV和精确率-召回率AUC(PR-AUC)。在19,088只眼(9,837名参与者)中,201只眼(1.1%)存在视野性青光眼。眼水平95%特异度下敏感度为70.6%(95% CI:63.8—76.8),ROC-AUC为0.911(95% CI:0.887—0.934),PR-AUC为0.343(95% CI:0.274—0.427)。参与者水平敏感度为68.8%(95% CI:61.8—75.9),ROC-AUC为0.909(95% CI:0.882—0.934)。总体上每检出1例青光眼对应5.1次转诊。真阳性者视野损伤较假阴性者更重(平均偏差中位数 -10.8 vs -5.8 dB;P < 0.001)。在既往有影像的真阳性者中,61例中有33例(54%)在转化前即被标记,通常在诊断前4—7年。90—100%特异度范围内的判别能力在以视盘为中心的CFP上高于以黄斑为中心的CFP(pAUC 0.860 vs 0.802;P = 0.003)。排除视神经乳头(ONH)可见不完整的CFP后,PPV明显提高。该DL算法在外部基于人群数据集中对视野性青光眼取得有意义的判别能力。被正确识别的病例常在更早一次检查中即被标记,早于视野性诊断数年。尽管仅用以黄斑为中心的CFP训练,该DL算法在以视盘为中心的CFP上未见判别性能下降。ONH可见不完整是假阳性的重要来源。这些发现支持基于CFP的深度学习作为青光眼筛查的可扩展分诊工具,并提示实施中需关注图像采集标准。
To determine the minimal duration of remote intraocular pressure (IOP) monitoring needed to yield accurate IOP fluctuation metrics in patients. Secondary modeling analysis of retrospective data, validated with a large national database. 397 patients from the Moran Eye Center and/or Wilmer Eye Institute and 1,579 patients from a MyEyes CorporationTM database who utilized an iCare HOME/HOME2 tonometer and recorded ≥3 measurements throughout each day over several consecutive days. Bootstrapped progressive day-censorship analyses and exponential decay modeling were used to estimate the number of monitoring days required to achieve 95% of the maximal model-based reduction in error for IOP metrics, including mean, maximum, range, and standard deviation (SD). Ground truth for each metric was defined using all available measurements within each eye-specific monitoring period. Sensitivity analyses assessing the effects of diagnosis, treatment, and three daily IOP measurements were also completed. Mean absolute error (MAE) and mean relative error (MRE) for IOP mean, maximum, range, and SD; the number of monitoring days required to achieve 95% of the maximal model-based reduction in error. Across both datasets, approximately 6-7 monitoring days were required to achieve 95% of the modeled reduction in error for daily mean, maximum, range, and SD of IOP in the primary analysis. Sensitivity analyses demonstrated longer monitoring requirements in primary open-angle glaucoma (9.1-10.0 days) compared with glaucoma suspects (5.5-6.7 days), secondary open-angle glaucoma (6.4-8.0 days), and primary angle-closure glaucoma (7.8-8.3 days). Monitoring durations remained relatively consistent before and after selective laser trabeculoplasty (8.4-9.0 days) and Hydrus microstent implantation (6.0-6.8 days). Restricting measurements to only three daily IOP recordings throughout the day extended monitoring duration to approximately 10 days in the Moran/Wilmer dataset and longer in the MyEyes dataset. Additionally, 74.1% of peak IOP measurements occurred outside typical clinic hours. Remote tonometry provides clinically meaningful characterization of IOP metrics beyond traditional office-based measurements. Depending on the clinical context, seven to ten consecutive monitoring days consisting of measurements across each day are needed to represent a patient's true IOP pattern.
中文摘要:为确定在患者中获得准确眼压波动指标所需的最短远程眼压监测时长,研究对回顾性数据进行了二次建模分析,并用大型全国数据库验证。数据包括来自Moran Eye Center和/或Wilmer Eye Institute的397例患者,以及MyEyes Corporation数据库中的1579例患者;这些患者使用iCare HOME/HOME2眼压计,并在连续数天内每天记录至少3次测量。研究采用自助法渐进式天数删失分析和指数衰减模型,估算使眼压均值、最大值、范围及标准差等指标的模型误差下降达到最大降幅95%所需的监测天数。每个指标的真实值定义为每只眼在相应监测期内所有可用测量结果。敏感性分析评估诊断、治疗以及每日3次眼压测量的影响。主要结局为眼压均值、最大值、范围和标准差的平均绝对误差与平均相对误差,以及达到模型误差最大降幅95%所需的监测天数。两个数据集中,主要分析显示眼压日间均值、最大值、范围及标准差达到模型误差最大降幅95%约需6至7个监测日。敏感性分析显示,原发性开角型青光眼所需监测时间较长,为9.1至10.0天;青光眼可疑者为5.5至6.7天,继发性开角型青光眼为6.4至8.0天,原发性闭角型青光眼为7.8至8.3天。选择性激光小梁成形术前后所需监测时长相对一致,为8.4至9.0天;Hydrus微支架植入前后为6.0至6.8天。将测量限制为每天仅3次眼压记录时,Moran/Wilmer数据集所需监测时长延长至约10天,MyEyes数据集更长。74.1%的眼压峰值测量发生在常规门诊时间之外。远程眼压测量可提供超出传统诊室测量的、具有临床意义的眼压指标特征。根据临床情境,连续7至10个监测日并覆盖每日多个时间点的测量,才能反映患者真实的眼压模式。
To evaluate 10-year risk trajectories of newly diagnosed neurodegenerative diseases among glaucoma patients across age-stratified cohorts and clinical subtypes. Retrospective cohort study. Using TriNetX data (2005-2025), glaucoma patients were propensity-matched 1:1 to controls based on baseline demographics, comorbidities, medications, and laboratory metrics. Outcomes were defined using International Classification of Diseases, Tenth Revision codes. Risks for mild cognitive impairment (MCI), Alzheimer's disease (AD), vascular dementia (VD), unspecified dementias, and Parkinson's disease (PD) were assessed. Cohorts were stratified by age (<45 vs >65 years) and subtype (primary open-angle [POAG], primary angle-closure [PACG], and normal-tension [NTG] glaucoma). 1-, 3-, 5-, and 10-year hazard ratios (HRs) and 95% confidence intervals (CIs). Among 384,256 matched pairs, glaucoma correlated with elevated 10-year risks for AD (HR = 1.485; 95% CI,1.427-1.546; P < .001), VD (HR = 1.213; 95% CI, 1.159-1.27; P < .001), and a delayed PD risk peaking at 10 years (HR = 1.115; 95% CI, 1.066-1.167; P < .001). AD and VD risks emerged early in late-onset glaucoma but showed delayed emergence in early-onset patients, where AD risk peaked at 10 years (HR = 2.320; P = .03). Subtype analysis revealed no significant AD associations for POAG (HR = 1.044; P = .10), PACG (HR = 1.096; P = .13), or NTG (HR = 1.097; P = .19). However, VD risk was elevated in POAG (HR = 1.203; 95% CI, 1.129-1.281; P < .001) and PACG (HR = 1.224; 95% CI, 1.056-1.419; P = .007), but not NTG (P = .08). MCI risk increased in POAG (HR = 1.201; 95% CI, 1.120-1.288; P < .001) and NTG (HR = 1.235; 95% CI, 1.089-1.401; P = .001). NTG demonstrated the only significant PD association (HR = 1.283; 95% CI, 1.043-1.577; P = .018), while POAG (P = .05) and PACG (P = .58) showed no correlation. All 3 subtypes maintained significant associations with unspecified dementia (all P < .05). Glaucoma is observationally associated with subsequent neurodegenerative diagnoses, with statistical trajectories varying by onset age and clinical subtype. These findings indicate population-level correlations rather than causal mechanistic linkages.
中文摘要:评估青光眼患者中新诊断神经退行性疾病在年龄分层队列和临床亚型中的10年风险轨迹。回顾性队列研究。使用TriNetX数据(2005-2025),青光眼患者根据基线人口学、合并症、药物和实验室指标与对照1:1倾向匹配。结局采用国际疾病分类第十版编码定义。评估轻度认知障碍(MCI)、阿尔茨海默病(AD)、血管性痴呆(VD)、未特指痴呆和帕金森病(PD)风险。队列按年龄(<45岁 vs >65岁)和亚型(原发性开角型[POAG]、原发性闭角型[PACG]和正常眼压型[NTG]青光眼)分层。计算1、3、5、10年风险比(HR)和95%置信区间(CI)。在384,256对匹配人群中,青光眼与10年AD风险升高相关(HR=1.485;95%CI 1.427-1.546;P<.001)、VD风险升高(HR=1.213;95%CI 1.159-1.27;P<.001),以及PD风险延迟升高、在10年达到峰值(HR=1.115;95%CI 1.066-1.167;P<.001)。晚发型青光眼中AD和VD风险出现较早,早发型患者中则延迟出现,其中AD风险在10年达到峰值(HR=2.320;P=.03)。亚型分析显示POAG(HR=1.044;P=.10)、PACG(HR=1.096;P=.13)或NTG(HR=1.097;P=.19)均无显著AD关联。但VD风险在POAG(HR=1.203;95%CI 1.129-1.281;P<.001)和PACG(HR=1.224;95%CI 1.056-1.419;P=.007)中升高,NTG中未升高(P=.08)。MCI风险在POAG(HR=1.201;95%CI 1.120-1.288;P<.001)和NTG(HR=1.235;95%CI 1.089-1.401;P=.001)中增加。NTG是唯一显示显著PD关联的亚型(HR=1.283;95%CI 1.043-1.577;P=.018),POAG(P=.05)和PACG(P=.58)无相关。三种亚型均与未特指痴呆保持显著关联(均P<.05)。观察性结果显示青光眼与后续神经退行性疾病诊断相关,统计轨迹随发病年龄和临床亚型变化。这些发现提示人群水平的相关性,而非因果机制联系。
To evaluate the epidemiology of acute angle-closure crisis (AACC), the safety of pharmacologic dilation, and medication-associated AACC risk in the United States. Retrospective clinical cohort study. Adults (≥18 years) in a multicenter federated electronic health record network. Using deidentified electronic medical record data from 2010 to 2025, AACC cases were identified using ICD-10-CM codes followed by definitive therapeutic intervention within 14 days. Incidence, prevalence, and diagnostic trends were evaluated with Mann-Kendall tests. Dilation-associated AACC risk was assessed among patients undergoing dilation-associated ophthalmic examinations, with incident AACC identified within 14 days (with 24-hour sensitivity analysis). Medication-associated AACC risk was evaluated using active-comparator cohorts with 1:1 propensity score matching and Cox proportional hazards models over a 30-day window. AACC incidence (per 100,000 dilation-associated examinations) and hazard ratios (HRs) with 95% confidence intervals (CIs) for medication-associated AACC risk. From 2010 to 2025, the cumulative incidence of AACC was 0.014%, and the prevalence of primary angle-closure glaucoma (PACG) among patients with AACC was 16.7%. AACC incidence and the prevalence of PACG among patients with AACC increased over time (all P < .001). Gonioscopy utilization declined, whereas anterior segment imaging increased (all P < .001). Across 3,400,372 dilation-associated examinations among 2,444,570 patients, post-dilation AACC was rare (3.1 per 100,000; 95% CI: 2.3-3.7), with similar findings in a 24-hour sensitivity analysis; events concentrated among patients with anatomical risk factors. Increased AACC risk was observed for medications with established associations and some with less established associations, including lactulose (HR: 1.67), metoclopramide (1.38), sumatriptan (1.64), prazosin (1.32), and terazosin (1.77) (all P < .05). Previously unreported associations were observed for calcitonin gene-related peptide (CGRP) monoclonal antibodies (erenumab [1.33]), calcium channel blockers (CCBs) (verapamil [1.89], diltiazem [1.74]), and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab [1.54], evolocumab [1.46]) (all P < .05). AACC following pharmacologic dilation was rare and occurred predominantly among anatomically predisposed patients, supporting the safety of dilation in routine care. Medication-associated risk signals highlight the importance of proactive ocular risk assessment and medication reconciliation. Novel associations with CCBs, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation.
中文摘要:评估美国急性闭角型危象(AACC)的流行病学、药物散瞳的安全性以及药物相关AACC风险。回顾性临床队列研究。研究对象为多中心联邦制电子健康记录网络中18岁及以上成人。利用2010至2025年去标识化电子病历数据,以ICD-10-CM编码并结合14天内确定性治疗干预识别AACC病例。采用Mann-Kendall检验评估发病率、患病率及诊断趋势。在接受散瞳相关眼科检查的患者中评估散瞳相关AACC风险,识别14天内新发AACC,并进行24小时敏感性分析。药物相关AACC风险采用活性对照队列、1:1倾向评分匹配及30天窗口内的Cox比例风险模型评估。主要指标为AACC发病率(每10万次散瞳相关检查)及药物相关AACC风险的风险比(HR)与95%置信区间(CI)。2010至2025年,AACC累积发病率为0.014%,AACC患者中原发性闭角型青光眼(PACG)患病率为16.7%。AACC发病率及AACC患者中PACG患病率随时间上升(均P<.001)。房角镜检查使用率下降,而前节影像检查增加(均P<.001)。在2,444,570例患者的3,400,372次散瞳相关检查中,散瞳后AACC罕见(每10万次3.1例;95%CI:2.3-3.7),24小时敏感性分析结果相似;事件集中于具有解剖危险因素的患者。已明确相关药物及部分相关性较弱的药物均观察到AACC风险升高,包括乳果糖(HR:1.67)、甲氧氯普胺(1.38)、舒马曲普坦(1.64)、哌唑嗪(1.32)与特拉唑嗪(1.77)(均P<.05)。还观察到既往未报道的相关性:降钙素基因相关肽(CGRP)单克隆抗体(依瑞奈尤单抗[1.33])、钙通道阻滞剂(CCB)(维拉帕米[1.89]、地尔硫䓬[1.74])及前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)抑制剂(阿利西尤单抗[1.54]、依洛尤单抗[1.46])(均P<.05)。药物散瞳后AACC罕见,且主要发生于解剖易感患者,支持常规诊疗中散瞳的安全性。药物相关风险信号提示应主动开展眼部风险评估与用药核对。CCB、CGRP单克隆抗体及PCSK9抑制剂的新关联值得进一步研究。
To determine whether the relationship between intraocular pressure (IOP) and the rate of visual field progression (ROP) differs according to ancestry. Retrospective cohort study. A total of 794 participants (1382 eyes) from the African Descent and Glaucoma Evaluation Study (ADAGES), including 478 glaucoma patients (696 eyes) and 555 glaucoma suspects (838 eyes). Participants self-identified as being of African descent (AD, n = 287) or European descent (ED, n = 507). A sliding-window framework was used to estimate moment-specific ROP from longitudinal visual field data. Multivariable mixed-effects linear regression was used to assess the main and interactive effects of race, IOP, age, gender, central corneal thickness, and mean deviation on ROP. Stratified analyses were performed to evaluate effect modification by ancestry, age, IOP, and disease severity. ROP per millimeter of mercury (mm Hg) IOP change (dB/y/mm Hg). In glaucomatous eyes, a higher IOP was associated with faster progression (β = -0.025 dB/y per mm Hg; P < .001). Race modified this relationship (race × IOP interaction β = 0.023 dB/y per mm Hg; P = .012), with steeper IOP-ROP slopes in AD (-0.014 dB/y per mm Hg; P < .001) than ED (-0.003 dB/y per mm Hg; P > .05) individuals. The difference was most pronounced in older and more advanced eyes; in severe glaucoma, each 1-mm Hg IOP increase corresponded to an increase in ROP (-0.044 dB/y in AD vs -0.032 dB/y in ED eyes; both P < .001). Racial differences in IOP sensitivity attenuated after trabeculectomy, and ROP in glaucoma suspects had little dependency on IOP. Glaucoma progression in response to IOP alteration differs between individuals of AD and ED, particularly at older ages and with greater disease severity. Reconsideration of IOP-targeting strategies that incorporate ancestry, age, and disease severity may be beneficial to reduce disparities in glaucoma outcomes in the future.
中文摘要:确定眼压(IOP)与视野进展速率(ROP)之间的关系是否因血统背景而异。回顾性队列研究。共纳入非洲裔与青光眼评估研究(ADAGES)的794名参与者(1382只眼),包括478例青光眼患者(696只眼)和555例青光眼可疑者(838只眼)。参与者自我认同为非洲裔(AD,n=287)或欧洲裔(ED,n=507)。采用滑动窗口框架从纵向视野数据估计特定时刻的ROP。多变量混合效应线性回归用于评估种族、IOP、年龄、性别、中央角膜厚度和平均偏差对ROP的主效应及交互效应。进行分层分析以评估血统背景、年龄、IOP和疾病严重程度的效应修饰。ROP以每毫米汞柱(mm Hg)IOP变化对应的dB/y表示(dB/y/mm Hg)。在青光眼眼中,较高的IOP与更快的进展相关(β=-0.025 dB/y每mm Hg;P<.001)。种族修饰了这一关系(种族×IOP交互β=0.023 dB/y每mm Hg;P=.012),AD个体的IOP-ROP斜率更陡(-0.014 dB/y每mm Hg;P<.001),高于ED个体(-0.003 dB/y每mm Hg;P>.05)。差异在年龄较大和更晚期眼中最明显;在重度青光眼中,IOP每增加1 mm Hg对应ROP增加(AD眼-0.044 dB/y vs ED眼-0.032 dB/y;均P<.001)。小梁切除术后IOP敏感性的种族差异减弱,青光眼可疑者的ROP对IOP依赖很小。AD与ED个体对IOP变化的青光眼进展反应不同,尤其在年龄较大和疾病严重程度较高时。重新考虑纳入血统背景、年龄和疾病严重程度的IOP目标策略,可能有助于未来减少青光眼结局差异。
To compare, in the context of a population-scale biobank, associations of established risk factors and severity biomarkers with different glaucoma disease definitions. Observational cohort study. Five hundred three thousand three hundred twenty-five participants in the UK Biobank. Odds ratios (ORs) for associations of established risk factors (corneal-compensated intraocular pressure [IOPcc] and polygenic risk score [PRS]) and clinical biomarkers of disease severity (macular retinal nerve fiber layer [mRNFL] and macular ganglion cell layer [mGCL] thickness) with different glaucoma definitions. Participants without glaucoma (n = 481 772) were compared with those with: (1) a diagnosis of glaucoma based on self-report or hospital inpatient or primary care records (diagnosis-only group; n = 16 154); or (2) a diagnosis plus evidence of treatment with glaucoma-specific medication or surgery (diagnosis and treatment group; n = 7012), either at baseline or during follow-up. For participants in the highest 5% of IOPcc compared with the remainder, ORs were 23.6 (95% confidence interval [CI], 21.3-26.2) in the diagnosis and treatment group versus 11.4 (95% CI, 10.6-12.3; P < 1 × 10-10 for difference) in the diagnosis-only group. Corresponding ORs were: 8.0 (95% CI, 6.9-9.2) in the diagnosis and treatment group vs 4.7 (95% CI, 4.2-5.3; P = 2.32 × 10-7 for difference) in the diagnosis-only group for the thinnest 5% mRNFL; 7.1 (95% CI, 6.1-8.3) in the diagnosis and treatment group vs 4.2 (95% CI, 3.7-4.7; P = 2.53 × 10-7 for difference) in diagnosis-only group for the thinnest 5% mGCL; and 8.4 (95% CI, 7.9-8.8) in the diagnosis and treatment group versus 5.6 (95% CI, 5.4-5.9; P < 1 × 10-10 for difference) in the diagnosis-only group for the highest 5% PRS. Similar patterns were found for the other risk factors studied. Definitions of glaucoma that combine both diagnostic and treatment evidence yielded substantially stronger ORs with IOPcc, mRNFL, and mGCL than definitions based on diagnostic evidence alone, suggesting implications for studies of glaucoma in population biobanks. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:在人群规模生物样本库背景下,比较已确立危险因素和严重程度生物标志物与不同青光眼疾病定义之间的关联。观察性队列研究。英国生物样本库503325名参与者。计算已确立危险因素(角膜补偿眼压[IOPcc]和多基因风险评分[PRS])及疾病严重程度临床生物标志物(黄斑视网膜神经纤维层[mRNFL]和黄斑神经节细胞层[mGCL]厚度)与不同青光眼定义关联的比值比(OR)。将无青光眼参与者(n=481772)与以下人群比较:(1) 基于自我报告或医院住院或初级保健记录诊断青光眼者(仅诊断组;n=16154);或(2) 诊断且有青光眼特异性药物或手术治疗证据者(诊断和治疗组;n=7012),证据见于基线或随访期间。对于IOPcc最高5%的参与者,与其余参与者相比,诊断和治疗组OR为23.6(95%置信区间[CI] 21.3-26.2),仅诊断组为11.4(95% CI 10.6-12.3;差异P<1×10^-10)。相应OR为:mRNFL最薄5%在诊断和治疗组为8.0(95% CI 6.9-9.2),仅诊断组为4.7(95% CI 4.2-5.3;差异P=2.32×10^-7);mGCL最薄5%在诊断和治疗组为7.1(95% CI 6.1-8.3),仅诊断组为4.2(95% CI 3.7-4.7;差异P=2.53×10^-7);PRS最高5%在诊断和治疗组为8.4(95% CI 7.9-8.8),仅诊断组为5.6(95% CI 5.4-5.9;差异P<1×10^-10)。其他所研究危险因素呈现相似模式。同时结合诊断和治疗证据的青光眼定义,与仅基于诊断证据的定义相比,与IOPcc、mRNFL和mGCL的OR明显更强,提示这对人群生物样本库中的青光眼研究有影响。专有或商业披露可在本文末脚注和披露中查阅。
To investigate the clinical usefulness of a glaucoma polygenic risk score (PRS) for glaucoma by benchmarking published glaucoma PRSs and by assessing how the best-performing PRS performs for assessing glaucoma risk, age at onset, and glaucoma prognosis. Cohort study. Four hundred two thousand seven hundred thirty-nine individuals in FinnGen, with 21 609 individuals who received a glaucoma diagnosis after 40 years of age. Lifetime risk of glaucoma, the need and escalation of intraocular pressure-lowering medication, need for laser therapies, and need for incisional surgery. Fourteen published glaucoma PRSs from the Polygenic Score Catalog were benchmarked comprehensively using Cox proportional hazards models. The best-performing PRS was selected to evaluate further the lifetime risk of glaucoma by 85 years of age using Kaplan-Meier survival analyses, both alone and alongside family history information. In addition, the impact of PRS on prognostic outcomes was assessed over a 20-year follow-up period. The PRS with the best performance had a hazard ratio (HR) of 3.32 (95% confidence interval [CI], 3.21-3.43) for glaucoma (≥90th PRS percentile vs. 20th-80th percentile). Lifetime risk of glaucoma increased considerably across PRS categories from 2.5% (95% CI, 1.7%-3.3%) among individuals in the less than first percentile, to 31.9% (95% CI, 30.5%-33.3%) in the 95th to 99th percentiles, and to 45.3% (95% CI, 42.3%-48.1%) in the 99th percentile or more. Family history and PRS contributed independently to glaucoma risk, with the PRS effect size decreasing only by 4.2% when adjusting the PRS effect for family history. Those in the highest PRS decile required more intensive glaucoma care, with higher cumulative incidences of medication escalation (60.6% vs. 38.4%), laser therapies (39.8% vs. 22.9%), and incisional surgeries (15.8% vs. 9.5%) compared with the lowest PRS decile over a 20-year follow-up. In this large biobank study, a glaucoma PRS effectively stratified individuals according to their lifetime risk of glaucoma, with substantial stratification evident already by midlife. The PRS provided a more precise risk assessment than family history alone, and it was effective in stratifying individuals based on several prognostic measures, including medical treatment escalation and surgical interventions. These findings support the potential usefulness of PRS-guided screening and management strategies in glaucoma, with future prospective studies warranted to evaluate the clinical implementation and cost-effectiveness. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:为评估青光眼多基因风险评分(PRS)的临床实用性,对已发表青光眼PRS进行基准比较,并分析表现最佳PRS在评估青光眼风险、发病年龄和预后方面的作用。研究为队列研究,纳入FinnGen中402739名个体,其中21609名在40岁后获青光眼诊断。观察指标包括青光眼终生风险、降眼压药物需求及升级、激光治疗需求和切开手术需求。利用Cox比例风险模型对多基因评分目录中14个已发表青光眼PRS进行全面基准比较,并选择表现最佳PRS,通过Kaplan-Meier生存分析评估85岁前青光眼终生风险,分别单独使用PRS及结合家族史信息分析。同时评估PRS对20年随访期内预后结局的影响。表现最佳PRS对青光眼的 hazard ratio(HR)为3.32(95%置信区间[CI],3.21-3.43),比较≥90th PRS百分位与20th-80th百分位。青光眼终生风险随PRS类别显著升高,从低于第1百分位个体的2.5%(95% CI,1.7%-3.3%)升至95th至99th百分位的31.9%(95% CI,30.5%-33.3%),再升至≥99th百分位的45.3%(95% CI,42.3%-48.1%)。家族史与PRS独立影响青光眼风险,校正家族史后PRS效应量仅下降4.2%。在20年随访中,PRS最高十分位个体需要更密集的青光眼医疗管理,其药物升级(60.6% vs. 38.4%)、激光治疗(39.8% vs. 22.9%)和切开手术(15.8% vs. 9.5%)的累积发生率均高于最低十分位。在这项大型生物样本库研究中,青光眼PRS可有效分层个体终生青光眼风险,且到中年时已可见明显分层。PRS提供的风险评估比单独家族史更精确,并能按药物治疗升级和手术干预等多项预后指标对个体进行有效分层。这些发现支持PRS指导青光眼筛查和管理策略的潜在价值,未来需开展前瞻性研究评估临床实施和成本效益。本文脚注和文末披露部分可能包含专有或商业披露信息。
To propose a novel, anatomically based classification system for eyes traditionally labeled as neovascular glaucoma (NVG) that better reflects disease severity, guides contemporary management, and aligns with modern anti-vascular endothelial growth factor (anti-VEGF) and angle-based surgical treatment paradigms. Perspective and conceptual framework. Not applicable. We synthesized contemporary clinical experience and published literature regarding the diagnosis and management of eyes with anterior segment neovascularization and elevated intraocular pressure (IOP). Emphasis was placed on iridocorneal angle anatomy, extent of peripheral anterior synechiae (PAS), disease activity in response to anti-VEGF therapy, and implications for medical and surgical management. Based on these considerations, we developed a staged classification system prioritizing angle status at the time of presentation. Development of a clinically intuitive, anatomically descriptive nomenclature to categorize disease severity, facilitate communication among clinicians, and support stage-specific treatment protocols. We propose the neovascular ocular hypertension (NVOH) spectrum, consisting of four stages arranged from least to most severe: pre-NVOH, presumed NVOH, NVOH, partial neovascular angle closure (NVAC), and total NVAC. Disease modifiers of active versus quiescent reflect the presence or regression of anterior segment neovascularization following anti-VEGF therapy. The framework also introduces the term acute neovascular crisis (ANC) to describe symptomatic, acutely elevated IOP associated with active partial or total NVAC. This classification emphasizes the extent of synechial angle closure as a key determinant of management, distinguishing eyes that may be candidates for angle-based microinvasive glaucoma surgery, after achieving quiescence, from those requiring urgent surgical IOP lowering. Limitations include the conceptual nature of the framework and the absence of prospective validation. The NVOH spectrum offers a modernized, anatomically grounded alternative to the ambiguous term "neovascular glaucoma." By prioritizing angle status and disease activity over optic nerve assessment, which is often unreliable in eyes with advanced retinal disease, this classification supports more precise diagnosis, tailored treatment selection, and improved interdisciplinary communication. Prospective studies are needed to validate this nomenclature, refine stage-specific treatment algorithms, and assess its impact on clinical outcomes.
中文摘要:提出一种基于解剖的新分类系统,用于传统上被称为新生血管性青光眼(NVG)的眼病,以更准确反映疾病严重程度、指导当代治疗,并与现代抗血管内皮生长因子(anti-VEGF)及房角相关手术治疗策略相衔接。本文为观点与概念框架,不适用。我们综合了前节新生血管形成伴眼压升高眼的诊断与治疗方面的当代临床经验和已发表文献,重点考虑虹膜角膜角解剖、周边虹膜前粘连(PAS)范围、对anti-VEGF治疗的反应所反映的疾病活动度,以及对药物和手术处理的提示。据此,我们建立了一个以就诊时房角状态为优先的分期分类系统。构建临床直观、解剖描述性的命名体系,以划分疾病严重度、促进临床医生交流,并支持按分期制定治疗方案。我们提出新生血管性眼压升高(NVOH)谱系,由轻到重分为四个阶段:NVOH前期、疑似NVOH、NVOH、部分新生血管性房角关闭(NVAC)和完全NVAC。活动期与静止期的疾病修饰因素反映anti-VEGF治疗后前节新生血管的存在或消退。该框架还引入急性新生血管危象(ANC)一词,描述与活动性部分或完全NVAC相关的有症状、眼压急性升高。该分类强调虹膜粘连性房角关闭范围是治疗决策的关键决定因素,区分在达到静止后可考虑房角相关微创青光眼手术的眼与需要紧急手术降眼压的眼。局限性包括框架的概念性质及缺乏前瞻性验证。NVOH谱系为含糊的「新生血管性青光眼」一词提供了现代化、以解剖为基础的替代方案。该分类将房角状态和疾病活动度置于视神经评估之前,因为后者在晚期视网膜疾病眼中常不可靠,从而支持更精确的诊断、个体化治疗选择及跨学科沟通。仍需前瞻性研究验证这一命名、完善分期特异性治疗流程,并评估其对临床结局的影响。
基础研究 (4篇)
To determine axonal content from optical coherence tomography (OCT)-derived circumpapillary retinal nerve fiber layer (RNFL) measures using histologically informed models in a non-human primate experimental glaucoma model. Unilateral experimental glaucoma was induced in 22 animals (mean age, 6.1 ± 1.9 years; 10 females) who were monitored with OCT. At varying stages of neuropathy, animals were euthanized and perfusion fixed. For RNFL histology, circumpapillary tissue (∼0.75 × 0.75 mm) from six equally spaced regions was obtained and processed for serial block face scanning electron microscopy in five animals. A single high-resolution image of the block face was used to quantify axon size (cross-sectional area) and non-axonal tissue area within the RNFL. Using the 95% limits of the histological data as a starting point, models for estimating axon count from OCT RNFL area were optimized and compared to total retrobulbar optic nerve axon counts in 22 animals. The mean circumpapillary RNFL thickness of control eyes was 112 ± 6 µm, and it was 70 ± 24 µm in eyes with experimental glaucoma. Axon size and non-axonal area varied across the circumpapillary regions (F5, 31 = 9.06 and F5, 36 = 3.94, respectively; both P < 0.01), but did not differ between the two eyes (F1, 22 = 0.59, P = 0.45 and F1, 15 = 2.10, P = 0.17). The optimized model for estimating axon content from the circumpapillary RNFL profile had good agreement with the retrobulbar axon count (mean difference = 25; 95% limits of agreement, -334,239 to 334,289). The axon size distribution and non-axonal area in the circumpapillary RNFL are similar between healthy and stable glaucomatous eyes. Building on this, a location-specific model is proposed that estimates axon content from the circumpapillary RNFL profile after accounting for regional variability in axonal and non-axonal components.
中文摘要:旨在在非人灵长类实验性青光眼模型中,利用组织学信息构建的模型,从光学相干断层扫描(OCT)获得的环视盘视网膜神经纤维层(RNFL)测量值确定轴突含量。对22只动物(平均年龄6.1±1.9岁;10只雌性)诱导单侧实验性青光眼,并用OCT监测。在神经病变不同阶段处死动物并灌注固定。为进行RNFL组织学检查,从六个等间距区域获取环视盘组织(约0.75×0.75 mm),其中5只动物用于连续块面扫描电子显微镜处理。使用块面的单张高分辨率图像量化RNFL内轴突大小(横截面积)和非轴突组织面积。以组织学数据的95%界限为起点,优化从OCT RNFL面积估算轴突计数的模型,并与22只动物的球后视神经总轴突计数比较。对照眼平均环视盘RNFL厚度为112±6 µm,实验性青光眼眼为70±24 µm。轴突大小和非轴突面积在环视盘各区域间存在差异(分别为F5,31=9.06和F5,36=3.94;均P<0.01),但两眼间无差异(F1,22=0.59,P=0.45;F1,15=2.10,P=0.17)。从环视盘RNFL轮廓估算轴突含量的优化模型与球后轴突计数具有良好一致性(平均差异=25;95%一致性界限,-334,239至334,289)。健康眼与稳定青光眼眼的环视盘RNFL轴突大小分布及非轴突面积相似。在此基础上,提出一种位置特异性模型,在考虑轴突和非轴突成分区域变异后,从环视盘RNFL轮廓估算轴突含量。
Diabetic glaucoma, a severe microvascular and neurodegenerative complication of diabetes, involves complex pathological mechanisms including chronic hyperglycemia‑induced oxidative stress, inflammatory responses, microcirculatory disturbances, and retinal ganglion cell (RGC) apoptosis. While conventional Western medicine has achieved significant success in intraocular pressure (IOP) control, it faces challenges in providing long‑term neuroprotection and delaying disease progression. Traditional Chinese Medicine (TCM), guided by its holistic concept and treatment based on syndrome differentiation, demonstrates unique advantages through multi-component, multi‑target, and multi‑pathway synergistic regulation. This review systematically elucidates the TCM pathogenesis evolution pattern of "deficiency leading to stasis, ocular collateral damage" in diabetic glaucoma and establishes correlation networks between TCM syndrome types and modern pathological mechanisms. Integrating epidemiological evidence, we analyze the core mechanisms of representative Chinese herbs and formulas-including Ginkgo biloba extract, indirubin‑related components, and the Si‑Hua formula-in exerting antioxidant, anti‑inflammatory, microcirculation‑improving, and direct neuroprotective effects through regulation of key signaling pathways such as PI3K/AKT, Nrf2, and NF‑κB. Importantly, this article employs network pharmacology methods to visually present the synergistic "component‑target‑pathway" interaction network of the Si‑Hua formula, and introduces a quantitative comparison of the regulatory intensity of key herbal components on signaling pathways. We also discuss the chemical structures of major secondary metabolites from these herbs and the principles of reverse pharmacology that connect TCM to modern drug discovery. By quantitatively evaluating the regulatory intensity of key herbal components on signaling pathways and exploring the interventional potential of TCM in emerging mechanisms like ferroptosis (Figure 9), this review aims to establish a comprehensive scientific framework for TCM prevention and treatment of diabetic glaucoma, providing solid academic support for the modernization and internationalization of TCM.
中文摘要:糖尿病性青光眼是糖尿病严重的微血管与神经退行性并发症,涉及慢性高血糖诱导的氧化应激、炎症反应、微循环障碍和视网膜神经节细胞(RGC)凋亡等复杂病理机制。常规西医在眼压控制方面已取得显著成效,但在提供长期神经保护和延缓疾病进展方面仍面临挑战。中医以整体观念和辨证论治为指导,通过多成分、多靶点、多通路的协同调控显示出独特优势。该综述系统阐明糖尿病性青光眼「虚致瘀、目络损伤」的中医病机演变规律,建立中医证型与现代病理机制之间的关联网络。结合流行病学证据,分析代表性中药及方剂,包括银杏叶提取物、靛玉红相关成分和 Si-Hua 方,通过调控 PI3K/AKT、Nrf2 和 NF-κB 等关键信号通路发挥抗氧化、抗炎、改善微循环和直接神经保护作用的核心机制。该综述采用网络药理学方法直观呈现 Si-Hua 方「成分-靶点-通路」的协同作用网络,并引入关键药味成分对信号通路调控强度的定量比较。还讨论这些中药主要次生代谢产物的化学结构,以及将中药与现代药物发现相连接的反向药理学原理。通过定量评价关键药味成分对信号通路的调控强度,并探讨中药在铁死亡(图9)等新兴机制中的干预潜力,该综述旨在为中医药防治糖尿病性青光眼建立全面的科学框架,为中医药现代化和国际化提供扎实的学术支撑。
Glaucoma is one of the leading causes of irreversible blindness, and lowering intraocular pressure alone is insufficient to rescue lost retinal ganglion cells (RGCs) or restore visual function. In this study, we intravitreally injected a liquid chitosan gel loaded with nerve growth factor (NGF), previously developed by our group, into the vitreous body of rats with ocular hypertension-induced glaucoma. Using a combination of techniques--including multiplex immunofluorescence staining, TUNEL staining, CTB tracing, Western blotting, visual electrophysiology, and behavioral assessments--we demonstrated that, compared with the lesion control (LC) group, the NGF-chitosan hydrogel significantly enhanced RGC survival following glaucomatous injury (by approximately 27%), preserved dendritic architecture and long-distance axonal projections, and promoted recovery of visual function. Mechanistically, treatment with the NGF-chitosan hydrogel upregulated the expression of NGF and its high-affinity receptor, tropomyosin receptor kinase A (TrkA), in the retina. In addition, it suppressed retinal glial activation and enhanced mammalian target of rapamycin (mTOR) signaling, collectively contributing to RGC protection and repair. Notably, we further observed activation of Nestin+ neural stem cells in the ciliary body region, along with their differentiation into BrdU+/Brn3a+ neuron-like cells; the precise mechanisms underlying this phenomenon warrant further investigation. In conclusion, intravitreal delivery of NGF-chitosan hydrogel provides novel mechanistic insights and represents a promising therapeutic strategy for the treatment of glaucoma.
中文摘要:青光眼是不可逆盲的主要原因之一,单纯降低眼压不足以挽救已丢失的视网膜神经节细胞(RGC)或恢复视功能。将负载神经生长因子(NGF)的液态壳聚糖凝胶(本团队前期开发)注射至眼压升高诱导青光眼大鼠的玻璃体腔。联合多重免疫荧光染色、TUNEL染色、CTB示踪、Western blotting、视觉电生理和行为学评估显示,与损伤对照组相比,NGF-壳聚糖水凝胶使青光眼损伤后RGC存活率显著提高约27%,保留树突结构和长距离轴突投射,并促进视功能恢复。机制上,NGF-壳聚糖水凝胶上调视网膜NGF及其高亲和力受体原肌球蛋白受体激酶A(TrkA)表达,抑制视网膜胶质细胞活化并增强哺乳动物雷帕霉素靶蛋白(mTOR)信号,共同促进RGC保护和修复。还观察到睫状体区域Nestin+神经干细胞活化,并分化为BrdU+/Brn3a+神经元样细胞;该现象的具体机制尚需进一步研究。玻璃体腔递送NGF-壳聚糖水凝胶提供了新的机制认识,是青光眼治疗的有前景策略。
Mitochondrial dysfunction plays a critical role in glaucomatous trabecular meshwork (TM) degeneration, whereas increasing intracellular nicotinamide adenine dinucleotide (NAD+) levels can restore mitochondrial homeostasis, offering therapeutic benefits for glaucoma. We propose that intracellular NAD+ can be boosted by promoting NAD+ biosynthesis through the co-delivery of nicotinamide (NAM), an NAD+ precursor, and the gene encoding nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1), the rate-limiting enzyme for NAD+ biosynthesis that consumes NAM. To achieve high gene transfection efficiency, the Nmnat1 gene was encapsulated in a multifunctional lipid nanoparticle (Nmnat1-LNPs). The combination of Nmnat1-LNPs and NAM synergistically reversed mitochondrial dysfunction in primary human trabecular meshwork cells (HTMCs) model. We then developed a new annular sector-shaped microneedle patch (AS-MNs), enabling localized delivery of Nmnat1-LNPs and NAM to the TM. Following application, Nmnat1-LNPs and NAM dual-loaded AS-MNs (Dual@AS-MNs) significantly enhanced the bioavailability of both the Nmnat1 gene and NAM in the TM tissue, leading to a marked reduction in intraocular pressure and alleviation of TM fibrosis in a dexamethasone-induced mice model of glaucoma, highlighting its therapeutic potential. This study presents the first development of an annular sector-shaped microneedle patch as a targeted TM drug delivery platform, and offers a promising new combinatorial strategy for glaucoma treatment.
中文摘要:线粒体功能障碍在青光眼小梁网退变中起关键作用,提高细胞内烟酰胺腺嘌呤二核苷酸(NAD+)水平可恢复线粒体稳态,为青光眼治疗带来获益。我们提出通过促进NAD+生物合成来提升细胞内NAD+:共递送NAD+前体烟酰胺(NAM)与编码烟酰胺单核苷酸腺苷酰转移酶1(Nmnat1)的基因,Nmnat1是消耗NAM的NAD+生物合成限速酶。为实现高基因转染效率,将Nmnat1基因包载于多功能脂质纳米颗粒(Nmnat1-LNPs)。Nmnat1-LNPs与NAM联用可协同逆转原代人小梁网细胞(HTMCs)模型中的线粒体功能障碍。随后开发新型环形扇区微针贴片(AS-MNs),可将Nmnat1-LNPs和NAM局部递送至小梁网。施用后,双载Nmnat1-LNPs和NAM的AS-MNs(Dual@AS-MNs)显著提高Nmnat1基因和NAM在小梁网组织中的生物利用度,在地塞米松诱导的小鼠青光眼模型中明显降低眼压并减轻小梁网纤维化,显示治疗潜力。本研究首次开发环形扇区微针贴片作为靶向小梁网药物递送平台,为青光眼治疗提供有前景的新联合策略。
3葡萄膜炎与免疫 (12篇)
临床研究 (10篇)
To evaluate short-term associations between bisphosphonate exposure and uveitis, scleritis, and cystoid macular edema (CME). Nationwide case-case-time-control (CCTC) study. Patients with incident uveitis, scleritis, or CME identified from Taiwan's national health claims data (2011-2021), with matched future cases serving as controls to adjust for temporal exposure trends. Bisphosphonate exposure during the 30-day hazard window immediately preceding each event was compared with exposure during an earlier 30-day reference window, separated by a 90-day washout period. Each case was matched to a future case to account for temporal trends in bisphosphonate use. Analyses were stratified by administration route and individual agent. Sensitivity analyses varied window lengths, washout periods, and lag structures. Denosumab and teriparatide served as negative-control exposures. Incident uveitis, scleritis, and CME, with associations quantified using CCTC odds ratios (ORs) and 95% confidence intervals (CIs). We identified 269,545 incident uveitis cases, 132,585 scleritis cases, and 115,914 CME cases; over 96% were matched to a future case and included in CCTC analyses. After accounting for exposure trends, any bisphosphonate use was associated with an increased short-term risk of uveitis (OR, 1.24; 95% CI, 1.00-1.56), driven primarily by anterior uveitis (OR 1.43; 95% CI, 1.10-1.86). In analyses stratified by administration route and individual agent, intravenous bisphosphonates (OR, 1.78; 95% CI, 1.22-2.61), particularly zoledronic acid (OR, 2.82; 95% CI, 1.70-4.67), were associated with increased uveitis risk. Oral bisphosphonates were not associated with uveitis (OR, 0.99; 95% CI, 0.74-1.33). No clear associations were observed for scleritis or CME. Findings were consistent across subgroup and sensitivity analyses, and associations for negative-control exposures were null. Short-term associations between bisphosphonate use and ocular inflammatory events varied by administration route and outcome. Increased uveitis risk was concentrated among intravenous formulations, particularly zoledronic acid, whereas no clear associations were found for scleritis or CME. These findings may inform monitoring for ocular symptoms among patients receiving intravenous bisphosphonates.
中文摘要:评估双膦酸盐暴露与葡萄膜炎、巩膜炎及黄斑囊样水肿(CME)之间的短期关联。全国性病例-病例-时间-对照(CCTC)研究。从台湾全民健康保险申报数据(2011-2021)中识别新发葡萄膜炎、巩膜炎或CME患者,并以匹配的未来病例作为对照,以校正暴露的时间趋势。将每个事件发生前30天危险窗内的双膦酸盐暴露与更早30天参考窗内的暴露进行比较,两窗之间设90天洗脱期。每例病例与一例未来病例匹配,以考虑双膦酸盐使用的时间趋势。分析按给药途径和单药分层。敏感性分析改变窗口长度、洗脱期和滞后结构。地舒单抗和特立帕肽作为阴性对照暴露。结局为新发葡萄膜炎、巩膜炎和CME,关联用CCTC比值比(OR)和95%置信区间(CI)量化。共识别269,545例新发葡萄膜炎、132,585例巩膜炎和115,914例CME;超过96%匹配到未来病例并纳入CCTC分析。校正暴露趋势后,任何双膦酸盐使用与葡萄膜炎短期风险升高相关(OR 1.24;95% CI 1.00-1.56),主要由前葡萄膜炎驱动(OR 1.43;95% CI 1.10-1.86)。按给药途径和单药分层分析中,静脉双膦酸盐(OR 1.78;95% CI 1.22-2.61),尤其是唑来膦酸(OR 2.82;95% CI 1.70-4.67),与葡萄膜炎风险升高相关。口服双膦酸盐与葡萄膜炎无关(OR 0.99;95% CI 0.74-1.33)。巩膜炎或CME未见明确关联。亚组和敏感性分析结果一致,阴性对照暴露的关联为零。双膦酸盐使用与眼部炎症事件的短期关联因给药途径和结局而异。葡萄膜炎风险升高集中在静脉制剂,尤其是唑来膦酸,而巩膜炎或CME未见明确关联。这些发现可为接受静脉双膦酸盐患者的眼部症状监测提供参考。
Evaluate the treatment outcomes of oral prednisone in HLA-B27-associated acute anterior uveitis (AAU). Retrospective single-center clinical cohort study. 462 eyes (462 subjects) with HLA-B27-associated AAU seen at Bascom Palmer Eye Institute between 2014 and 2025. Treatment strategy of the first observed AAU episode was categorized as topical corticosteroids (TCS) plus oral prednisone (TCS+PRED, n = 74), or TCS only (n = 388). Collected data included demographics, ocular findings, and treatment type and duration. The outcomes were analyzed by Kaplan-Meier plots with log-rank tests, hazard ratio (HR), and 95% confidence interval (CI) calculations. Forest plot analysis with Cox proportional hazard modeling was used to compare treatment groups and multiple baseline predictor variables. Time from treatment initiation to complete control of inflammation (grade 0 anterior chamber cells) and time from treatment initiation to medication discontinuation. TCS+PRED significantly decreased the median time from treatment initiation to achieving complete control of inflammation compared with TCS only (28 days [95% CI: 24-35 days] vs. 41 days [95% CI: 35-44 days], P < 0.001). After adjusting for significant covariates between groups, treatment with TCS+PRED was the only variable associated with complete control of inflammation (HR: 2.19; 95% CI: 1.56-3.10, P < 0.001). There were no significant differences in the time from treatment initiation to discontinuation of medication (62 days [95% CI: 51-77 days] vs. 61 days [95% CI: 56-68 days], P = 0.505) between both groups. Prescribing ≥8 drops of TCS at presentation was significantly associated with earlier medication discontinuation (HR: 1.56; 95% CI: 1.04-2.30, P = 0.030). TCS+PRED for 14 days or less or for greater than 14 days showed no significant differences in the median time from treatment initiation to complete control of inflammation (28 days vs. 26 days, P = 0.270) or discontinuation of medication (55 days vs. 62 days, P = 0.120). Patients with HLA-B27-associated AAU treated with TCS+PRED had earlier control of anterior chamber inflammation despite the probable selection bias for oral steroids to be used in cases with more severe initial presentations. Extending treatment with prednisone for longer than 14 days did not improve results.
中文摘要:评估口服泼尼松治疗HLA-B27相关急性前葡萄膜炎(AAU)的结局。回顾性单中心临床队列研究。纳入2014年至2025年在Bascom Palmer Eye Institute就诊的462眼(462例)HLA-B27相关AAU。首次观察到的AAU发作的治疗策略分为局部糖皮质激素(TCS)联合口服泼尼松(TCS+PRED,n=74)或单用TCS(n=388)。收集的数据包括人口学资料、眼部表现以及治疗类型和疗程。结局采用Kaplan-Meier曲线、log-rank检验、风险比(HR)和95%置信区间(CI)计算进行分析。使用森林图分析和Cox比例风险模型比较治疗组及多个基线预测变量。观察结局为从开始治疗至炎症完全控制(前房细胞0级)的时间,以及从开始治疗至停药的时间。与单用TCS相比,TCS+PRED显著缩短从开始治疗至炎症完全控制的中位时间(28天[95% CI:24-35天] vs. 41天[95% CI:35-44天],P<0.001)。校正组间显著协变量后,TCS+PRED是唯一与炎症完全控制相关的变量(HR:2.19;95% CI:1.56-3.10,P<0.001)。两组从开始治疗至停药的时间无显著差异(62天[95% CI:51-77天] vs. 61天[95% CI:56-68天],P=0.505)。初诊时TCS处方≥8滴与更早停药显著相关(HR:1.56;95% CI:1.04-2.30,P=0.030)。TCS+PRED疗程≤14天与>14天在从开始治疗至炎症完全控制的中位时间(28天 vs. 26天,P=0.270)或停药时间(55天 vs. 62天,P=0.120)上无显著差异。接受TCS+PRED治疗的HLA-B27相关AAU患者前房炎症控制更早,尽管口服激素可能更倾向于用于初始表现更重的病例,存在选择偏倚。将泼尼松疗程延长至14天以上并未改善结果。
Immune-mediated non-infectious uveitis (NIU) is a leading cause of blindness in high-income countries. Adalimumab is the only licensed non-corticosteroid drug for non-infectious intermediate, posterior or panuveitis. We evaluated the efficacy, safety and cost-effectiveness of an adalimumab biosimilar as add-on therapy for a broad NIU population. This multicentre, placebo-controlled randomised trial recruited adults with sight-threatening or controlled NIU requiring oral prednisolone >5 mg/day from 18 UK NHS ophthalmology departments between 29 July 2021 and 7 June 2024. After a 16-week treatment run-in (TRI) with adalimumab, responders (prednisolone ≤5 mg/day, no active disease) were randomised 1:1 (parallel groups; concealed web-based allocation) to fortnightly subcutaneous 40 mg adalimumab (biosimilar) or placebo as add-on therapy; all but the trial statistician were masked. The primary outcome, time to treatment failure (TF; disease activity or prednisolone >5 mg/day), was analysed at 12 months by intention to treat. The health economic evaluation was pre-specified in the trial protocol; we estimated incremental cost per TF avoided, NHS perspective. Registered: ISRCTN31474800. 182 participants completed the TRI, 119 (65.4%) responded, and 115 were randomised (60 adalimumab, 55 placebo). At 12 months, 31.4% (adalimumab) and 59.0% (placebo) had experienced TF (hazard ratio 0.42, 95% CI 0.23-0.75, p = 0.003). Among patients ineligible for NHS treatment (85%), the effect was similar (hazard ratio 0.37, 95% CI 0.20-0.71, p = 0.003). Adverse events were similarly frequent; two were serious, one per group. Incremental cost was £2320 per TF avoided. Adalimumab added to standard care reduces treatment failure in NIU, including in patients with macular oedema, unilateral disease, and steroid-dependent inactive uveitis, and is affordable. Future work should identify complementary treatments for disease refractory to adalimumab. Health Technology Assessment Programme, National Institute for Health and Care Research (NIHR); Biogen International GmbH (Baar, Switzerland) provided the placebo for the trial.
中文摘要:免疫介导的非感染性葡萄膜炎(NIU)是高收入国家致盲的主要原因之一。阿达木单抗是唯一获批用于非感染性中间型、后型或全葡萄膜炎的非皮质类固醇药物。研究评估阿达木单抗生物类似药作为附加治疗用于广泛NIU人群的有效性、安全性和成本效果。这项多中心、安慰剂对照随机试验于2021年7月29日至2024年6月7日在英国18个NHS眼科部门招募需要口服泼尼松龙>5 mg/天、存在视力威胁或病情受控的NIU成人患者。经过16周阿达木单抗治疗导入期(TRI),应答者(泼尼松龙≤5 mg/天且无活动性疾病)按1:1随机分配(平行组;隐藏式网络分配)接受每两周皮下注射40 mg阿达木单抗生物类似药或安慰剂作为附加治疗;除试验统计师外均设盲。主要结局为至治疗失败时间(TF;疾病活动或泼尼松龙>5 mg/天),按意向治疗在12个月时分析。健康经济学评价在试验方案中预先设定;从NHS视角估算每避免一例TF的增量成本。注册号:ISRCTN31474800。182名参与者完成TRI,119名(65.4%)应答,115名被随机分配(阿达木单抗60名,安慰剂55名)。12个月时,阿达木单抗组31.4%和安慰剂组59.0%发生TF(风险比0.42,95% CI 0.23-0.75,p=0.003)。在不符合NHS治疗条件者(85%)中,效应相似(风险比0.37,95% CI 0.20-0.71,p=0.003)。不良事件频率相似;两例为严重不良事件,每组各一例。每避免一例TF的增量成本为2320英镑。在标准治疗基础上加用阿达木单抗可减少NIU的治疗失败,包括黄斑水肿、单侧病变和激素依赖性非活动性葡萄膜炎患者,且具有可负担性。未来工作应识别对阿达木单抗难治性疾病的补充治疗。资助:健康技术评估项目,国家卫生与护理研究所(NIHR);Biogen International GmbH(瑞士巴尔)提供试验安慰剂。
This study aimed to investigate switching strategies of biologics in noninfectious uveitis (NIU) refractory to anti-tumor necrosis factor alpha (TNFα) agents. Noninfectious uveitis often requires biologic therapy when conventional immunosuppression fails. Tumor necrosis factor alpha inhibitors, such as adalimumab and infliximab, are commonly used as first-line biologics, but up to one-third of patients experience inadequate responses. We conducted a systematic review and meta-analysis to evaluate clinical outcomes following biologic switching in patients with NIU refractory to anti-TNFα therapy. This review was registered at PROSPERO (CRD420251071702). PubMed, EMBASE, and Cochrane Library were searched through January 5, 2025. Switching strategies were categorized as either intraclass (switching between anti-TNFα agents) or interclass (switching from an anti-TNFα agent to a different class biologic). Pooled response rates were compared between the two approaches. Risk of bias was assessed using the Joanna Briggs Institute (JBI) checklists for case reports/series and the Newcastle-Ottawa Scale for comparative studies. Certainty of evidence for primary outcome was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach. A total of 136 studies (129 case reports/series and 7 comparative studies) were included for systematic review, with 89 studies contributing to the meta-analysis. Using the JBI tool, 11 of 77 studies had high risk of bias, while the remainder were of at least fair quality. Among comparative studies, one-third had moderate risk of bias, while the rest were rated as low risk. The overall pooled response rate after switching was 83% (95% confidence interval [CI]: 76%-90%; I2 = 30.2%; 466 patients). Intraclass switching showed a pooled response rate of 77% (95% CI: 65%-87%; I2 = 36%), which was lower than that of interclass switching showing 89% (95% CI: 80%-96%; I2 = 18%, P = 0.0995). Sensitivity analyses showed a 71% (95% CI: 59%-82%, I2 = 54.5%) pooled response rate for intraclass switch and 85% (95% CI: 77%-93%, I2 = 32.8%) for interclass switch, revealing statistically significant difference (P = 0.044). The certainty of evidence was graded as low for the overall pooled response rate after switching. Both intraclass and interclass switching strategies appear effective, with interclass switching showing higher response rates; however, these findings warrant cautious interpretation given the limited certainty of evidence. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:本研究旨在探讨抗肿瘤坏死因子α(TNFα)药物治疗难治的非感染性葡萄膜炎(NIU)时生物制剂的转换策略。非感染性葡萄膜炎在常规免疫抑制治疗失败后常需生物制剂治疗。阿达木单抗和英夫利西单抗等TNFα抑制剂常作为一线生物制剂,但多达三分之一患者应答不足。我们开展系统综述与荟萃分析,评估抗TNFα治疗难治的NIU患者转换生物制剂后的临床结局。本综述已在PROSPERO注册(CRD420251071702)。检索PubMed、EMBASE和Cochrane Library,截至2025年1月5日。转换策略分为类内转换(抗TNFα药物之间转换)和类间转换(从抗TNFα药物转换为不同类别生物制剂)。比较两种策略的合并应答率。使用JBI病例报告/系列清单和纽卡斯尔-渥太华量表分别评估病例报告/系列和比较研究的偏倚风险。主要结局的证据确定性采用GRADE方法评价。共纳入136项研究进行系统综述,包括129项病例报告/系列和7项比较研究,其中89项研究纳入荟萃分析。采用JBI工具评估,77项研究中11项为高偏倚风险,其余至少为一般质量。比较研究中三分之一为中等偏倚风险,其余为低风险。转换后总体合并应答率为83%(95% CI:76%-90%;I²=30.2%;466例患者)。类内转换的合并应答率为77%(95% CI:65%-87%;I²=36%),低于类间转换的89%(95% CI:80%-96%;I²=18%,P=0.0995)。敏感性分析显示类内转换合并应答率为71%(95% CI:59%-82%,I²=54.5%),类间转换为85%(95% CI:77%-93%,I²=32.8%),差异有统计学意义(P=0.044)。转换后总体合并应答率的证据确定性为低。类内转换和类间转换策略均似乎有效,类间转换应答率更高;鉴于证据确定性有限,这些发现需谨慎解读。专有或商业利益披露见文末脚注与披露部分。
We investigated factors associated with delayed diagnosis of childhood onset uveitis. Prospective Cohort: United Kingdom Uveitis in Childhood National Inception Cohort (UNICORN) Study SUBJECTS: Children (aged < 18 years) newly diagnosed with non-infectious uveitis between 1st March 2020 and 28th February 2023. Descriptive analysis of disease onset and presentation, with linear and logistic regression modelling to identify factors independently associated with increased time from onset to diagnosis (symptomatic disease) and structural complications at diagnosis (all cases). Among 221 children (median age, 10.9 years; 52% girls), the majority, 69%, were diagnosed following symptomatic onset, most commonly with redness, pain, or photophobia. Median time from symptom onset to diagnosis was 9 days (range, 0-568), with 50% having at least one complication at presentation with symptomatic onset. Independent predictors of increased time to diagnosis, following adjustment for the COVID-19 pandemic 'lockdown' period were bilateral disease (adjusted coefficient 38.1 days, 95% confidence interval 8.7 to 67.6, p = .01) and initial presentation to primary care versus eye services (62.6, 13.7 to 111.5, p = 0.01). Structural complications at diagnosis were independently associated with younger age (odds ratio 1.4, 1.3 to 1.7, p < 0.001) and socioeconomic deprivation (4.5 for lowest quintile, 1.5 to 13.2, p < 0.01). Delays in diagnosis occur in childhood uveitis of symptomatic onset, with symptoms being prevalent in disease. Improved awareness of this blinding disorder among primary-care practitioners, standardized referral pathways for childhood eye complaints, and equitable access to eye services are needed to prevent childhood onset, life-long visual disability.
中文摘要:我们调查了儿童期起病葡萄膜炎诊断延迟的相关因素。研究为前瞻性队列:英国儿童葡萄膜炎全国起始队列(UNICORN)研究。对象为2020年3月1日至2023年2月28日期间新诊断非感染性葡萄膜炎的18岁以下儿童。对疾病起病与就诊表现进行描述性分析,并用线性回归和logistic回归模型识别与起病至诊断时间延长(有症状病例)及诊断时结构并发症(全部病例)独立相关的因素。221名儿童中位年龄10.9岁,52%为女孩;69%在出现症状后获得诊断,最常见表现为眼红、眼痛或畏光。从症状起病至诊断的中位时间为9天(范围0至568天),有症状起病者中50%在就诊时已有至少一种并发症。校正COVID-19疫情封控期后,诊断时间延长的独立预测因素为双眼患病(校正系数38.1天,95%置信区间8.7至67.6,p=0.01)以及首诊于基层医疗而非眼科服务(62.6,13.7至111.5,p=0.01)。诊断时结构并发症与年龄较小(比值比1.4,1.3至1.7,p<0.001)和社会经济剥夺(最低五分位组4.5,1.5至13.2,p<0.01)独立相关。有症状起病的儿童葡萄膜炎存在诊断延迟,症状在该病中常见。需要提高基层医疗从业者对这一致盲性眼病的认识,建立儿童眼部问题的标准化转诊路径,并保障眼科服务的公平可及,以预防儿童期起病并持续终生的视觉残疾。
This study aims to evaluate the psychiatric comorbidities of noninfectious uveitis (NIU) and screening tool usage through a matched case-control approach. Retrospective cross-sectional study. Patients with NIU and without NIU were chosen from the All of Us database with consent and information provided via electronic health records. The All of Us database was searched for NIU cases using International Classification of Diseases (ICD) and Systematized Nomenclature of Medicine: ICD10CM-H44.13 and Systematized Nomenclature of Medicine 128473001, and matched controls (1:3). Comorbidity frequencies for NIU patients (n = 3266) and case controls (n = 9798), and PHQ screening tool usage were recorded. Case controls were matched across all demographic variables offered through All of Us: race, age, sex, ethnicity, smoking status, and social determinants of health, including employment status, income, education, and insurance status. Wald's test logistic regression compared both groups (P < .05). Frequency of psychiatric comorbidities in NIU patients and control patients, including across race. Frequency of mental health screening usage among NIU patients. Psychiatric diseases were selected for analysis based on their pertinence to psychiatric health and were among the few that were sufficiently powered from the possible comorbidities in the All of Us database. NIU patients had higher frequency of personality disorder (5.2%, OR 3.74 [2.97-4.75]), mood disorder (46.4%, OR 3.31 [3.08-3.56]), depressive disorder (44.0%, OR 3.34 [3.10-3.60]), anxiety (44.3%, OR 3.13 [2.92-3.37]), insomnia (25.3%, OR 2.93 [2.60-3.30]), substance abuse (16.1%, OR 2.34 [2.05-2.67]), schizophrenia (3.0%, OR 2.38 [1.70-3.31]), bipolar disorder (7.8%, OR 2.16 [1.81-2.60]), and opioid abuse (3.0%, OR 2.06 [1.59-2.69]) (P < .05, all). The association between NIU and depression, anxiety, substance and opioid abuse was stronger in Black participants than White participants. The frequency of PHQ-2 and PHQ-9 questionnaire usage was low among NIU patients, with a total of 4.8% and 1.4%, respectively. NIU is strongly associated with psychiatric comorbidities, particularly in Black patients. Ophthalmologic examination and the use of screening tools for psychiatric comorbidities can provide early observation of symptoms and are recommended in NIU patients.
中文摘要:本研究通过匹配病例对照方法评估非感染性葡萄膜炎(NIU)的精神共病情况及筛查工具使用情况。研究为回顾性横断面研究。从All of Us数据库中选取知情同意并通过电子健康记录提供信息的NIU患者和无NIU患者。使用国际疾病分类和医学系统命名法在All of Us数据库中检索NIU病例:ICD10CM-H44.13和医学系统命名法128473001,并按1:3匹配对照。记录NIU患者(n=3266)和病例对照(n=9798)的共病频率及PHQ筛查工具使用情况。病例对照在All of Us提供的所有人口学变量上进行匹配:种族、年龄、性别、民族、吸烟状况和社会健康决定因素,包括就业状况、收入、教育程度和保险状况。采用Wald检验的逻辑回归比较两组(P < .05)。分析NIU患者和对照患者精神共病的频率,包括按种族分层。分析NIU患者心理健康筛查工具的使用频率。精神疾病根据其与精神健康的相关性选择分析,并且是All of Us数据库中可能共病里少数具有足够统计效能的疾病。NIU患者的人格障碍(5.2%,OR 3.74 [2.97-4.75])、心境障碍(46.4%,OR 3.31 [3.08-3.56])、抑郁障碍(44.0%,OR 3.34 [3.10-3.60])、焦虑(44.3%,OR 3.13 [2.92-3.37])、失眠(25.3%,OR 2.93 [2.60-3.30])、物质滥用(16.1%,OR 2.34 [2.05-2.67])、精神分裂症(3.0%,OR 2.38 [1.70-3.31])、双相障碍(7.8%,OR 2.16 [1.81-2.60])和阿片类药物滥用(3.0%,OR 2.06 [1.59-2.69])频率更高(P < .05,所有)。NIU与抑郁、焦虑、物质滥用和阿片类药物滥用的关联在黑人参与者中强于白人参与者。NIU患者中PHQ-2和PHQ-9问卷使用频率较低,分别为4.8%和1.4%。NIU与精神共病强相关,尤其在黑人患者中。眼科检查和精神共病筛查工具的使用有助于早期观察症状,推荐用于NIU患者。
To define and evaluate the Stalagmite Sign, a multimodal pattern of multifocal, elongated, elevated, hyperreflective preretinal deposits on spectral-domain optical coherence tomography corresponding to discrete nodular paravascular hyporeflective lesions on coregistered near-infrared reflectance imaging, as a diagnostic biomarker for infectious peripheral retinitis in patients with posterior uveitis. Multicenter retrospective case series with diagnostic accuracy analysis. Forty-six eyes (44 patients) with the Stalagmite Sign, evaluated at tertiary uveitis referral centers between January 2024 and December 2025. For diagnostic accuracy analysis, 360 sign-negative comparator eyes were added (148 infectious, 212 noninfectious posterior uveitis), total: 406 eyes. A 2 × 2 contingency table was constructed using confirmed etiology as the reference standard, and diagnostic accuracy metrics were calculated with Wilson score 95% confidence intervals. Clinical features, intraocular polymerase chain reaction (PCR) results, and visual outcomes were assessed. Sensitivity, specificity, positive predictive value, and positive likelihood ratio (LR+) of the Stalagmite Sign for the diagnosis of infectious peripheral retinitis; intraocular PCR positivity rate; deposit resolution following antimicrobial therapy; and best-corrected visual acuity outcomes. An infectious etiology was confirmed in 44 (95.7%) of 46 sign-positive eyes: toxoplasmosis (32, 69.6%), herpetic retinitis (7, 15.2%), ocular syphilis (3, 6.5%), and fungal endophthalmitis (2, 4.3%). Peripheral retinitis was identified in 35 (76.1%) eyes; posterior pole retinitis in only 8 (17.4%). Two cases were noninfectious, presenting with deposits following silicone-oil removal, with spontaneous resolution. Specificity was 99.1% (95% CI 96.7%-99.7%), positive predictive value 95.7% (95% CI 85.5%-98.8%), and LR+ 24.5; sensitivity was 22.9% (95% CI 17.5%-29.4%). PCR was positive in all 18 eyes. Deposits resolved within 3 months of antimicrobial therapy. Mean logMAR best-corrected visual acuity improved from 0.64 ± 0.40 to 0.43 ± 0.45 over 9.7 months mean follow-up (Friedman test, P < .001). The Stalagmite Sign is a high-specificity OCT-infrared biomarker (99.1%, LR+ 24.5) for infectious peripheral retinitis, whose recognition should prompt comprehensive peripheral retinal evaluation, intraocular PCR, and antimicrobial therapy, while withholding corticosteroid monotherapy to prevent fulminant retinal necrosis. PCR is especially recommended in diagnostically uncertain cases, as a positive result is highly likely in the presence of the Stalagmite Sign.
中文摘要:定义并评估「石笋征」作为后葡萄膜炎患者感染性周边视网膜炎诊断生物标志物的价值。该征象为频域光学相干断层扫描上多灶、细长、隆起、高反射的视网膜前沉积物,并与同机近红外反射成像上离散的结节状血管旁低反射病灶相对应,构成多模态模式。采用多中心回顾性病例系列并作诊断准确性分析。纳入2024年1月至2025年12月在三级葡萄膜炎转诊中心评估的46眼(44例)存在「石笋征」的患者。诊断准确性分析另加入360只征象阴性对照眼(148只感染性、212只非感染性后葡萄膜炎),共406眼。以确诊病因作为参考标准构建2×2列联表,采用Wilson评分95%置信区间计算诊断准确性指标。评估临床特征、眼内聚合酶链反应(PCR)结果和视力结局。主要指标包括「石笋征」诊断感染性周边视网膜炎的敏感度、特异度、阳性预测值和阳性似然比(LR+),眼内PCR阳性率,抗微生物治疗后沉积物消退情况,以及最佳矫正视力结局。46只征象阳性眼中44只(95.7%)确认感染性病因:弓形虫病32只(69.6%)、疱疹性视网膜炎7只(15.2%)、眼梅毒3只(6.5%)、真菌性眼内炎2只(4.3%)。35只眼(76.1%)识别出周边视网膜炎,仅8只眼(17.4%)为后极部视网膜炎。2例为非感染性,表现为硅油取出后出现沉积物并自行消退。特异度为99.1%(95% CI 96.7%-99.7%),阳性预测值为95.7%(95% CI 85.5%-98.8%),LR+为24.5;敏感度为22.9%(95% CI 17.5%-29.4%)。18只眼PCR均为阳性。沉积物在抗微生物治疗3个月内消退。平均随访9.7个月,平均logMAR最佳矫正视力由0.64±0.40改善至0.43±0.45(Friedman检验,P<.001)。「石笋征」是感染性周边视网膜炎的高特异度OCT-红外生物标志物(99.1%,LR+24.5),识别该征象应促使全面评估周边视网膜、进行眼内PCR和抗微生物治疗,同时避免单用糖皮质激素,以防暴发性视网膜坏死。对诊断不确定病例尤其推荐PCR,因为存在「石笋征」时阳性结果可能性很高。
The recombinant zoster vaccine is recommended for adults 19 years or older who are immunodeficient or immunosuppressed. However, vaccine uptake in patients with noninfectious ocular inflammatory diseases (NOID) receiving immunosuppressive therapy remains unclear. Retrospective cohort study using a de-identified electronic health record platform (TriNetX). Adults aged 19-49 with NOID receiving short-term (< 1 year) or long-term (≥ 1 year) immunosuppressive therapy were compared with adults aged ≥ 50 years with NOID receiving comparable immunosuppressive therapy after 1:1 propensity score matching. All patients had an index event occurring on or after July 23rd, 2021. Recombinant zoster vaccine uptake following NOID diagnosis and initiation of immunosuppressive therapy was evaluated using Cox proportional hazards models. Propensity score matching was performed using demographic and clinical comorbidities. Influenza vaccine uptake was additionally evaluated as a comparative measure of general vaccine utilization behavior. Hazard ratios (HR) for recombinant zoster vaccine uptake and influenza vaccine uptake. Compared with adults aged ≥ 50 years, adults aged 19-49 years demonstrated significantly lower recombinant zoster vaccine uptake in both the short-term immunosuppression cohort (n = 1 128 matched pairs; HR 0.53, 95% CI 0.32-0.87) and long-term immunosuppression cohort (n = 785 matched pairs; HR 0.49, 95% CI 0.28-0.84). In contrast, influenza vaccine uptake was significantly higher among adults aged 19-49 years in both the short-term immunosuppression cohort (HR 1.80, 95% CI 1.20-2.70) and long-term immunosuppression cohort (HR 1.58, 95% CI 1.06-2.38). Adults aged 19-49 years receiving immunosuppressive therapy for NOID demonstrated lower documented recombinant zoster vaccine uptake than older immunosuppressed adults despite current CDC recommendations supporting vaccination in both groups. These findings highlight a potential opportunity for improved vaccine counseling and implementation strategies among younger immunosuppressed adults.
中文摘要:重组带状疱疹疫苗推荐用于19岁及以上免疫功能缺陷或免疫抑制的成人。非感染性眼部炎症性疾病(NOID)患者接受免疫抑制治疗时的疫苗接种情况仍不清楚。该回顾性队列研究使用去标识化电子健康记录平台TriNetX,将19-49岁接受短期(<1年)或长期(≥1年)免疫抑制治疗的NOID成人,与≥50岁接受相应免疫抑制治疗的NOID成人进行1:1倾向评分匹配后比较。所有患者的索引事件发生于2021年7月23日或之后。采用Cox比例风险模型评估NOID诊断并开始免疫抑制治疗后重组带状疱疹疫苗的接种情况。倾向评分匹配基于人口学特征和临床合并症。流感疫苗接种情况作为一般疫苗接种行为的比较指标另行评估。主要指标为重组带状疱疹疫苗接种和流感疫苗接种的风险比(HR)。与≥50岁成人相比,19-49岁成人在短期免疫抑制队列(1128对匹配;HR 0.53,95%CI 0.32-0.87)和长期免疫抑制队列(785对匹配;HR 0.49,95%CI 0.28-0.84)中重组带状疱疹疫苗接种率均显著更低。相反,19-49岁成人在短期免疫抑制队列(HR 1.80,95%CI 1.20-2.70)和长期免疫抑制队列(HR 1.58,95%CI 1.06-2.38)中流感疫苗接种率均显著更高。尽管当前CDC建议两组均应接种,接受免疫抑制治疗的19-49岁NOID成人有记录的重组带状疱疹疫苗接种率仍低于较年长的免疫抑制成人。这些发现提示,在较年轻的免疫抑制成人中改进疫苗咨询和实施策略存在潜在机会。
This study evaluated the structural and functional alterations of corneal nerves in unilateral noninfectious anterior uveitis patients. Cross-sectional study. Eighty-two patients with unilateral noninfectious anterior uveitis were included. Affected eyes were assigned to the affected group, contralateral clinically unaffected eyes to the unaffected group, and eyes from 25 healthy subjects to the control group. Corneal sensitivity was assessed using noncontact corneal aesthesiometer (NCCA), followed by Cochet-Bonnet aesthesiometer. Corneal subbasal nerve plexus was imaged using in vivo confocal microscopy, and nerve morphology parameters were quantified using ACCMetrics software. A masked observer assessed central corneal inflammatory cell density and microneuroma counts. Based on anterior chamber cell grade and treatment status, patients were further stratified into subgroups for exploratory analyses. NCCA thresholds were significantly higher in affected eyes than in controls (β = 0.97; 95% CI, 0.63-1.31) and in unaffected eyes (β = 0.48; 95% CI, 0.23-0.72; all adjusted P < .001). Moreover, compared with controls, affected eyes exhibited significantly lower corneal nerve parameters, notably CNFL (β = -6.09; 95% CI, -7.44 to -4.74), alongside higher inflammatory cell density and microneuroma counts (all adjusted P < .001). Relative to controls, unaffected eyes also demonstrated measurable differences, including higher NCCA thresholds, reduced CNFL, CNFD, and CFracDim, as well as increased microneuroma counts (all adjusted P < .010). Unilateral noninfectious anterior uveitis was associated with reduced corneal nerve sensitivity and altered nerve parameters in the affected eye, and measurable differences in the contralateral eye.
中文摘要:评估单侧非感染性前葡萄膜炎患者角膜神经的结构与功能改变。横断面研究。纳入82例单侧非感染性前葡萄膜炎患者。患眼归入患眼组,对侧临床未受累眼归入未受累组,25名健康受试者的眼归入对照组。使用非接触式角膜感觉计(NCCA)评估角膜敏感性,随后使用Cochet-Bonnet角膜感觉计。采用活体共聚焦显微镜成像角膜上皮下神经丛,并用ACCMetrics软件量化神经形态参数。由设盲观察者评估中央角膜炎症细胞密度和微神经瘤计数。根据前房细胞分级和治疗状态,将患者进一步分层为亚组进行探索性分析。患眼的NCCA阈值显著高于对照组(β=0.97;95% CI,0.63-1.31)和未受累眼(β=0.48;95% CI,0.23-0.72;校正后P均<.001)。与对照组相比,患眼的角膜神经参数显著降低,尤其是CNFL(β=-6.09;95% CI,-7.44至-4.74),同时炎症细胞密度和微神经瘤计数更高(校正后P均<.001)。与对照组相比,未受累眼也表现出可测量的差异,包括NCCA阈值升高,CNFL、CNFD和CFracDim降低,以及微神经瘤计数增加(校正后P均<.010)。单侧非感染性前葡萄膜炎与患眼角膜神经敏感性降低和神经参数改变相关,对侧眼也存在可测量的差异。
To evaluate the effect of a digital mindfulness-based program (Calm Health) on mental health outcomes in adults with noninfectious uveitis (NIU). Single-center, single-masked, waitlist-controlled, randomized clinical trial. One hundred adults aged ≥18 years with active or inactive NIU and baseline mild or greater anxiety or depression were randomized 1:1 to immediate access to a mindfulness application (app) (Calm Health) or to a waitlist control group. Participants in the intervention group were instructed to use the Calm Health mobile app for ≥10 minutes daily for 8 weeks. Controls received no new mindfulness intervention during this period. Outcomes were assessed at baseline and 8 weeks using validated surveys. The primary outcome was the mean difference in the anxiety symptom severity score measured by the Generalized Anxiety Disorder-7 (GAD-7) at 8 weeks. Secondary outcomes included changes in depression (Patient Health Questionnaire-9 [PHQ-9]), perceived stress (Perceived Stress Scale-10 [PSS-10]), and vision-related quality of life (National Eye Institute Visual Function Questionnaire-25 [NEI VFQ-25]). Outcomes were analyzed using linear analysis of covariance (ANCOVA) models, adjusting for baseline scores. Of 100 randomized participants (median age 43.5 years; 75% female), 70 completed the primary endpoint assessment. Median [Q1, Q3] total app use among intervention participants was 578.62 [397.79, 923.00] minutes over 8 weeks. After adjustment for baseline scores, the intervention group had a significantly lower GAD-7 score at 8 weeks compared with controls (mean difference -1.7 points; 95% CI, -3.17 to -0.23, P = 0.02). Secondary analyses showed significantly greater reductions in PHQ-9 scores (-1.90 points; 95% CI, -3.04 to -0.76, P = 0.001) and PSS-10 scores (-3.69 points; 95% CI, -6.00 to -1.37, P = 0.002) in the intervention group. Changes in NEI VFQ-25 scores were not statistically significant between groups (mean difference 1.98 points; 95% CI, -0.90 to 4.86, P = 0.18). Sensitivity analyses accounting for missing data and clinical covariates yielded similar results. A digital mindfulness-based intervention (Calm Health) significantly reduced anxiety, depression, and perceived stress in adults with NIU. Digital mindfulness tools may serve as a feasible, scalable adjunct to uveitis care, particularly in settings with limited access to traditional mental health services. Proprietary or commercial disclosure may be found after the references.
中文摘要:评估数字化正念项目(Calm Health)对非感染性葡萄膜炎(NIU)成人心理健康结局的影响。单中心、单盲、等待名单对照随机临床试验。100名年龄≥18岁、患活动性或非活动性NIU且基线焦虑或抑郁为轻度或以上的成人,按1:1随机分配至立即使用正念应用程序(app)(Calm Health)组或等待名单对照组。干预组被指导每日使用Calm Health移动app至少10分钟,持续8周;对照组在此期间不接受新的正念干预。基线和8周时使用经验证问卷评估结局。主要结局为8周时广泛性焦虑障碍-7(GAD-7)测量的焦虑症状严重程度评分平均差异。次要结局包括抑郁(患者健康问卷-9,PHQ-9)、感知压力(感知压力量表-10,PSS-10)和视功能相关生活质量(美国国家眼科研究所视功能问卷-25,NEI VFQ-25)的变化。使用线性协方差分析模型调整基线评分后分析结局。100名随机参与者(中位年龄43.5岁;75%女性)中70名完成主要终点评估。干预参与者8周内app使用总时间中位数[Q1,Q3]为578.62[397.79,923.00]分钟。调整基线评分后,干预组8周时GAD-7评分显著低于对照组(平均差异-1.7分;95%CI,-3.17至-0.23,P=0.02)。次要分析显示干预组PHQ-9评分(-1.90分;95%CI,-3.04至-0.76,P=0.001)和PSS-10评分(-3.69分;95%CI,-6.00至-1.37,P=0.002)下降显著更大。NEI VFQ-25评分变化组间无统计学显著性(平均差异1.98分;95%CI,-0.90至4.86,P=0.18)。考虑缺失数据和临床协变量的敏感性分析结果相似。数字化正念干预(Calm Health)显著降低NIU成人焦虑、抑郁和感知压力。数字正念工具可作为葡萄膜炎诊疗的可行、可扩展辅助手段,尤其在传统心理健康服务可及性有限的环境中。专有或商业披露见参考文献后。
基础研究 (2篇)
Autoimmune uveitis (AU) is a sight-threatening intraocular inflammatory disorder with limited safe therapeutic options. Pathological progression of experimental autoimmune uveitis (EAU) follows a temporally staged pattern: early disease onset is driven by aberrant microglial activation that initiates blood-retinal barrier (BRB) disruption, while advanced stages are characterized by reactive oxygen species accumulation and robust infiltration of pathogenic CD44+ immune cells. Capitalizing on this stage-dependent pathological feature, we design a thermosensitive poly (dl-lactide)-b-poly (ethylene glycol)-b-poly (dl-lactide) (PLEL) composite hydrogel (Mino&nanoCur@PLEL) co-loaded with minocycline (Mino) and CD44-targeted curcumin nanoparticles (nanoCur). The engineered platform delivers programmable biphasic drug release to implement stepwise immunomodulation, matching the dynamic EAU pathological process. Rapidly released Mino suppresses early microglial overactivation and stabilizes retinal innate immune homeostasis, whereas sustained nanoCur release enables precise targeting of proinflammatory CD44+ macrophages to block inflammatory cascades and protect BRB structure. In EAU rats, single subconjunctival hydrogel administration efficiently restrains inflammatory deterioration by disrupting the bidirectional proinflammatory interplay between myeloid immune cells and BRB-resident endothelial/retinal pigment epithelial cells, remodeling retinal immune microenvironments and restoring both inner and outer BRB integrity. This pathology-adaptive dual-target immunotherapeutic system offers a translatable precision strategy for AU treatment.
中文摘要:自身免疫性葡萄膜炎(AU)是一种威胁视力的眼内炎症性疾病,安全治疗选择有限。实验性自身免疫性葡萄膜炎(EAU)的病理进展呈时间分期模式:疾病早期由异常小胶质细胞激活驱动,启动血视网膜屏障(BRB)破坏;晚期则以活性氧蓄积和致病性CD44+免疫细胞大量浸润为特征。基于这一阶段依赖性病理特征,我们设计了一种温度敏感型聚(dl-丙交酯)-b-聚(乙二醇)-b-聚(dl-丙交酯)(PLEL)复合水凝胶(Mino&nanoCur@PLEL),共载米诺环素(Mino)和CD44靶向姜黄素纳米颗粒(nanoCur)。该工程化平台实现可编程双相药物释放,以分步免疫调节匹配EAU动态病理过程。快速释放的Mino抑制早期小胶质细胞过度激活并稳定视网膜先天免疫稳态,持续释放的nanoCur则精准靶向促炎CD44+巨噬细胞,阻断炎症级联并保护BRB结构。在EAU大鼠中,单次结膜下给予水凝胶即可通过打断髓系免疫细胞与BRB驻留内皮细胞/视网膜色素上皮细胞之间的双向促炎互作,有效抑制炎症恶化,重塑视网膜免疫微环境并恢复内、外层BRB完整性。这一病理自适应双靶点免疫治疗系统为AU治疗提供了可转化的精准策略。
Autoimmune uveitis (AU) is a leading cause of irreversible blindness driven by pathogenic T helper 17 (TH17) cell-mediated inflammation, yet current therapies are limited by efficacy and side effects, with immunometabolic mechanisms remaining poorly defined. By integrating single-cell RNA sequencing and multilayered metabolomic profiling in patients with AU and experimental AU models, we identified the lipid-sensing G protein-coupled receptor GPR183 as a key immunometabolic regulator in pathogenic CD4+ T cells. Upon activation, GPR183 modulates intracellular signaling via suppression of cyclic adenosine monophosphate-cAMP-dependent protein kinase activity and promotion of son-of-sevenless-dependent KRAS activation, which in turn elicits copper overload-induced mitochondrial oxidative stress, structural impairment, and metabolic rewiring toward glycolysis, thereby promoting TH17 cell pathogenicity. For clinical translation, virtual screening of Food and Drug Administration-approved drugs coupled with molecular docking and microscale thermophoresis validation identified fluvoxamine (FLV) as a direct GPR183 antagonist. In in vivo and in vitro uveitis and colitis models, FLV attenuated GPR183-KRAS signaling, dampened pathogenic TH17 cell responses, and alleviated tissue inflammation. These findings delineate a unique GPR183-KRAS-mitochondrial damage axis governing TH17-driven autoimmunity and support repurposing FLV as a translatable therapeutic approach for AU and other autoimmune inflammatory disorders.
中文摘要:自身免疫性葡萄膜炎(AU)是由致病性辅助性T细胞17(TH17)介导的炎症驱动的一种不可逆失明主要原因,现有治疗在疗效和副作用方面受限,免疫代谢机制仍不明确。通过整合AU患者的单细胞RNA测序和多层代谢组学分析以及实验性AU模型,我们发现脂质感应G蛋白偶联受体GPR183是致病性CD4+ T细胞中的关键免疫代谢调节因子。激活后,GPR183通过抑制环磷酸腺苷-cAMP依赖性蛋白激酶活性并促进son-of-sevenless依赖的KRAS激活来调节细胞内信号,进而引发铜过载诱导的线粒体氧化应激、结构损伤和向糖酵解的代谢重编程,从而增强TH17细胞的致病性。为临床转化,对FDA批准药物进行虚拟筛选,并结合分子对接和微量热泳动验证,鉴定出氟伏沙明(FLV)为GPR183的直接拮抗剂。在体内和体外葡萄膜炎及结肠炎模型中,FLV减弱GPR183-KRAS信号,抑制致病性TH17细胞反应,并减轻组织炎症。这些发现阐明了GPR183-KRAS-线粒体损伤轴调控TH17驱动的自身免疫,并支持将FLV重定位用于AU及其他自身免疫炎症性疾病的可转化治疗。
4角膜与眼表疾病 (10篇)
临床研究 (5篇)
To longitudinally compare changes in ocular surface signs and symptoms over 2 to 3 years in patients with isolated KCS (KCS-only) and those with concomitant SjD (KCS + SjD). Prospective cohort study using data from the Sjögren's International Collaborative Clinical Alliance (SICCA) registry. Participants were enrolled from 2003 to 2012 and invited for 2- to 3-year follow-up. Participants with KCS (defined as ocular staining score [OSS] ≥ 5) who presented at both baseline and follow-up visits were included. Participants underwent standardized ocular surface testing, including OSS, Schirmer I, tear break-up time (TBUT), and Ocular Surface Disease Index-6 (OSDI-6), at baseline and follow-up visits. Multivariable linear regression models evaluated differences in longitudinal change in ocular metrics between KCS-only and KCS + SjD participants. Changes in ocular metrics, including OSS, Schirmer I, TBUT, and OSDI-6, from baseline to follow-up. This analysis included data from 427 participants (mean age: 54.4 ± 12.8 years, 94.8% female), including 305 with KCS + SjD and 122 with KCS-only. Participants with KCS + SjD exhibited significantly more severe dry eye signs than those with KCS-only at both time points. After adjusting for covariates, the change score for OSS was 1.51 points higher (95% confidence interval [CI], 0.99-2.04; p < .001) in the KCS + SjD groups compared to the KCS-only group. Similarly, participants with KCS + SjD demonstrated greater longitudinal decline in TBUT (-1.10 sec, 95% CI: -1.56 to -0.65; p < .001) and in Schirmer I (-2.16 mm, 95% CI: -3.31 to -1.01; p < .001). The difference in OSDI-6 scores was not statistically significant (0.36, 95% CI, -0.60 to 1.33; p = .46). Participants with KCS + SjD exhibited more severe baseline signs and greater longitudinal worsening of objective ocular findings compared to KCS-only participants. These findings support the hypothesis that KCS associated with SjD and isolated KCS may represent distinct clinical forms of dry eye disease and may help differentiate these dry eye subtypes.
中文摘要:纵向比较孤立性KCS(KCS-only)患者与合并干燥综合征(SjD)的KCS(KCS + SjD)患者在2至3年间眼表体征和症状的变化。研究为前瞻性队列研究,使用Sjögren国际协作临床联盟(SICCA)登记数据。参与者于2003年至2012年入组,并被邀请进行2至3年随访。纳入基线及随访均到访、且KCS定义为眼染色评分(OSS)≥5的参与者。参与者在基线和随访时接受标准化眼表检查,包括OSS、Schirmer I、泪膜破裂时间(TBUT)和眼表疾病指数-6(OSDI-6)。多变量线性回归模型评估KCS-only与KCS + SjD参与者眼表指标纵向变化的差异。结局为OSS、Schirmer I、TBUT和OSDI-6从基线至随访的变化。分析纳入427名参与者(平均年龄54.4 ± 12.8岁,94.8%为女性),其中305例为KCS + SjD,122例为KCS-only。KCS + SjD参与者在两个时间点的干眼体征均显著更重。校正协变量后,KCS + SjD组OSS变化评分较KCS-only组高1.51分(95%置信区间[CI] 0.99-2.04;p < .001)。同样,KCS + SjD参与者TBUT纵向下降更大(-1.10秒,95% CI -1.56至-0.65;p < .001),Schirmer I下降也更大(-2.16 mm,95% CI -3.31至-1.01;p < .001)。OSDI-6评分差异无统计学意义(0.36,95% CI -0.60至1.33;p = .46)。与KCS-only参与者相比,KCS + SjD参与者基线体征更重,客观眼部表现纵向恶化更明显。这些结果支持以下假设:合并SjD的KCS与孤立性KCS可能代表干眼病的不同临床类型,并可能有助于区分这些干眼亚型。
To evaluate the safety and efficacy of cultured human corneal endothelial cell (cHCEC) injection therapy in phakic eyes with bullous keratopathy (BK), for which endothelial keratoplasty may accelerate cataract progression due to intraoperative manipulation and postoperative gas tamponade. Multicenter retrospective interventional case series. Five consecutive phakic eyes of 5 patients with BK who underwent cHCEC injection therapy and completed 6 months of follow-up. Best-corrected visual acuity (BCVA), central corneal thickness (CCT), endothelial cell density (ECD), intraocular pressure (IOP) and cataract progression. Mean logMAR best-corrected visual acuity (BCVA) improved from 1.06 ± 0.57 preoperatively to 0.22 ± 0.36 at 6 months (mean change, -0.84; 95% CI, -1.32 to - 0.36; p = .008). Mean central corneal thickness (CCT) decreased from 782 ± 104 µm to 578 ± 61 µm (mean change, -204 µm; 95% CI, -306 to - 102 µm; p = .005). Corneal clarity improved in all eyes and remained stable throughout the 6-month follow-up. Endothelial cell density (ECD) was not measurable preoperatively because of severe corneal edema. At 6 months, postoperative ECD ranged from 693 to 1622 cells/mm². Mean intraocular pressure (IOP) changed from 10.1 ± 4.3 mm Hg to 11.7 ± 3.1 mm Hg (mean change, 1.54 mm Hg; 95% CI, -4.39 to 7.47 mm Hg; p = .511). No intraoperative or postoperative complications, including cystoid macular edema, were observed. No clinically significant cataract progression was noted during follow-up. cHCEC injection therapy demonstrated favorable short-term clinical outcomes in phakic eyes with BK and may represent a promising lens-preserving treatment option. Larger controlled studies with longer follow-up are warranted.
中文摘要:评估培养的人角膜内皮细胞(cHCEC)注射治疗在有晶状体眼大疱性角膜病变(BK)中的安全性和有效性;此类眼接受角膜内皮移植术时,术中操作和术后气体顶压可能加速白内障进展。研究为多中心回顾性干预性病例系列,纳入连续5例接受cHCEC注射治疗并完成6个月随访的有晶状体眼BK患者,共5眼。观察指标包括最佳矫正视力(BCVA)、中央角膜厚度(CCT)、内皮细胞密度(ECD)、眼压(IOP)和白内障进展。平均logMAR BCVA由术前1.06±0.57改善至6个月时0.22±0.36(平均变化-0.84;95%CI -1.32至-0.36;p=.008)。平均CCT由782±104 µm降至578±61 µm(平均变化-204 µm;95%CI -306至-102 µm;p=.005)。所有眼角膜透明度均改善,并在6个月随访期间保持稳定。术前因严重角膜水肿无法测量ECD;6个月时术后ECD范围为693至1622 cells/mm²。平均IOP由10.1±4.3 mm Hg变为11.7±3.1 mm Hg(平均变化1.54 mm Hg;95%CI -4.39至7.47 mm Hg;p=.511)。未观察到术中或术后并发症,包括黄斑囊样水肿。随访期间未见有临床意义的白内障进展。cHCEC注射治疗在有晶状体眼BK中显示出良好的短期临床结局,可能成为有前景的保留晶状体治疗选择。仍需更大样本、更长随访的对照研究。
To evaluate whether chronic pain conditions (CPCs) are associated with increased risk of incident dry eye disease (DED) and prescription-requiring DED in a large electronic health record network. Retrospective cohort study. Adults aged 18 years or older in the TriNetX Analytics Network (2005-2025) with a qualifying ophthalmology examination and no prior DED diagnosis. The exposure cohort included patients with at least one CPC diagnosis before the index visit; controls had no CPC diagnoses before or after the index visit. After 1:1 propensity score-matching, 538 364 patients were included per cohort. A validation cohort restricted to patients with age-related cataract included 506 763 matched patients per group. Patients were identified using ICD-10-CM, SNOMED, and CPT codes. Propensity score matching balanced demographics and comorbidities. Two outcomes were assessed at 1, 2, and 3 years after the index visit: incident DED, defined by a new diagnosis of dry eye syndrome or keratoconjunctivitis sicca not specified as Sjögren's, and prescription-requiring DED, defined by initiation of topical cyclosporine or lifitegrast. Risk ratios with 95% confidence intervals were calculated. Time-to-event analyses used Kaplan-Meier curves and multivariable Cox proportional hazards models. Incident DED and prescription-requiring DED. Patients with at least one CPC diagnosis had significantly higher risk of incident DED compared with controls at all follow-up intervals. At 1 year, incident DED occurred in 3.34% of the CPC cohort versus 0.72% (RR 4.64; 95% CI, 4.49-4.81; P < .0001). At 3 years, cumulative incidence increased to 7.16% versus 1.50% (RR 4.78; 95% CI, 4.66-4.89; P < .0001). Prescription-requiring DED was also more common in the CPC cohort at 3 years (0.79% vs 0.30%; RR 2.60; 95% CI, 2.45-2.75). In multivariable Cox regression, CPCs were independently associated with increased hazard of incident DED (hazard ratio 4.85; 95% CI, 4.76-4.94; P < .0001). Findings were consistent in the validation cohort. CPCs are strongly associated with an increased risk of incident and prescription-requiring DED. These findings support consideration of CPCs as risk factors in the evaluation and management of DED and suggest that a subset of patients with DED may reflect broader pain-processing abnormalities.
中文摘要:评估在大型电子健康记录网络中,慢性疼痛疾病(CPC)是否与干眼病(DED)新发风险及需要处方治疗的DED风险升高相关。回顾性队列研究。纳入TriNetX Analytics Network(2005—2025年)中18岁及以上、具有符合条件的眼科检查且既往无DED诊断的成人。暴露队列为索引就诊前至少有一次CPC诊断的患者;对照在索引就诊前后均无CPC诊断。经1:1倾向评分匹配后,每队列纳入538 364例患者。限制于年龄相关性白内障患者的验证队列每组包含506 763例匹配患者。患者通过ICD-10-CM、SNOMED和CPT编码识别。倾向评分匹配平衡人口学特征与合并症。在索引就诊后1、2、3年评估两个结局:新发DED,定义为新诊断干眼综合征或未特指舍格伦的角结膜炎干燥症;需要处方治疗的DED,定义为开始使用局部环孢素或利非司特。计算风险比及95%置信区间。时间到事件分析采用Kaplan-Meier曲线和多变量Cox比例风险模型。结局为新发DED与需要处方治疗的DED。至少有一次CPC诊断的患者在所有随访间隔的新发DED风险均显著高于对照。1年时,CPC队列新发DED为3.34%,对照为0.72%(RR 4.64;95% CI 4.49-4.81;P<0.0001)。3年时,累积发生率升至7.16%对1.50%(RR 4.78;95% CI 4.66-4.89;P<0.0001)。需要处方治疗的DED在3年时CPC队列也更常见(0.79%对0.30%;RR 2.60;95% CI 2.45-2.75)。多变量Cox回归中,CPC与新发DED风险升高独立相关(风险比4.85;95% CI 4.76-4.94;P<0.0001)。验证队列结果一致。CPC与新发DED及需要处方治疗的DED风险升高强相关。这些发现支持在DED评估和管理中将CPC视为危险因素,并提示部分DED患者可能反映更广泛的疼痛处理异常。
Limbal stem cell deficiency (LSCD) is a rare but often progressive condition associated with significant ocular morbidity and visual loss. LSCD can be partial or total and can affect one or both eyes, important factors to consider when planning disease management. Decades of laboratory and clinical research have provided the basis for the contemporary understanding and management of this condition. In this narrative review, we highlight the important breakthroughs in limbal stem cell science which have shaped limbal stem cell therapy, current cell culture techniques, and the respective merits of the substrates used. We outline the key management principles in the treatment of LSCD, where a multi-disciplinary approach is essential in optimizing outcomes, and describe the current clinical and surgical options available. We also explore the emerging treatments on the horizon.
中文摘要:角膜缘干细胞缺乏(LSCD)是一种少见但常呈进展性的疾病,可导致明显的眼部病变负担和视力丧失。LSCD可为部分性或完全性,可累及单眼或双眼,这些是制定疾病管理方案时需要考虑的重要因素。数十年的实验室与临床研究为当代对该病的认识和管理奠定了基础。在这篇叙述性综述中,我们梳理了塑造角膜缘干细胞治疗格局的角膜缘干细胞科学重要突破、当前细胞培养技术以及所用载体的各自优势。我们概述了LSCD治疗的关键管理原则,其中多学科协作对于优化结局至关重要,并描述了当前可用的临床与手术选择。我们也探讨了即将出现的新兴治疗。
To identify areas of consensus among global experts on the clinical management of pediatric endothelial keratoplasty (EK), including patient selection, timing, preoperative evaluation, technique selection, intraoperative standards, and postoperative care, and to provide a practical framework for surgeons earlier in their pediatric EK learning curve. Modified Delphi-based global consensus study. International ophthalmologists with expertise in endothelial keratoplasty and pediatric corneal diseases. A series of consensus statements on pediatric EK were developed from iterative rounds of structured questions and statements posed to a panel of experts. Two rounds of asynchronous electronic questionnaires were followed by a structured hybrid discussion of unresolved items. Experts responded anonymously to statements assessing consensus and to revised items addressing indications, contraindications, timing, preoperative workup, technique selection, intraoperative standards, and postoperative management. Results are reported using item-specific denominators because occasional non-response occurred across the survey items. Consensus was defined as ≥70% agreement among the experts. Agreement between 60% and 69.9% was considered to be near consensus. The consensus supported pediatric EK for congenital hereditary endothelial dystrophy, aphakic or pseudophakic corneal edema, persistent corneal edema in congenital glaucoma, X-linked endothelial corneal dystrophy, iatrogenic endothelial decompensation, and trauma-related decompensation. EK was inappropriate for severe anterior segment dysgenesis with keratolenticular or extensive iridocorneal adhesions. In Round 2, experts further endorsed EK for failed penetrating keratoplasty due to endothelial failure, congenital glaucoma with visually significant Haab's striae, and forceps injury involving the visual axis. There was a consensus that the timing of intervention should be guided primarily by amblyopia risk rather than by a specific age cut off. Essential preoperative assessments included examination under anesthesia, B-scan ultrasonography, anterior segment optical coherence tomography, intraocular pressure measurement, ultrasound biomicroscopy, and refraction. Experts agreed that ultrathin-DSAEK and DSAEK are the predominant techniques, whereas DMEK is currently selectively reserved, usually for older children with uncomplicated anterior segment anatomy. Preferred intraoperative principles included air tamponade, anterior chamber maintenance, and donor graft under-sizing relative to the corneal diameter. Postoperative recommendations included early intraocular pressure assessment, topical corticosteroid therapy for > 6 months, regular monitoring for steroid response, selective contact lens use, and individualized long-term follow-up. The consensus statements provide globally endorsed recommendations for the clinical management of pediatric EK. These guidelines are relevant for corneal specialists providing a practical framework to benchmark practice, reduce variability, and guide future multicenter investigations.
中文摘要:旨在明确全球专家对儿童内皮角膜移植术(EK)临床管理的共识领域,包括患者选择、干预时机、术前评估、技术选择、术中标准和术后护理,并为处于儿童EK学习曲线较早阶段的手术医生提供实用框架。研究为改良德尔菲法全球共识研究,参与者为在内皮角膜移植术和儿童角膜疾病方面具有专长的国际眼科医生。通过向专家组反复提出结构化问题和陈述,形成一系列儿童EK共识声明。先进行两轮异步电子问卷,随后对未解决条目开展结构化混合讨论。专家匿名回答评估共识的陈述及修订条目,内容涉及适应证、禁忌证、时机、术前检查、技术选择、术中标准和术后管理。由于调查条目偶有未应答,结果按条目特定分母报告。共识定义为专家一致率≥70%,一致率60%至69.9%视为接近共识。共识支持儿童EK用于先天性遗传性内皮营养不良、无晶状体或人工晶状体眼性角膜水肿、先天性青光眼持续性角膜水肿、X连锁内皮性角膜营养不良、医源性内皮失代偿及外伤相关失代偿。对于伴角膜晶状体粘连或广泛虹膜角膜粘连的严重前节发育不良,EK不适用。第二轮中,专家进一步支持EK用于内皮失败导致的穿透性角膜移植失败、伴视觉显著性Haab纹的先天性青光眼及累及视轴的产钳伤。共识认为干预时机应主要以弱视风险为指导,而非依据特定年龄界限。必要术前评估包括麻醉下检查、B超、前节光学相干断层扫描、眼压测量、超声生物显微镜和验光。专家一致认为超薄DSAEK和DSAEK是主要技术,DMEK目前选择性保留,通常用于前节解剖无复杂情况的较大儿童。偏好的术中原则包括空气填充、维持前房及供体植片相对角膜直径偏小。术后建议包括早期眼压评估、局部糖皮质激素治疗超过6个月、定期监测激素反应、选择性使用接触镜及个体化长期随访。这些共识声明为儿童EK临床管理提供了全球认可的建议,适用于角膜专科医生,为对标实践、减少差异并指导未来多中心研究提供实用框架。
基础研究 (5篇)
The cornea is among the most densely innervated tissues in the body and depends on intact sensory and autonomic innervation to maintain epithelial integrity, tear film homeostasis, and ocular surface defense. Corneal nerve injury may occur after surgery, infection, inflammation, trauma, or systemic disease and can lead to reduced corneal sensitivity, impaired epithelial healing, dry eye, neuropathic pain, and neurotrophic keratopathy. Effective management requires both treatment of the underlying cause and restoration of a microenvironment permissive for reinnervation. This review examines the mechanisms underlying corneal nerve injury and repair, with emphasis on therapeutic strategies relevant to clinical translation. These include anti-inflammatory and immunomodulatory agents, growth factors and cytokines, blood-derived products, extracellular matrix-based therapies, stem cell- and secretome-based approaches, surgical neurotization, and physical stimulation modalities. We also highlight emerging challenges in the field, including the gap between structural nerve regeneration and functional recovery, limitations in clinical evidence, and barriers to therapeutic accessibility and implementation.
中文摘要:角膜是人体神经支配最密集的组织之一,依赖完整的感觉与自主神经支配维持上皮完整性、泪膜稳态和眼表防御。角膜神经损伤可发生于手术、感染、炎症、外伤或全身性疾病之后,并可能导致角膜敏感性下降、上皮愈合受损、干眼、神经病理性疼痛和神经营养性角膜病变。有效处理既需要治疗原发病因,也需要恢复允许神经再支配的微环境。本综述考察角膜神经损伤与修复的机制,重点讨论与临床转化相关的治疗策略,包括抗炎与免疫调节药物、生长因子与细胞因子、血液制品、基于细胞外基质的治疗、干细胞及分泌组方法、手术神经化以及物理刺激方式。文章还指出该领域新出现的挑战,包括结构性神经再生与功能恢复之间的差距、临床证据的局限,以及治疗可及性和实施方面的障碍。
To review current and emerging biomaterial-based strategies for corneal repair and replacement, with emphasis on biological scaffolds, biofabricated constructs, artificial stromal substitutes, and keratoprosthetic technologies. Literature review. Review of experimental, translational, and clinical literature on biomaterial platforms for corneal reconstruction, including decellularized matrices, collagen-based and extracellular matrix-derived scaffolds, 3-dimensional printed and bioprinted constructs, endothelial carrier systems, and synthetic and biologic keratoprostheses, with particular attention to layer-specific applications. Corneal biomaterials are progressing from passive substitutes to increasingly sophisticated regenerative and prosthetic platforms. Biological scaffolds such as decellularized cornea, collagen-based implants, and amniotic membrane derivatives may support epithelial, stromal, and endothelial repair, whereas 3-dimensional printing and bioprinting now enable more precise, layer-specific constructs. Endothelial tissue engineering appears particularly promising, with bioengineered grafts and synthetic barrier devices showing encouraging early results. Keratoprostheses remain the most clinically mature option for end-stage disease but continue to be limited by sequala of incomplete biointegration. Across platforms, key barriers to routine clinical use include long-term durability, optical stability, manufacturability, and regulatory complexity CONCLUSIONS: Biomaterial-based corneal reconstruction is entering a translational era in which layer-specific and hybrid approaches may expand therapeutic options beyond conventional keratoplasty. Continued progress will depend on improving biologic integration, long-term functional durability, and alignment of biomaterials innovation with surgical and regulatory realities.
中文摘要:综述当前及新兴的基于生物材料的角膜修复与替代策略,重点涉及生物支架、生物制造构建体、人工基质替代物及人工角膜技术。文献综述。回顾用于角膜重建的生物材料平台的实验、转化与临床文献,包括脱细胞基质、胶原基及细胞外基质来源支架、三维打印与生物打印构建体、内皮载体系统以及合成与生物性人工角膜,并特别关注分层应用。角膜生物材料正从被动替代物向日益精细的再生与假体平台发展。脱细胞角膜、胶原基植入物和羊膜衍生物等生物支架可能支持上皮、基质和内皮修复,而三维打印与生物打印现已能够实现更精确的分层构建体。内皮组织工程尤其显得有前景,生物工程移植物和合成屏障装置显示出令人鼓舞的早期结果。人工角膜仍是终末期疾病中临床最成熟的选项,但仍受限于生物整合不完整带来的后遗症。在各平台中,常规临床使用的关键障碍包括长期耐久性、光学稳定性、可制造性和监管复杂性。结论:基于生物材料的角膜重建正进入转化时代,分层与混合方法可能将治疗选择扩展到传统角膜移植之外。持续进展将取决于改善生物整合、长期功能耐久性,以及使生物材料创新与外科和监管现实相协调。
Dry eye disease (DED) is a prevalent, age-related ocular disorder that severely impairs vision and quality of life. Age-related cellular senescence drives disease progression through the senescence-associated secretory phenotype (SASP), which establishes a self-perpetuating cycle of oxidative stress and chronic inflammation. However, current therapeutic options are insufficient to directly disrupt this pathogenic feedback loop. To address this, we developed a dynamically responsive polypeptide-based nanosenolytic eye drop co-encapsulating quercetin and superoxide dismutase (SOD). Quercetin serves a dual function as both an anti-aging agent and a hydrophobic motif driving nanocarrier self-assembly, enabling efficient SOD loading and pH-responsive endosomal escape. This nanoplatform demonstrated superior corneal permeability compared to free SOD, leading to suppressed oxidative stress and apoptosis, restored lacrimal gland function, and reversed key DED manifestations. Furthermore, by effectively attenuating SASP activity in aged DED models, the treatment showed profound disease-modifying efficacy. Collectively, this work establishes local nanosenolysis as a potent therapeutic strategy for multifactorial DED by simultaneously targeting oxidative damage and cellular senescence.
中文摘要:干眼病(DED)是一种常见的年龄相关眼病,严重损害视力和生活质量。年龄相关细胞衰老通过衰老相关分泌表型(SASP)推动疾病进展,形成氧化应激与慢性炎症的自我维持循环。现有治疗不足以直接打断这一致病反馈环路。为此,我们开发了一种动态响应型多肽纳米衰老细胞清除滴眼液,共包载槲皮素和超氧化物歧化酶(SOD)。槲皮素兼具抗衰老剂与疏水基元双重作用,驱动纳米载体自组装,实现高效SOD负载和pH响应性内体逃逸。该纳米平台较游离SOD具有更优的角膜渗透性,可抑制氧化应激和凋亡,恢复泪腺功能,并逆转DED关键表现。在衰老DED模型中有效减弱SASP活性后,治疗显示出显著的疾病修饰疗效。总体而言,本工作确立局部纳米衰老细胞清除作为针对多因素DED的有效治疗策略,可同时靶向氧化损伤和细胞衰老。
The tarsus is critical for maintaining eyelid structural integrity, functional stability, and ocular surface health. Tarsal defects result in dual impairments of mechanical support and meibomian gland secretion, leading to severe complications such as corneal exposure and epithelial damage. However, current tarsal substitute materials fail to simultaneously meet the requirements of anatomical biomimicry, mechanical compatibility, and functional tissue integration, thereby constituting a significant bottleneck in clinical repair. To address this challenge, we developed a novel biomimetic tarsal microtissue strategy: based on the natural anatomical structure of the tarsus, a structurally zoned gelatin methacryloyl (GelMA) hydrogel scaffold was fabricated via digital light processing (DLP) 3D printing. Its mechanical properties were further enhanced by mechanical stimulation combined with salting-out, achieving a strength and flexibility comparable to those of native tarsal tissue. Subsequently, the scaffold was seeded with rosiglitazone (Rosi)-induced differentiated human meibomian gland epithelial cells (hMGECs) to construct the biomimetic tarsal microtissue. In vitro and in vivo experiments demonstrated that this microtissue exerted excellent substitution effects. When implanted in situ into rat eyelid defects, it effectively provided mechanical support and promoted tissue regeneration. This integrated strategy offers a promising approach to structural reconstruction and clinical functional amelioration of tarsal defects, with significant potential to improve ocular surface health and clinical outcomes for patients.
中文摘要:睑板对维持眼睑结构完整性、功能稳定性和眼表健康至关重要。睑板缺损会造成机械支撑与睑板腺分泌的双重损害,导致角膜暴露、上皮损伤等严重并发症。现有睑板替代材料难以同时满足解剖仿生、力学匹配和功能性组织整合的要求,成为临床修复的瓶颈。为应对这一挑战,我们提出一种仿生睑板微组织策略:依据睑板自然解剖结构,通过数字光处理(DLP)3D打印制备结构分区明胶甲基丙烯酰基(GelMA)水凝胶支架,并采用机械刺激联合盐析进一步提升其力学性能,使其强度与柔韧性接近天然睑板组织。随后将罗格列酮(Rosi)诱导分化的人睑板腺上皮细胞(hMGECs)接种于支架,构建仿生睑板微组织。体外与体内实验显示该微组织具有良好替代效果。将其原位植入大鼠眼睑缺损后,可有效提供机械支撑并促进组织再生。该整合策略为睑板缺损的结构重建与临床功能改善提供了有前景的途径,在改善眼表健康和患者临床结局方面具有显著潜力。
Dry eye disease (DED) is a common ocular disorder that severely impairs daily life. Oxidative stress has been identified as a key pathogenic factor driving cellular senescence and corneal epithelial damage in DED. Herein, we developed a biocompatible supramolecular complex based on the host-guest interaction of TEMPO-modified β-cyclodextrin (TCD) and puerarin (Pue), designated as P@TCD, for managing DED. The P@TCD could mitigate the ROS accumulation, reduce DNA damage, promote cell cycle progression, and attenuate cellular senescence in the corneal epithelium, thus preventing the further deterioration of DED. In two DED mouse models, P@TCD demonstrated favorable therapeutic efficacy by reversing corneal epithelial defects, alleviating conjunctival damage, and accelerating lacrimal gland recovery, thereby restoring tear film homeostasis, especially improving tear film stability with TBUT values of more than 5.3 s, compared to the DED models of less than 2.8 s, which is even more than the Cycloome® of 3.7 s. These results suggested the considerable potential of this dual ROS scavenging strategy for the effective treatment of DED.
中文摘要:干眼病(DED)是常见眼病,会严重影响日常生活。氧化应激已被认定为驱动DED中细胞衰老和角膜上皮损伤的关键致病因素。为此,我们构建了基于TEMPO修饰β-环糊精(TCD)与葛根素(Pue)主客体相互作用的生物相容性超分子复合物,命名为P@TCD,用于治疗DED。P@TCD可减轻ROS蓄积、减少DNA损伤、促进细胞周期进展并减弱角膜上皮细胞衰老,从而阻止DED进一步恶化。在两种DED小鼠模型中,P@TCD表现出良好疗效,可逆转角膜上皮缺损、减轻结膜损伤并加速泪腺恢复,进而恢复泪膜稳态,尤其改善泪膜稳定性,TBUT值超过5.3 s,而DED模型低于2.8 s,甚至高于Cycloome®的3.7 s。这些结果提示这种双重ROS清除策略在有效治疗DED方面具有较大潜力。
5白内障与屈光手术 (5篇)
临床研究 (2篇)
Robust randomized trials have demonstrated that routine testing before cataract surgery does not improve outcomes; however, despite this evidence and long-standing professional society recommendations discouraging routine testing, preoperative testing remains frequent in real-world practice, with most patients undergoing cataract surgery receiving at least 1 preoperative test. To measure whether electronic health record (EHR)-embedded, behavioral science-informed nudges reduce preoperative testing. This pragmatic randomized clinical trial was conducted at a large academic health system (UCLA Health) in Los Angeles, California. Physicians performing preoperative evaluations were randomized to 1 of 3 EHR nudge alerts or usual care. All encounters with patients undergoing a preoperative visit with a randomized physician within 30 days of cataract surgery were silently enrolled. Patients were enrolled from June 24, 2021, to April 11, 2023. Data were analyzed from June 2020 (1 year prior to first enrollment) to April 2024 (1 year after last enrollment). The EHR interruptive alerts cited professional society recommendations against routine testing; each emphasized a different potential patient harm, including lack of safety benefit, financial burden, or psychological stress. The primary outcome was the change in the proportion of preoperative cataract surgery encounters with any signed testing order(s) between the 12-month period before the physicians' first encounter (enrollment) and the 12-month postencounter period. Secondary outcomes included order cancellation rates among clinicians exposed to the intervention, separate comparisons of each nudge, and analyses comparing orders for specific categories of tests. During the enrollment period, 229 of 776 randomized physicians had 1 or more eligible encounter during which a patient was enrolled. Together, these clinicians had 1045 preoperative encounters during the intervention period with 967 unique patients. Mean (SD) patient age was 72.1 (9.1) years, and 595 encounters (56.9%) were with female patients. Mean (SD) signed preoperative testing rates decreased from 83% (29%) to 79% (31%) in the combined intervention arms vs 84% (30%) to 82% (31%) in the control arm. In mixed-effects models, exposure to any nudge was not associated with a reduction in overall testing (adjusted odds ratio [aOR], 0.68; 95% CI, 0.34-1.34). In prespecified secondary analyses, 16% of orders were cancelled following exposure to a nudge, and the psychological stress nudge was associated with decreases in rates of complete blood cell count (aOR, 0.37; 95% CI, 0.18-0.75; P = .01) and electrocardiogram orders (aOR, 0.42; 95% CI, 0.21-0.83; P = .01) vs control. This randomized clinical trial of EHR nudges did not reach statistical significance on the primary outcome of overall preoperative testing. Secondary outcomes suggest future studies might consider the role of a psychological stress nudge in combination with other behavioral, workflow, and/or payment changes. ClinicalTrials.gov Identifier: NCT04104256.
中文摘要:强有力的随机试验已证实白内障手术前常规检查不改善结局;尽管有这一证据以及专业学会长期建议不鼓励常规检查,真实世界实践中术前检查仍很常见,多数接受白内障手术的患者至少接受1项术前检查。评估嵌入电子健康记录(EHR)的、基于行为科学的提醒是否减少术前检查。这项实用性随机临床试验在加利福尼亚州洛杉矶一家大型学术医疗系统(UCLA Health)开展。执行术前评估的医生被随机分配到3种EHR提醒警报之一或常规照护。所有在随机化医生处进行术前访视且距白内障手术30天内的患者被隐性纳入。患者纳入时间为2021年6月24日至2023年4月11日。数据分析时间为2020年6月(首例入组前1年)至2024年4月(末例入组后1年)。EHR中断式警报引用专业学会反对常规检查的建议;每种警报强调不同的潜在患者伤害,包括缺乏安全性获益、经济负担或心理压力。主要结局是医生首次访视(入组)前12个月与首次访视后12个月之间,有任何已签署检查医嘱的术前白内障手术访视比例变化。次要结局包括暴露于干预的临床医生中的医嘱取消率、每种提醒的单独比较,以及特定检查类别医嘱的比较。入组期间,776名随机化医生中有229名至少有1次符合条件的访视并纳入患者。这些临床医生在干预期间共有1045次术前访视,涉及967名不同患者。患者平均(SD)年龄为72.1(9.1)岁,595次访视(56.9%)为女性患者。联合干预组中已签署术前检查率的平均值(SD)从83%(29%)降至79%(31%),对照组从84%(30%)降至82%(31%)。在混合效应模型中,暴露于任何提醒与总体检查减少无关(校正比值比[aOR],0.68;95% CI,0.34-1.34)。在预设次要分析中,暴露于提醒后16%的医嘱被取消,心理压力提醒与对照组相比与全血细胞计数(aOR,0.37;95% CI,0.18-0.75;P=.01)和心电图医嘱(aOR,0.42;95% CI,0.21-0.83;P=.01)率下降相关。这项EHR提醒随机临床试验未在总体术前检查的主要结局上达到统计学显著性。次要结局提示未来研究可考虑心理压力提醒与其他行为、工作流程和/或支付变化结合的作用。ClinicalTrials.gov标识符:NCT04104256。
To determine whether tomographically measured surgically induced astigmatism (SIA) is reflected in the manifest refraction, and whether the ocular residual astigmatism (ORA) precedes surgery and is stable per eye. Single-center, longitudinal, comparative vector analysis. Eyes underwent non-toric intraocular lens (IOL) or phakic implantable collamer lens (ICL) implantation. Total corneal refractive power (Pentacam) and manifest subjective refractive astigmatism at the corneal plane were expressed as Cartesian double-angle power vectors before and 3 months after surgery, yielding tomographic SIA (tSIA), refractive SIA (rSIA), their vector difference ΔSIA, and the pre- and postoperative ORA. Each SIA was decomposed into its flattening effect and torque at the incision meridian. Centroids were tested against the null by eye side. Of 290 eyes (256 IOL; 34 ICL), tSIA magnitude was small (IOL 0.47D; ICL 0.34-0.39D) with centroids near null. ΔSIA had a large mean magnitude (IOL 0.74-0.88D) but a near-origin centroid, significant only in IOL right eyes. Mean corneal flattening effect (+0.008D right, +0.140D left eyes) did not predict its refractive counterpart. ORA did not differ between cohorts (-0.11D, 95%-CI -0.25 to +0.02) and remained significant postoperatively, yet per eye only half the offset persisted in phakic and less in pseudophakic eyes. The per-eye tSIA was uncorrelated with the refractive SIA and carried no systematic direction, as power vectors or flattening effect, which stayed below a quarter of a toric cylinder step. ORA preceded surgery and remained systematically stable. Individually measured tSIA has only limited value for toric IOL planning.
中文摘要:旨在确定断层扫描测得的手术源性散光(SIA)是否反映在显性屈光中,以及眼残余散光(ORA)是否在术前即存在并在单眼层面保持稳定。单中心、纵向、比较性矢量分析。眼接受非散光型人工晶状体(IOL)或有晶状体眼可植入胶原透镜(ICL)植入。术前及术后3个月,将Pentacam测得的总角膜屈光力和角膜平面显性主觉屈光散光表示为笛卡尔双角幂矢量,得到断层扫描SIA(tSIA)、屈光SIA(rSIA)、二者矢量差ΔSIA以及术前和术后ORA。每项SIA按切口子午线分解为变平效应和扭矩。按眼别检验质心是否偏离零。290眼(IOL 256眼;ICL 34眼)中,tSIA幅度较小(IOL 0.47D;ICL 0.34-0.39D),质心接近零。ΔSIA平均幅度较大(IOL 0.74-0.88D),但质心接近原点,仅在IOL右眼有显著性。平均角膜变平效应(右眼+0.008D,左眼+0.140D)不能预测其屈光对应值。ORA在两组间无差异(-0.11D,95%置信区间-0.25至+0.02),术后仍显著,但单眼层面仅有晶状体眼约一半偏移持续存在,人工晶状体眼更少。单眼tSIA与屈光SIA不相关,无论以幂矢量还是变平效应表示均无系统方向,且低于散光型IOL柱镜一个阶梯的四分之一。ORA术前即存在并保持系统性稳定。单独测量的tSIA对散光型IOL规划价值有限。
基础研究 (3篇)
Neuromorphic vision is reaching an important transition from proof-of-concept device demonstrations toward quantitative energy benchmarks and scalable hardware integration. Yet, a chemistry-centered understanding of what attojoule-scale neuromorphic vision requires from materials and interfaces remains underdeveloped. Two-terminal (2T) photoelectric synapses are particularly well positioned for this transition by integrating sensing, memory, and computation within compact device architectures, while their performance, stability, scalability, and sustainability are fundamentally governed by materials selection and interfacial chemistry. This review therefore examines 2T photoelectric synapses from a coupled materials-device-system perspective. Starting from biological synapses and the human visual pathway, key biological concepts are translated into measurable device metrics and learning rules, followed by a comparison of the structural and operational characteristics of 2T and three-terminal (3T) architectures. The principal physical mechanisms governing photoelectric synaptic plasticity are then systematically discussed. Building on this mechanistic framework, materials-by-design strategies are examined across oxides, organic semiconductors, halide perovskites, and two-dimensional materials, with particular attention to their roles in device performance, stability, and energy efficiency. Representative neuromorphic vision functions, ranging from retina-inspired preprocessing to image recognition, are further reviewed together with device- and system-level energy considerations. Finally, safe-and-sustainable-by-design (SSbD) principles are incorporated to connect materials development with long-term technological and environmental requirements. Overall, this review highlights how coordinated materials, device, and system design can guide the development of energy-efficient, scalable, stable, and sustainable 2T photoelectric synapses for next-generation neuromorphic vision.
中文摘要:神经形态视觉正从概念验证器件演示迈向定量能量基准与可扩展硬件集成的重要转变。然而,从化学中心视角理解阿焦耳尺度神经形态视觉对材料与界面的要求仍不充分。两端(2T)光电突触将感知、记忆与计算集成于紧凑器件架构中,因而特别适合这一转变;其性能、稳定性、可扩展性与可持续性从根本上受材料选择与界面化学调控。本综述因此从材料—器件—系统耦合视角考察2T光电突触。从生物突触与人视觉通路出发,将关键生物学概念转化为可测量的器件指标与学习规则,随后比较2T与三端(3T)架构的结构与运行特征。系统讨论主导光电突触可塑性的主要物理机制。在这一机制框架上,考察氧化物、有机半导体、卤化物钙钛矿与二维材料中的材料按需设计策略,重点关注其在器件性能、稳定性与能效中的作用。进一步评述从视网膜启发预处理到图像识别的代表性神经形态视觉功能,并结合器件级与系统级能量考量。纳入安全与可持续设计(SSbD)原则,将材料开发与长期技术与环境要求相连接。本综述强调材料、器件与系统的协同设计可引导开发高能效、可扩展、稳定且可持续的2T光电突触,服务于下一代神经形态视觉。
Thiolated cyclodextrins represent a rapidly evolving class of multifunctional excipients that extend the role of cyclodextrins beyond solubilization toward active participation in mucosal drug delivery. By integrating the inclusion complexation capacity of cyclodextrins with the reactivity of thiol groups, these systems can enhance drug residence time on target tissues, epithelial permeation, and cellular uptake. This review discusses the generational evolution of thiolated cyclodextrins, from first-generation derivatives bearing free sulfhydryl groups to advanced S-protected systems designed to improve stability, control reactivity, and enable deeper mucus penetration. Particular emphasis is placed on how second- and third-generation thiolated cyclodextrins overcome key limitations of conventional thiomers, including premature oxidation and superficial binding to the rapidly cleared mucus layer. We further highlight their emerging role as performance-enhancing excipients in oral, ocular, respiratory, and other mucosal delivery platforms, such as nanocarrier systems. By linking structural modification, mucoadhesion, mucus penetration, and absorption-enhancing mechanisms, this review provides a forward-looking perspective on thiolated cyclodextrins as next-generation tools for designing more efficient and biologically responsive drug delivery systems.
中文摘要:巯基化环糊精是一类快速发展的多功能辅料,使环糊精的作用不再局限于增溶,而是主动参与黏膜药物递送。该类系统将环糊精的包合络合能力与巯基的反应性结合,可延长药物在靶组织上的滞留时间,并促进上皮渗透和细胞摄取。本综述讨论巯基化环糊精的代际演变,从带有游离巯基的第一代衍生物,到为改善稳定性、控制反应性并实现更深层黏液穿透而设计的S-保护型高级系统。重点阐述第二代和第三代巯基化环糊精如何克服传统硫代聚合物的关键局限,包括过早氧化以及与快速清除的黏液层发生表层结合。进一步强调其作为性能增强型辅料在口腔、眼部、呼吸道及其他黏膜递送平台中的新兴作用,例如纳米载体系统。通过关联结构修饰、黏膜黏附、黏液穿透和吸收促进作用,本综述对巯基化环糊精作为下一代工具、用于设计更高效且具有生物响应性的药物递送系统提供前瞻性视角。
Perineuronal nets (PNNs) regulate the maturation of parvalbumin-positive (PV+) interneurons during postnatal critical periods and continue to support their function thereafter. Their disruption is implicated in neuropsychiatric disorders such as schizophrenia, yet key endogenous PNN regulators remain unknown. Here, we identify the schizophrenia-associated glycoprotein Adamtsl3 as a PV+ cell-autonomous regulator of PNN integrity. Using mouse genetics, morphological and biochemical analyses, we demonstrate that Adamtsl3 deletion, both in early postnatal and adult stages, results in PNN deficits. Mechanistically, Adamtsl3 modulates matrix metalloprotease-9 (MMP9) activity, and Adamtsl3 deletion results in elevated MMP9 levels, PNN reduction, decreased Otx2 uptake, and heightened oxidative stress in PV+ cells. MMP9 hyperactivity and PNN reduction can be rescued by pharmacological inhibition of MMP9. Deletion of Adamtsl3 in PV+ interneurons revealed its cell-autonomous function in modulating PNN integrity. Notably, conditional Adamtsl3 deletion in adult PV+ cells reactivated juvenile-like ocular dominance plasticity. These results position Adamtsl3 as a persistent, PV+ specific PNN regulator with direct implications for the pathophysiology of schizophrenia.
中文摘要:周围神经网(PNNs)在出生后关键期调控小清蛋白阳性(PV+)中间神经元的成熟,并在其后持续支持其功能。PNNs破坏与精神分裂症等神经精神疾病相关,但其关键内源性调控因子仍不清楚。本研究报告精神分裂症相关糖蛋白Adamtsl3是PV+细胞自主的PNN完整性调控因子。利用小鼠遗传学、形态学和生化分析,证明在出生后早期及成年阶段敲除Adamtsl3均导致PNN缺陷。机制上,Adamtsl3调节基质金属蛋白酶-9(MMP9)活性,Adamtsl3缺失导致PV+细胞中MMP9水平升高、PNN减少、Otx2摄取下降及氧化应激增强。药理学抑制MMP9可挽救MMP9过度活性和PNN减少。在PV+中间神经元中敲除Adamtsl3显示其细胞自主调控PNN完整性的功能。成年PV+细胞条件性敲除Adamtsl3可重新激活幼年样眼优势可塑性。这些结果将Adamtsl3定位为持续存在的PV+特异性PNN调控因子,对精神分裂症病理生理具有直接意义。
6神经眼科 (3篇)
临床研究 (3篇)
The game-based virtual reality field (VRF) testing algorithm has shown promise in pediatric neuro-ophthalmic patients, but the faster Humphrey visual field (HVF) equivalent algorithm has not been studied in this population. The purpose of this study was to compare testing outcomes between tabletop HVF and VRF (HVF-equivalent algorithm) in a pediatric neuro-ophthalmic population. Prospective comparison of diagnostic perimetry testing modalities. Children (<18 years of age) with a known or suspected neuro-ophthalmic condition. Consecutive pediatric patients presenting to one neuro-ophthalmic clinic between January 2025 and April 2026 had clinically indicated visual field testing first with tabletop HVF testing (24-2, Size III, SITA Fast) and then VRF in the HVF-equivalent algorithm (24-2, Size III, AVA Fast). Global parameters, field defect agreement via masked grading, and point-by-point agreement (including total deviation [TD] and pattern deviation [PD] plots) between modalities were evaluated. HVFs with false-negative/false-positive rates >35% or fixation losses >50% were considered unreliable, applying less stringent reliability criteria for this pediatric population. Agreement rate between HVF and VRF in both defect detection by region (quadrants, and center) and individual plot points (<0.5% probability defect threshold). Comparisons across patient characteristics, perimetry results, and testing modality (HVF vs. VRF). One hundred fourteen patients (210 eyes; mean age 11.4 ± 3.6 years) were enrolled. Ninety-two children (168 eyes) completed both HVF and VRF testing, including 128 reliable and 40 unreliable HVF examinations. Regional defect agreement between HVF and VRF was 65.9% on average, while point-by-point agreement rates for TD and PD plots were 76.6% and 83.7%, respectively. Moderate positive associations were observed between HVF and VRF for mean deviation (R2M = .398, P < .001) and pattern standard deviation (R2M = .576, P < .001). VRF was significantly faster than HVF (2.1 ± 0.17 minutes vs 4.4 ± 1.2 minutes; P < .001) and most queried patients (51/53; 96.2%) preferred VRF to HVF testing. VRF (HVF-equivalent algorithm) testing showed moderate to good concordance with tabletop HVF testing in pediatric neuro-ophthalmic patients, with shorter testing duration and high patient preference, supporting its potential clinical value.
中文摘要:基于游戏的虚拟现实视野(VRF)检测算法在儿科神经眼科患者中已显示出应用前景,但更快速的汉弗莱视野(HVF)等效算法尚未在该人群中研究。本研究旨在比较桌面式HVF与VRF(HVF等效算法)在儿科神经眼科人群中的检测结果。前瞻性比较诊断性视野检测方式。研究对象为已知或疑似神经眼科疾病的儿童(<18岁)。2025年1月至2026年4月在一家神经眼科门诊就诊的连续儿科患者,先接受临床所需的桌面式HVF检测(24-2、Size III、SITA Fast),随后接受HVF等效算法的VRF检测(24-2、Size III、AVA Fast)。评估两种方式间的全局参数、经盲法分级判断的视野缺损一致性,以及逐点一致性(包括总偏差[TD]和模式偏差[PD]图)。假阴性/假阳性率>35%或固视丢失>50%的HVF视为不可靠,并针对该儿科人群采用较宽松的可靠性标准。计算HVF与VRF在按区域(象限和中心)检测缺损以及单个图点(<0.5%概率缺损阈值)上的一致性率。比较患者特征、视野检测结果和检测方式(HVF与VRF)之间的差异。共纳入114例患者(210眼;平均年龄11.4±3.6岁)。92名儿童(168眼)完成HVF和VRF两项检测,其中128次HVF检查可靠,40次不可靠。HVF与VRF的区域缺损一致率平均为65.9%,TD图和PD图的逐点一致率分别为76.6%和83.7%。HVF与VRF在平均偏差(R2M=.398,P<.001)和模式标准差(R2M=.576,P<.001)上呈中度正相关。VRF显著快于HVF(2.1±0.17分钟 vs 4.4±1.2分钟;P<.001),多数被询问的患者(51/53;96.2%)更偏好VRF而非HVF检测。在儿科神经眼科患者中,VRF(HVF等效算法)检测与桌面式HVF检测呈中至良好一致性,检测时长更短且患者偏好度高,支持其潜在临床价值。
To determine whether the cup-to-disc ratio (CDR) of patients with glucagon-like peptide 1 receptor agonist (GLP-1 RA) -associated nonarteritic anterior ischemic optic neuropathy (NAION) is similar to the CDR of patients with NAION without GLP-1 RA exposure and to stratify the odds of developing NAION based on CDR. A retrospective, multicenter, case-control study of the CDR of NAION cases diagnosed between 2018 and 2024. The Disc-at-Risk Study Group included 16 neuro-ophthalmology centers that reviewed medical records of 1812 unaffected fellow eyes from 2169 consecutive patients with NAION. The control group included both eyes of 465 patients. The study compared the unaffected fellow eyes of 3 groups of patients with NAION: semaglutide users (117 eyes), nonsemaglutide GLP-1 RA users (83 eyes), and No GLP-1 RA medications (1612 eyes). Control eyes defined the distribution of CDR in the general population. The CDR of unaffected fellow eyes of patients with NAION with and without exposure to GLP-1 RA medications. The average provider-estimated CDR in unaffected fellow eyes of patients with NAION was 0.13, with no significant difference among the 3 groups. A measured CDR ≤ 0.40 was found in 94% of fellow eyes but only 56% of controls (P < 0.001). A measured CDR ≤ 0.20 was found in 54% of fellow eye photographs but only 9% of controls (P < 0.001). Eyes with a measured CDR ≤ 0.20 have the highest NAION odds (odds ratio = 46.3; 95% confidence interval, 22.9-93.4), and eyes with a CDR > 0.20 and ≤0.40 had more modest odds (odds ratio = 6.8; 95% confidence interval, 3.5-13.2) compared with eyes with a measured CDR > 0.40. Patients with NAION with and without exposure to GLP-1 RA medications have the same high prevalence of crowded optic discs. The odds of NAION are inversely proportional to CDR. Irrespective of GLP-1 RA exposure, eyes with a photo-measured CDR ≤ 0.20 have 46 times greater odds of NAION than eyes with a CDR > 0.40. Although the absolute risk of NAION is low, this quantification of NAION risk may help better inform patients concerned about NAION risk. This study does not assess whether GLP-1 RA medications are an independent risk factor for NAION. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:旨在确定胰高血糖素样肽1受体激动剂(GLP-1 RA)相关非动脉炎性前部缺血性视神经病变(NAION)患者的杯盘比(CDR)是否与未暴露于GLP-1 RA的NAION患者相似,并按CDR分层评估发生NAION的比值比。研究为回顾性、多中心、病例对照研究,纳入2018年至2024年诊断的NAION病例。Disc-at-Risk研究组包括16家神经眼科中心,复习了2169例连续NAION患者中1812只未受影响的对侧眼的病历。对照组包括465例患者的双眼。研究比较3组NAION患者未受影响的对侧眼:司美格鲁肽使用者117眼、非司美格鲁肽GLP-1 RA使用者83眼、未使用GLP-1 RA药物者1612眼。对照眼用于定义一般人群中CDR的分布。主要观察有和无GLP-1 RA药物暴露的NAION患者未受影响对侧眼的CDR。NAION患者未受影响对侧眼中,医生估计的平均CDR为0.13,3组间无显著差异。测量CDR≤0.40见于94%的对侧眼,而对照组仅56%(P < 0.001)。测量CDR≤0.20见于54%的对侧眼照片,而对照组仅9%(P < 0.001)。与测量CDR > 0.40的眼相比,测量CDR≤0.20的眼发生NAION的比值比最高(比值比=46.3;95%置信区间22.9-93.4),CDR > 0.20且≤0.40的眼比值比相对较低(比值比=6.8;95%置信区间3.5-13.2)。有和无GLP-1 RA药物暴露的NAION患者均具有相同的高视盘拥挤患病率。NAION的比值比与CDR呈反向关系。无论是否暴露于GLP-1 RA,照片测量CDR≤0.20的眼发生NAION的比值比是CDR > 0.40眼的46倍。尽管NAION的绝对风险较低,这种风险量化可能有助于更好地告知关注NAION风险的患者。本研究未评估GLP-1 RA药物是否为NAION的独立危险因素。专有或商业利益披露见文末脚注和披露部分。
Giant cell arteritis (GCA) is a clinically heterogeneous disease, which complicates both diagnosis and management. This study aimed to identify genetic risk factors associated with GCA clinical manifestations and evaluate their utility for defining clinical phenotypes. Genome-wide genotype data from 3498 patients with GCA and 15,550 controls were analysed to investigate the genetic architecture of GCA manifestations. Logistic regression was used to compare patients with and without each manifestation, as well as each subgroup of patients vs controls. Gene annotation was conducted based on functional information using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS). Latent class analysis (LCA) was applied to evaluate the ability of associated variants to classify patients with GCA into genetic subgroups. We identified 7 human leukocyte antigen (HLA) variants specifically associated with different clinical features. Furthermore, 7 non-HLA associations across 6 clinical manifestations were found. Gene prioritisation highlighted biologically relevant candidate genes for GCA pathogenesis, including IL17A (limb claudication) and IL22RA1 (jaw claudication), both involved in the Th17 pathway, and ATP2A2 (extracranial form), encoding a transporter that promotes aortic aneurysms. Notably, LCA grouped GCA clinical predisposition into 4 classes capturing cranial-predominant, mixed, extracranial, and ischaemic/occlusive patterns, the latter representing a high-risk subgroup for severe ischaemic and ocular complications. This first genome-wide association study stratified by GCA-specific manifestations deepens our understanding of the genetic basis underlying GCA clinical heterogeneity. Our findings highlight HLA and non-HLA contributors to specific disease phenotypes and support the potential of genetic profiling to guide early diagnosis and personalised management in GCA.
中文摘要:巨细胞动脉炎(GCA)临床表现异质,给诊断和管理带来困难。研究旨在识别与GCA临床表现相关的遗传危险因素,并评估其用于界定临床表型的价值。分析3498例GCA患者和15550名对照者的全基因组基因型数据,以探讨GCA表现的遗传结构。采用逻辑回归比较有无某一表现的患者,以及各患者亚组与对照者。基于功能信息,使用FUMA GWAS进行基因注释。应用潜在类别分析评估相关变异将GCA患者分入遗传亚组的能力。识别出7个与不同临床特征特异性相关的人类白细胞抗原(HLA)变异。另在6种临床表现中发现7个非HLA关联。基因优先级分析提示GCA发病机制中具生物学相关性的候选基因,包括与肢体跛行相关的IL17A和与下颌跛行相关的IL22RA1,二者均参与Th17通路,以及与外颅型相关的ATP2A2,其编码促进主动脉瘤的转运体。潜在类别分析将GCA临床易感性分为4类,分别涵盖以颅部为主、混合型、颅外型和缺血/闭塞型模式,后者代表严重缺血和眼部并发症的高危亚组。这是首个按GCA特异性表现分层的全基因组关联研究,加深了对GCA临床异质性遗传基础的理解。研究结果突出HLA和非HLA因素对特定疾病表型的贡献,并支持遗传谱分析用于指导GCA早期诊断和个体化管理的潜力。
7基因治疗与再生医学 (3篇)
临床研究 (2篇)
To map the published interventional gene-based therapies relevant to children with inherited retinal diseases (IRDs), with a focus on efficacy, safety, and durability, including pediatric-vs-adult patterns where available. This scoping review followed a prospectively registered protocol specifying the search strategy, eligibility criteria, screening process, data-charting framework, and synthesis plan. PubMed and Embase were searched from January 1, 2008, to April 13, 2026. Retrieved records were independently screened by 2 reviewers to identify prospective interventional studies of gene-targeted therapies for molecularly confirmed IRDs enrolling participants younger than 18 years; unresolved disagreements were adjudicated by a third reviewer. Overlapping reports were grouped into trial clusters with a primary anchor record. Records with at least 3 pediatric participants and separately extractable pediatric data were classified as Tier 1 and included in the main synthesis; other eligible records were retained as Tier 2 contextual evidence. Where sufficient individual-level or subgroup-level data were available, review authors extracted descriptive pediatric-vs-adult patterns. Twenty-four records, grouped into 17 trial clusters across 8 genotypes, were included; 14 met Tier 1 criteria. RPE65-associated disease provided the largest pediatric evidence base and the most consistent efficacy and durability signals, although responses varied between trial clusters. AIPL1 gene supplementation showed substantial treated-eye functional gains with relative structural preservation at up to 4 years in 4 very young children, and high-dose GUCY2D gene supplementation improved retinal sensitivity in 3 children within a mixed-age cohort. CEP290-targeted splice modulation and gene editing showed early functional signals, but interpretation was limited by dose-related cataract with sepofarsen and few pediatric participants with EDIT-101. Evidence for RPGR, CNGB3, RS1, and MERTK did not support robust pediatric-specific efficacy conclusions. Serious ocular events were predominantly procedure-related, with no reproducible pediatric-specific toxicity signal. Formal age-stratified analyses were uncommon, and several pediatric-vs-adult patterns required review-author extraction. Pediatric benefit from IRD gene therapy depends on genotype, residual retinal structure, therapeutic platform, dose, surgical strategy, and outcome measure. The major evidence gaps are long-term pediatric durability and inconsistent age-stratified reporting. Future pediatric-inclusive trials should prespecify subgroup analyses, embed prospective long-term follow-up, use developmentally appropriate endpoints, and report individual-level data sufficient to support pediatric inference.
中文摘要:该范围综述旨在梳理已发表的、与患遗传性视网膜疾病(IRDs)儿童相关的介入性基因治疗研究,重点关注疗效、安全性和持久性,并在有资料时纳入儿科与成人模式的比较。综述遵循前瞻性注册方案,明确检索策略、纳入标准、筛选流程、数据提取框架和综合计划。检索PubMed和Embase,时间范围为2008年1月1日至2026年4月13日。检索记录由2名评审独立筛选,以识别针对分子确诊IRDs、纳入18岁以下参与者的基因靶向治疗前瞻性介入研究;未解决的分歧由第三名评审裁定。重叠报告按试验集群归组并设主要锚定记录。至少含3名儿科参与者且儿科数据可单独提取的记录归为Tier 1并纳入主要综合;其他符合条件记录作为Tier 2背景证据保留。若有足够的个体水平或亚组水平数据,综述作者提取描述性儿科与成人模式。共纳入24条记录,归为17个试验集群,覆盖8种基因型;其中14条符合Tier 1标准。RPE65相关疾病提供了最大的儿科证据基础和最一致的疗效与持久性信号,但不同试验集群间反应存在差异。AIPL1基因补充在4名非常年幼儿童中显示治疗眼功能显著改善,并在长达4年内相对保留结构;高剂量GUCY2D基因补充在混合年龄队列中使3名儿童视网膜敏感性改善。CEP290靶向剪接调节和基因编辑显示早期功能信号,但sepofarsen相关剂量性白内障及EDIT-101儿科参与者过少限制了结果解读。RPGR、CNGB3、RS1和MERTK的证据不足以支持稳健的儿科特异性疗效结论。严重眼部事件主要与操作相关,未发现可重复的儿科特异性毒性信号。正式的年龄分层分析不常见,若干儿科与成人模式需综述作者提取。IRD基因治疗对儿童的获益取决于基因型、残余视网膜结构、治疗平台、剂量、手术策略和结局指标。主要证据缺口是儿科长期持久性和年龄分层报告不一致。未来纳入儿童的试验应预设亚组分析、嵌入前瞻性长期随访、采用适合发育阶段的终点,并报告足以支持儿科推断的个体水平数据。
Inherited retinal disorders (IRDs) are a group of ophthalmic conditions that are characterized by progressive degeneration of photoreceptors and/or retinal pigment epithelium (RPE), leading to irreversible vision loss. IRDs are a promising target for stem cell therapies, which have largely aimed to restore vision by either replacement of degenerated photoreceptors or retinal pigment epithelial cells via transplantation of stem cells or preservation of cells through expression of neuroprotective factors. Several therapies have recently moved into early clinical trials, demonstrating that stem cell therapies can be safely administered through different routes of administration including intravitreal, sub-retinal, and suprachoroidal injection. However, further larger-scale studies are needed to demonstrate efficacy of these treatments for the prevention or reversal of vision loss from photoreceptor or RPE degeneration.
中文摘要:遗传性视网膜疾病(IRDs)是一组以光感受器和/或视网膜色素上皮(RPE)进行性变性为特征的眼科疾病,可导致不可逆的视力丧失。IRDs是干细胞治疗颇具前景的靶点,相关策略主要通过移植干细胞以替代退变的光感受器或视网膜色素上皮细胞,或通过表达神经营养保护因子保存细胞,从而恢复视力。近来已有多种疗法进入早期临床试验,显示干细胞治疗可通过玻璃体腔、视网膜下和脉络膜上腔注射等不同给药途径安全实施。仍需更大规模研究证实这些治疗在预防或逆转光感受器与RPE变性所致视力丧失方面的疗效。
基础研究 (1篇)
The goal of this study was to examine focused ultrasound blood-retina barrier opening (FUS-BRBO) as a method to deliver gene therapy to the eye. We compared AAV.FUS.3, an engineered variant optimized for FUS-enhanced delivery to the central nervous system, and AAV9 for their utility as neuronal gene vectors. Mouse eyes were insonated by 4.667 MHz FUS in a custom-designed nosecone. Evans blue dye was administered intravenously to verify the presence of blood-retina barrier opening. Once BRBO was demonstrated, viral vectors were administered before ultrasound scanning to allow crossing into the retina. Viral tropism among different cell types was analyzed, and structural changes were investigated. FUS-BRBO was achieved across a range of pressures. FUS-BRBO allowed for retinal transduction of systemically administered viral vectors. We found 2.1-fold improvement of transduction of AAV.FUS.3 over AAV9 in the insonated area and 19.5-fold improvement over the uninsonated retina. Within that area, the ganglion cell layer showed the highest levels of transduction at 22% for AAV.FUS. No gross tissue damage was noted. FUS-BRBO has the potential to non-surgically deliver AAV-based vectors to spatially-defined regions of the retina. AAV.FUS.3 showed significantly improved transduction over AAV9 at the same dose. Further research to improve efficiency of delivery to the outer retina could expand utility of FUS-BRBO.
中文摘要:研究考察聚焦超声开放血视网膜屏障(FUS-BRBO)作为一种向眼内递送基因治疗的方法。比较了AAV.FUS.3与AAV9作为神经元基因载体的用途,其中AAV.FUS.3是为聚焦超声增强的中枢神经系统递送而优化的工程化变体。用4.667 MHz聚焦超声经定制鼻锥形装置照射小鼠眼。静脉给予伊文思蓝染料以验证血视网膜屏障开放。确认BRBO后,在超声扫描前给予病毒载体,使其进入视网膜。分析不同细胞类型间的病毒嗜性,并检查结构变化。FUS-BRBO可在一定压力范围内实现。FUS-BRBO使全身给予的病毒载体能够转导视网膜。在照射区域内,AAV.FUS.3的转导效率较AAV9提高2.1倍,较未照射视网膜提高19.5倍。该区域内,神经节细胞层的转导水平最高,AAV.FUS达到22%。未观察到明显组织损伤。FUS-BRBO有望以非手术方式将AAV载体递送至视网膜空间限定区域。相同剂量下,AAV.FUS.3的转导效率显著优于AAV9。进一步提高向视网膜外层递送效率的研究可能拓展FUS-BRBO的用途。
8影像与人工智能 (3篇)
临床研究 (3篇)
There is an urgent global need for affordable, large-scale health screening to enhance preventive care in the ageing population. Using low-cost, non-invasive retinal photographs and leveraging large foundation models, we developed a deep learning-based biomarker, Retinal Mortality Equivalent (RetiME), that directly mapped retinal features to individual mortality risk. Trained on a European cohort and externally validated across three independent external cohorts spanning Southeast Asia, Eurasia and North America, RetiME showed robust associations with all-cause and cause-specific mortality and predicted the incidence of a wide range of systemic and ocular diseases. Crucially, beyond static risk estimation, RetiME re-timed mortality risk by reconstructing personalized lifespan trajectories that were associated with observed mortality outcomes (for example, age of death). Clustering of these trajectories revealed distinct mortality patterns, spanning cancer-predominant, cardiometabolic and neurodegenerative risks, reflecting diverse ageing pathways captured by RetiME. Interpretability analyses showed that RetiME captures diverse biological and retinal features underlying mortality risk. Genome-wide analyses further identified genetic loci associated with RetiME. Collectively, these findings support further evaluation of retinal imaging and trajectory modelling as one component of a comprehensive assessment of mortality risk.
中文摘要:全球亟需可负担的大规模健康筛查,以加强老龄人口的预防性照护。利用低成本、非侵入性的视网膜照片并借助大型基础模型,我们开发了深度学习生物标志物RetiME,可将视网膜特征直接映射到个体死亡风险。RetiME在欧洲队列中训练,并在覆盖东南亚、欧亚大陆和北美的三个独立外部队列中验证,与全因死亡和特定原因死亡均呈稳健关联,并能预测多种全身性疾病和眼部疾病的发生。关键在于,RetiME不止于静态风险评估,还通过重建与观察到的死亡结局(例如死亡年龄)相关的个体化寿命轨迹,对死亡风险进行时间重定。这些轨迹的聚类揭示了不同的死亡模式,涵盖以癌症为主、心脏代谢和神经退行性风险,反映出RetiME捕捉到的多样衰老路径。可解释性分析显示,RetiME捕捉了死亡风险背后的多种生物学和视网膜特征。全基因组分析进一步识别了与RetiME相关的遗传位点。这些发现支持进一步评估视网膜成像和轨迹建模,将其作为死亡风险综合评估的一个组成部分。
Rosacea is a chronic central face dermatosis caused by a combination of dysregulated innate and adaptive immunity and hyperreactive cutaneous neurovasculature. Although classically associated with lighter skin phototypes, rosacea may affect up to 2-4% of Black, Asian, Pacific Islander, and Hispanic/Latino American populations and its prevalence is likely underestimated given our current diagnostic reliance on phenotypic expression (e.g., fixed erythema with or without intermittent exacerbations, flushing, and/or telangiectasias) that may be difficult to appreciate in more heavily pigmented skin. In patients with richly pigmented skin, a careful history of symptoms to assess the minor/secondary criteria (i.e., burning or stinging, edema, dryness, flushing, low tolerance for over-the-counter products, symptoms with classic 'triggers', family history and/or ocular symptoms), along with patient participation during the physical exam to establish their baseline skin tone, may facilitate diagnosis. Rosacea treatment regimens are centered around presentation and can include over-the-counter agents, lifestyle modifications, prescription topical, systemic, and procedural therapies. Optimal regimens may be tailored to best address patient-perceived disease severity and concerns and to minimize any further irritation/inflammation which may drive pigmentary alteration.
中文摘要:玫瑰痤疮是一种慢性面中部皮肤病,由固有免疫与适应性免疫失调以及皮肤神经血管高反应性共同参与致病。该病在经典上被认为多见于肤色较浅的皮肤光型,但在黑人、亚裔、太平洋岛民以及西班牙裔/拉丁裔美国人群中患病率可达2%–4%;诊断目前高度依赖表型表现(如固定性红斑伴或不伴间歇性加重、阵发性潮红和/或毛细血管扩张),而这些表现在色素较深的皮肤上不易辨识,实际患病率可能因此被低估。对于色素沉着明显的皮肤,仔细询问症状史以评估次要/继发标准(即烧灼感或刺痛感、水肿、干燥、潮红、对非处方产品耐受性低、对经典「诱发因素」出现症状、家族史和/或眼部症状),并让患者在体格检查中参与以确定其基线肤色,有助于明确诊断。玫瑰痤疮的治疗方案围绕具体表现制定,可包括非处方外用制剂、生活方式调整、处方外用药物、系统治疗及程序性治疗。最佳方案可针对患者自感的疾病严重程度与关切进行个体化调整,并尽量减少可能促使色素改变加重的进一步刺激与炎症。
In order to better understand medical students' decision-making to pursue ophthalmology, and inform efforts to recruit more diverse and inspired ophthalmologists, we aim to characterize values and experiences of medical students pursuing ophthalmology. Retrospective cross-sectional study. U.S. medical students who responded to American Association of Medical Colleges (AAMC) Matriculating Student and Graduation Questionnaires (MSQ & GQ) between 2013 and 2022. We examined survey responses pertaining to personal values, medical school experiences, and use of resources. Univariate analyses were performed to compare the odds of pursuing ophthalmology versus other specialties. Association of values and experiences with odds of pursuing ophthalmology versus another specialty. Among 134,723 matriculating students who completed the MSQ, those interested in ophthalmology (2425 students) were more likely to value high income (OR: 1.46, p < .001) and work-life balance (OR: 1.44, p < .001), and less likely to value social change (OR: 0.76, p < .001), leadership (OR: 0.94, p = .011), OR: creativity (OR: 0.94, p = .025). Of 98,628 graduates who completed the GQ, those pursuing ophthalmology (2150 students) valued salary (OR: 1.73, p < .001), family considerations (OR: 1.31, p < .001), and work-life balance (OR: 2.40, p < .001) more than those pursuing other specialties. Students pursuing ophthalmology rated their clerkships in neurology (OR: 1.22 [1.16-1.29], p < .001), internal medicine (OR: 1.19 [1.12-1.28], p < .001), surgery (OR: 1.18 [1.12-1.25], p < .001), psychiatry (OR: 1.16 [1.09-1.23], p < .001), and emergency medicine (OR: 1.08 [1.01-1.16], p = .02) more highly compared to other core clerkships. Students pursuing ophthalmology were more likely to perform research (OR: 4.75, p < .001) than those pursuing other fields. These students also more frequently relied on web-based resources (OR: 1.58, p < .001), group panels (OR: 1.39, p < .001), and extra electives (OR: 1.30, p < .001) for specialty information compared to other students, but not mentorship, school workshops, or AAMC-provided information. Medical students pursuing ophthalmology valued lifestyle factors rather than leadership, creativity, or social change and were also more likely to perform research. They were more likely to rely on non-mentorship resources for specialty information. Efforts are needed to refine the perception of ophthalmology, increase focus on creativity and innovation, and improve the recruitment of diverse and inspired future ophthalmologists.
中文摘要:为了更好理解医学生选择眼科的决策,并为招募更多元、更有热情的眼科医生提供依据,我们旨在描述选择眼科的医学生的价值观与经历。回顾性横断面研究。研究对象为2013至2022年间回答美国医学院协会(AAMC)入学学生问卷和毕业问卷(MSQ与GQ)的美国医学生。我们检查了与个人价值观、医学院经历和资源使用有关的调查回答。采用单变量分析比较选择眼科与其他专科的比值比。分析价值观和经历与选择眼科而非其他专科的比值比之间的关联。在完成MSQ的134723名入学学生中,对眼科感兴趣者(2425名学生)更可能重视高收入(OR:1.46,p < .001)和工作与生活平衡(OR:1.44,p < .001),较不可能重视社会变革(OR:0.76,p < .001)、领导力(OR:0.94,p = .011)或创造力(OR:0.94,p = .025)。在完成GQ的98628名毕业生中,选择眼科者(2150名学生)比选择其他专科者更重视薪酬(OR:1.73,p < .001)、家庭因素(OR:1.31,p < .001)和工作与生活平衡(OR:2.40,p < .001)。选择眼科的学生对神经内科(OR:1.22 [1.16-1.29],p < .001)、内科(OR:1.19 [1.12-1.28],p < .001)、外科(OR:1.18 [1.12-1.25],p < .001)、精神科(OR:1.16 [1.09-1.23],p < .001)和急诊医学(OR:1.08 [1.01-1.16],p = .02)实习轮转的评价高于其他核心轮转。选择眼科的学生比选择其他领域者更可能开展研究(OR:4.75,p < .001)。这些学生也比其他学生更常依赖网络资源(OR:1.58,p < .001)、小组讨论会(OR:1.39,p < .001)和额外选修课(OR:1.30,p < .001)获取专科信息,但不更常依赖导师指导、学校工作坊或AAMC提供的信息。选择眼科的医学生重视生活方式因素,而非领导力、创造力或社会变革,也更可能开展研究。他们更可能依赖非导师类资源获取专科信息。需要努力改善对眼科的认知,增加对创造力和创新的关注,并改进对多元且有热情的未来眼科医生的招募。
9近视与屈光不正 (2篇)
临床研究 (2篇)
The current study investigates the contrast sensitivity (CS) of ON and OFF visual pathways across a broad spatial frequency range in individuals with varying severities of myopia. The CS function (CSF) was measured in 60 adults (emmetropes, low myopes, and high myopes) using a psychophysical paradigm that could selectively activate the ON and OFF pathways, combined with the quick CSF method. Stimuli included bipolar, increment, and decrement bandpass-filtered noise across 15 spatial frequency levels (0.25-25.85 cycles per degree). Tests were performed under binocular, dominant eye (DE), and non-DE (NDE) conditions. High myopes exhibited significant deficits in ordinary (bipolar) and ON pathway (increment) CS, primarily manifested as reduced peak sensitivity. The increment/decrement (ON/OFF) area under log CSF ratio was significantly lower in the high myopia group than that in the emmetropia group (P < 0.001) and the low myopia group (P = 0.009), indicating a selective ON pathway deficit. The ratio correlated with the spherical equivalent refraction (r = 0.484; P < 0.001) and axial length (r = -0.490; P < 0.001). High myopia exhibited reduced ordinary and ON pathway CS. The ON pathway-selective CS deficits were significantly correlated with myopia severity and predominantly observed at low SFs. These findings provide a theoretical basis for understanding visual function in myopia, developing effective functional evaluation tools, and designing targeted intervention strategies.
中文摘要:本研究考察不同近视严重程度个体在较宽空间频率范围内ON与OFF视觉通路的对比敏感度。使用可选择性激活ON和OFF通路的行为心理物理学范式,结合quick CSF方法,测量60名成人(正视眼、低度近视和高度近视)的CSF。刺激为15个空间频率水平(0.25–25.85周/度)的双极、增量与减量带通滤波噪声。测试在双眼、主导眼(DE)与非主导眼(NDE)条件下进行。高度近视者在普通(双极)和ON通路(增量)对比敏感度上表现出显著缺陷,主要表现为峰值敏感度降低。高度近视组的增量/减量(ON/OFF)对数CSF曲线下面积比显著低于正视眼组(P < 0.001)和低度近视组(P = 0.009),提示选择性ON通路缺陷。该比值与球镜等效屈光度(r = 0.484;P < 0.001)和眼轴长度(r = -0.490;P < 0.001)相关。高度近视表现为普通和ON通路对比敏感度降低。ON通路选择性对比敏感度缺陷与近视严重程度显著相关,主要见于低空间频率。这些发现为理解近视视觉功能、开发有效功能评估工具以及设计针对性干预策略提供了理论依据。
The rising comorbidity of myopia and overweight/obesity (OWOB) in children shares modifiable behavioral pathways, yet evidence for integrated prevention remains limited. We conducted a cluster-randomized, hybrid type I effectiveness-implementation trial in 36 pair-matched Beijing schools. Of 4991 enrolled students in Grades 1-4 and 7, 3426 (68.6%) completed the 12-month follow-up. The school-centered "22510SS" intervention targeted outdoor activity, screen time, diet, sleep, and health monitoring. No statistically significant between-group differences were observed in spherical equivalent or BMI change, or in the prevalence of myopia, OWOB, or their comorbidity. The intervention improved the overall behavior-improvement rate (39.7% vs. 33.7%; OR, 1.34; 95% CI, 1.00-1.80). In a prespecified analysis, students in Grades 1-4 showed slower myopia progression (OR, 0.46; 95% CI, 0.25-0.86); an exploratory analysis suggested benefits among children from less supportive family environments. Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) evaluation showed 100% fidelity for school-based activities, approximately 60% completion of family-facing health-tip dissemination, an incremental cost of ¥215.43 per participant, and a Program Sustainability Assessment Tool (PSAT) score of 6.10/7. The intervention was feasible and improved targeted behaviors but did not produce significant population-level clinical effects within 12 months. Stronger family engagement and longer follow-up may be needed. Trial Registration: NCT05275959.
中文摘要:儿童近视与超重/肥胖共病呈上升趋势,二者共享可改变的行为路径,但整合预防的证据仍有限。我们在北京市36所配对匹配学校开展了一项整群随机、Ⅰ型混合效果-实施试验。4991名入组学生中,3426名(68.6%)完成12个月随访,学生来自1—4年级和7年级。以学校为中心的「22510SS」干预针对户外活动、屏幕时间、饮食、睡眠和健康监测。在等效球镜度或BMI变化,以及近视、超重/肥胖或其共病患病率方面,未观察到组间差异有统计学意义。干预提高了总体行为改善率(39.7%与33.7%相比;OR 1.34;95% CI 1.00—1.80)。在预设分析中,1—4年级学生的近视进展较慢(OR 0.46;95% CI 0.25—0.86);探索性分析提示,家庭支持环境较差的儿童可能获益。RE-AIM评价显示,学校活动执行保真度为100%,面向家庭的健康提示传播完成率约60%,每名参与者的增量成本为215.43元,项目可持续性评估工具(PSAT)评分为6.10/7。该干预可行并改善了目标行为,但未在12个月内产生显著的人群层面临床效果。可能需要更强的家庭参与和更长的随访。试验注册号:NCT05275959。
10小儿眼科与斜视 (2篇)
临床研究 (2篇)
To evaluate rates of vision screening failure, eye examination completion, eyeglass prescribing, and follow-up recommendations from a school-based vision program (SBVP). Retrospective cross-sectional analysis. Prekindergarten through fifth-grade students (aged 4-13 years) who underwent school-based screening in Fort Worth, Texas, from 2022 to 2024. Students who failed screening were offered school-based eye examinations. Parent-reported demographics and school-level economic disadvantage (free or reduced-price meals [FARMs]%) were extracted. Mixed-effects logistic regression evaluated associations of grade, sex, race, ethnicity, eyeglass wear at screening, and FARMs% for screening failure, eye examination after failure, and eyeglass prescription among examination completers. Associations between ocular diagnoses and follow-up intervals, categorized as <6 or ≥6 months, were tested using χ2 or Fisher exact tests. Rates of screening failure, eye examination completion, eyeglass prescription, and follow-up interval. Among 41236 students screened across 81 schools (median FARMs%: 93.9%), 64.0% were Hispanic. Overall, 8682 (21.1%) failed screening and 3873 (44.6%) completed an eye examination. Hispanic and Black students had higher odds of screening failure (odds ratio [OR], 1.35; 95% confidence interval [CI], 1.25-1.46; OR, 1.36; 95% CI, 1.25-1.48) compared with non-Hispanic and non-Black students, respectively. After screening failure, Hispanic students had higher odds of completing an eye examination (OR, 1.27; 95% CI, 1.08-1.48), whereas Black students had lower odds (OR, 0.82; 95% CI, 0.69-0.97). Students with greater school-level economic disadvantage had higher odds of screening failure (OR, 1.17 per 10% FARMs increase; 95% CI, 1.14-1.21) and completing an examination after failure (OR, 1.24 per 10% increase; 95% CI, 1.13-1.38). Among 3767 students examined, 14.2% were recommended for follow-up <6 months. Earlier follow-up was more common among those with amblyopia or amblyopia suspects (68.9% vs. 6.6%) and strabismus (64.1% vs. 13.3%) compared with those without either diagnosis (both P < 0.001). In a predominantly Hispanic, economically disadvantaged district, this SBVP identified substantial unmet vision needs with disparities in screening failure and eye examination completion. Earlier follow-up recommendations were more common for high-risk diagnoses. Future work should focus on understanding whether students connect to follow-up care and developing guidelines to support children with ongoing eye care needs. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:评估基于学校的视力项目(SBVP)中视力筛查未通过率、眼科检查完成率、眼镜处方率及随访建议。回顾性横断面分析。对象为2022至2024年在美国德克萨斯州Fort Worth接受校内筛查的学前班至五年级学生(4-13岁)。筛查未通过者获提供校内眼科检查。提取家长报告的人口学资料及学校层面经济弱势比例(免费或减价餐[FARMs]%)。采用混合效应logistic回归评估年级、性别、种族、民族、筛查时戴镜情况及FARMs%与筛查未通过、未通过后完成眼科检查及完成检查者中眼镜处方的关联。眼部诊断与随访间隔(<6个月或≥6个月)的关联采用χ2或Fisher精确检验。主要指标为筛查未通过率、眼科检查完成率、眼镜处方率及随访间隔。81所学校共41236名学生接受筛查(FARMs%中位数93.9%),64.0%为西班牙裔。总体8682名(21.1%)筛查未通过,3873名(44.6%)完成眼科检查。西班牙裔学生较非西班牙裔学生筛查未通过比值更高(OR 1.35,95%CI 1.25-1.46),黑人学生较非黑人学生亦更高(OR 1.36,95%CI 1.25-1.48)。筛查未通过后,西班牙裔学生完成眼科检查的比值更高(OR 1.27,95%CI 1.08-1.48),黑人学生更低(OR 0.82,95%CI 0.69-0.97)。学校层面经济弱势程度越高,筛查未通过比值越高(FARMs每增加10%,OR 1.17,95%CI 1.14-1.21),未通过后完成检查的比值也越高(每增加10%,OR 1.24,95%CI 1.13-1.38)。3767名接受检查的学生中,14.2%被建议<6个月随访。弱视或弱视疑似者(68.9%对6.6%)及斜视者(64.1%对13.3%)较无相应诊断者更常见较早随访(均P<0.001)。在一个以西班牙裔为主的经济弱势学区,该SBVP发现大量未满足的视力需求,筛查未通过及眼科检查完成存在差异。高风险诊断更常获得较早随访建议。未来工作应关注学生是否进入随访照护,并制定指南以支持有持续眼保健需求的儿童。文末脚注和披露部分可能包含专有或商业披露。
To compare the documented prevalence of common treatable ocular conditions among US adults with and without autism spectrum disorder (ASD) in a large, socioeconomically diverse cohort. Propensity score-matched cohort study. Adults aged 18 years or older in the National Institutes of Health All of Us Research Program database, version 8, with electronic health record data. Adults with ASD were propensity score-matched 1:4 to adults without ASD on age, sex assigned at birth, race and ethnicity, and duration of electronic health record observation. Prevalence of each ocular condition was compared between groups, and absolute prevalence differences were estimated. Logistic regression was used to evaluate the association between ASD and ocular conditions; sequential models adjusted for household income, educational attainment, and health insurance status. Documented diagnoses of refractive/accommodative error, cataract, glaucoma, strabismus, dry eye disease, and any ocular condition. Among 5250 matched participants, 1050 adults had ASD, and 4200 were controls; the cohort had a mean age of 39.1 years and was 49.3% male. Adults with ASD had higher documented prevalence of any ocular condition (29.5% vs 17.8%), refractive/accommodative error (22.3% vs 14.0%), cataract (9.9% vs 5.2%), dry eye disease (9.0% vs 5.5%), glaucoma (3.6% vs 1.5%), and strabismus (3.8% vs 1.7%) compared with controls. In fully adjusted models, ASD was associated with increased odds of any ocular condition (odds ratio [OR] = 2.09; 95% confidence interval [CI], 1.78-2.45), glaucoma (OR = 2.56; 95% CI, 1.67-3.88), strabismus (OR = 2.31; 95% CI, 1.53-3.44), cataract (OR = 2.16; 95% CI, 1.68-2.77), refractive/accommodative error (OR = 1.92; 95% CI, 1.61-2.29), and dry eye disease (OR = 1.80; 95% CI, 1.39-2.32). Associations were similar from unadjusted through fully adjusted models. Adults with ASD had higher documented prevalence and odds of multiple treatable ocular conditions when compared to matched adults without ASD. Greater attention should be directed toward autism-informed adult eye care, including proactive screening, sensory and communication accommodations, and coordinated follow-up to support timely identification and management of ocular diseases in this population.
中文摘要:在美国一个社会经济背景多样的大型队列中,比较伴与不伴孤独症谱系障碍(ASD)的成年人常见可治疗眼部疾病的记录患病率。倾向评分匹配队列研究。纳入美国国立卫生研究院All of Us研究计划数据库第8版中具有电子健康记录数据的18岁及以上成年人。伴ASD成年人与不伴ASD成年人按年龄、出生时指定性别、种族和族裔以及电子健康记录观察时长进行1:4倾向评分匹配。比较两组各眼部疾病的患病率,并估计绝对患病率差异。采用逻辑回归评估ASD与眼部疾病的关联,序贯模型分别调整家庭收入、教育程度和医疗保险状况。记录诊断包括屈光/调节异常、白内障、青光眼、斜视、干眼症和任何眼部疾病。匹配后共5250名参与者,其中1050名伴ASD,4200名为对照;平均年龄39.1岁,男性占49.3%。与对照组相比,伴ASD成年人任何眼部疾病(29.5% vs 17.8%)、屈光/调节异常(22.3% vs 14.0%)、白内障(9.9% vs 5.2%)、干眼症(9.0% vs 5.5%)、青光眼(3.6% vs 1.5%)和斜视(3.8% vs 1.7%)的记录患病率更高。在完全调整模型中,ASD与任何眼部疾病风险增加相关(OR=2.09;95%CI 1.78-2.45)、青光眼(OR=2.56;95%CI 1.67-3.88)、斜视(OR=2.31;95%CI 1.53-3.44)、白内障(OR=2.16;95%CI 1.68-2.77)、屈光/调节异常(OR=1.92;95%CI 1.61-2.29)和干眼症(OR=1.80;95%CI 1.39-2.32)。从未调整模型到完全调整模型,关联结果相似。与匹配的不伴ASD成年人相比,伴ASD成年人多种可治疗眼部疾病的记录患病率和患病比值更高。应更多关注面向孤独症成年人的眼科照护,包括主动筛查、感官与沟通方面的适配以及协调随访,以支持该人群眼部疾病的及时识别和管理。
11眼肿瘤 (2篇)
临床研究 (2篇)
To evaluate the real-world diagnostic performance of the Interleukin Score for IntraOcular Lymphoma Diagnosis (ISOLD) score-a probabilistic formula based on absolute intraocular interleukin-10 (IL-10) and IL-6 levels-and to compare it with absolute cytokine thresholds and the IL-10/IL-6 ratio for vitreoretinal lymphoma (VRL) diagnosis. Because the comparison group consists predominantly of patients who underwent anterior chamber paracentesis (ACP), this study primarily assesses ISOLD performance on aqueous humor (AH) samples while providing additional data on vitreous specimens. Retrospective comparative diagnostic analysis. A total of 166 patients who underwent intraocular sampling for IL-6 and IL-10 measurement at a tertiary VRL referral center between January 2017 and June 2019, yielding 183 samples (156 AH from ACP and 27 vitreous). Furthermore, 25 patients had confirmed VRL (18 AH samples, 20 vitreous samples; 13 had both, 7 vitreous only, and 5 AH only). The comparison group comprised 141 non-VRL patients: 9 patients with confirmed CNS lymphoma without ocular involvement (PCNSL+ non-VRL group, 9 AH only) and 132 patients without lymphomatous disease (non-PCNSL group, 129 AH and 7 vitreous). IL-6 and IL-10 were measured in undiluted intraocular samples by cytometric bead array. The ISOLD score was calculated using published formulas specific to AH and vitreous. Diagnostic performance (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]) was assessed for the ISOLD score and the IL-10/IL-6 ratio, stratified by sample type. Receiver operating characteristic (ROC) curve analysis was performed to identify optimal thresholds. Sensitivity, specificity, PPV, and NPV of the ISOLD score and the IL-10/IL-6 ratio for VRL diagnosis were reported separately for AH and vitreous samples. At a threshold of 0, the ISOLD score yielded an overall sensitivity of 86.8%, specificity of 98.6%, PPV of 94.3%, and NPV of 96.6% across all 183 samples. For AH samples (n = 156), which constitute most of this data set, sensitivity, specificity, PPV, and NPV were 77.8%, 98.6%, 87.5%, and 97.1%, respectively; the optimal AH threshold by ROC analysis was -5.2, yielding a sensitivity of 94.4%, specificity of 96.7%, PPV of 73.9%, NPV of 99.3%, and an area under the curve (AUC) of 0.966. For vitreous samples (n = 27), performance at a threshold of 0 was 95.0%, 100%, 100%, and 87.5%, respectively; the optimal vitreous threshold was -2.55, yielding 100% sensitivity, specificity, PPV, and NPV, with an AUC of 1.0. Two false positives occurred in varicella zoster virus-associated ocular disease; 5 false negatives were observed, predominantly in patients receiving systemic corticosteroids and/or chemotherapy. The IL-10/IL-6 ratio at a threshold of 0.6 in AH (n = 150) demonstrated a sensitivity of 77.8%, specificity of 93.9%, PPV of 63.6%, and NPV of 96.9%; at a threshold of 1 in vitreous (n = 27), sensitivity, specificity, PPV, and NPV were 80%, 100%, 100%, and 63.6%, respectively. The optimal AH threshold by ROC analysis for the IL-10/IL-6 ratio was 0.48, yielding a sensitivity of 83.3%, specificity of 93.9%, PPV of 65.2%, NPV of 97.6%, and an AUC of 0.942. For vitreous samples, performance at a threshold of 0.195 was 100%, 100%, 100%, and 100%, respectively, with an AUC of 1.0. Bilateral involvement and intermediate uveitis were significantly more frequent in the VRL group (P = .008 and P = .005, respectively). The ISOLD score is a reliable tool for VRL diagnosis in routine clinical practice, with performance validated primarily on AH samples obtained by ACP. It outperforms the IL-10/IL-6 ratio alone by providing a continuous probabilistic estimate. False-negative results may occur in immunosuppressed patients or those receiving corticosteroids or chemotherapy. A larger vitreous sample would be required to draw definitive conclusions regarding ISOLD performance on this specimen type. Cytological analysis of vitreous samples remains the gold standard for definitive VRL confirmation.
中文摘要:评估ISOLD评分(基于眼内IL-10与IL-6绝对水平的概率公式)在真实临床实践中诊断玻璃体视网膜淋巴瘤(VRL)的表现,并将其与绝对细胞因子阈值及IL-10/IL-6比值进行比较。由于对照组主要由接受前房穿刺(ACP)的患者组成,本研究主要评估ISOLD评分对房水(AH)样本的诊断表现,同时补充玻璃体样本数据。回顾性对比诊断分析。纳入2017年1月至2019年6月在一家VRL三级转诊中心因检测IL-6和IL-10接受眼内采样的166例患者,共183份样本(156份AH来自ACP,27份玻璃体)。25例确诊VRL(18份AH样本,20份玻璃体样本;13例两者均有,7例仅玻璃体,5例仅AH)。对照组141例非VRL患者:9例确诊中枢神经系统淋巴瘤但无眼部受累(PCNSL+非VRL组,仅9份AH)和132例无淋巴瘤性疾病(非PCNSL组,129份AH和7份玻璃体)。用细胞计数微珠阵列检测未稀释眼内样本的IL-6和IL-10。ISOLD评分按已发表的AH和玻璃体专用公式计算。按样本类型分层评估ISOLD评分和IL-10/IL-6比值的诊断性能(敏感性、特异性、阳性预测值[PPV]、阴性预测值[NPV])。进行ROC曲线分析确定最佳阈值。分别报告AH和玻璃体样本中ISOLD评分与IL-10/IL-6比值诊断VRL的敏感性、特异性、PPV和NPV。阈值0时,ISOLD评分在全部183份样本中的总体敏感性86.8%、特异性98.6%、PPV94.3%、NPV96.6%。占本数据集多数的AH样本(n=156)敏感性、特异性、PPV、NPV分别为77.8%、98.6%、87.5%、97.1%;ROC分析最佳AH阈值为-5.2,敏感性94.4%、特异性96.7%、PPV73.9%、NPV99.3%,曲线下面积(AUC)0.966。玻璃体样本(n=27)阈值0时分别为95.0%、100%、100%、87.5%;最佳玻璃体阈值-2.55,敏感性、特异性、PPV、NPV均为100%,AUC 1.0。2例假阳性见于水痘带状疱疹病毒相关眼病;5例假阴性,主要见于接受全身糖皮质激素和/或化疗的患者。AH中IL-10/IL-6比值阈值0.6(n=150)时敏感性77.8%、特异性93.9%、PPV63.6%、NPV96.9%;玻璃体阈值1(n=27)时敏感性、特异性、PPV、NPV分别为80%、100%、100%、63.6%。ROC分析IL-10/IL-6比值最佳AH阈值0.48,敏感性83.3%、特异性93.9%、PPV65.2%、NPV97.6%,AUC0.942。玻璃体样本阈值0.195时敏感性、特异性、PPV、NPV均为100%,AUC1.0。VRL组双侧受累和中间葡萄膜炎显著更常见(P=.008和P=.005)。ISOLD评分是常规临床实践中诊断VRL的可靠工具,其性能主要在ACP获取的AH样本中得到验证。它通过提供连续概率估计优于单用IL-10/IL-6比值。免疫抑制患者或接受糖皮质激素或化疗者可能出现假阴性。要就ISOLD评分在玻璃体样本中的表现得出明确结论,需要更大的玻璃体样本。玻璃体样本细胞学分析仍是确诊VRL的金标准。
Recipients of solid organ transplants (SOT) undergo long-term immunosuppressive therapy, placing them at a high risk for developing skin cancer. Given that the conjunctiva and skin share key risk factors for neoplasia, we conducted a study to examine the association between immunosuppressive agents used in recipients of SOT and risk of ocular surface neoplasia (OSSN). Retrospective cohort study using the TriNetX US Collaborative Network. We included individuals ≥18 years of age receiving oral or intravenous tacrolimus, cyclosporine, sirolimus, mycophenolate mofetil or sodium, everolimus, or azathioprine. Individuals without subsequent ophthalmology follow-up or with prior OSSN diagnoses were excluded. The control cohort included individuals with multiple ophthalmology follow-ups, no prior OSSN diagnoses, and no exposure to the medications of interest. Propensity score matching (1:1) was used to control for covariates such as demographics and known risk factors of OSSN. Odds ratios with 95% confidence intervals were calculated using univariate analysis to compare outcomes. Multiple sub analyses were performed, in which we required additional exposure to the medications, controlled for common autoimmune disorders, or excluded all recipients of SOT. Risk of a new OSSN diagnosis during the study period. After matching, 43 580 individuals were included for analysis. There were 46 (0.11%) new cases of OSSN in the exposure cohort and 20 (0.05%) cases in the control cohort. Those on immunosuppressive therapy had a 2.3 times higher risk of developing OSSN (odds ratio [OR] 2.30 [95% CI 1.36 to 3.89]) during the study period. Sensitivity analyses requiring additional instances of medication exposure (OR 3.67 [95% CI 1.94 to 6.95]) or controlling for other indications of immunosuppressive therapy (OR 1.70 [95% CI 1.06 to 2.74]) showed consistent results. Excluding all recipients of SOT resulted in no significant association with OSSN (OR 1.31 [95% CI 0.64 to 2.69]). Recipients of SOT who underwent immunosuppressive therapy experienced a significantly increased risk of developing OSSN. Appropriate ophthalmological monitoring for OSSN in these populations is recommended.
中文摘要:实体器官移植受者接受长期免疫抑制治疗,皮肤癌风险高。结膜与皮肤共享肿瘤发生的关键危险因素,因此开展研究考察实体器官移植受者所用免疫抑制药与眼表肿瘤风险之间的关联。采用TriNetX美国协作网络进行回顾性队列研究。纳入18岁及以上接受口服或静脉他克莫司、环孢素、西罗莫司、吗替麦考酚酯或麦考酚钠、依维莫司或硫唑嘌呤者。排除后续无眼科随访或既往诊断眼表肿瘤者。对照队列为多次眼科随访、无既往眼表肿瘤诊断且未暴露于目标药物者。用倾向评分匹配(1:1)控制人口学和已知眼表肿瘤危险因素等协变量。用单因素分析计算比值比及95%置信区间比较结局。进行多项亚组分析,要求额外药物暴露、控制常见自身免疫病或排除所有实体器官移植受者。主要结局为研究期间新发眼表肿瘤诊断。匹配后纳入43 580人分析。暴露队列新发眼表肿瘤46例(0.11%),对照队列20例(0.05%)。接受免疫抑制治疗者研究期间发生眼表肿瘤风险高2.3倍(OR 2.30,95% CI 1.36至3.89)。要求额外药物暴露(OR 3.67,95% CI 1.94至6.95)或控制免疫抑制治疗其他适应证(OR 1.70,95% CI 1.06至2.74)的敏感性分析结果一致。排除所有实体器官移植受者后与眼表肿瘤无显著关联(OR 1.31,95% CI 0.64至2.69)。接受免疫抑制治疗的实体器官移植受者发生眼表肿瘤风险显著增加,建议对该人群进行适当眼科监测以筛查眼表肿瘤。
12斜视 (1篇)
临床研究 (1篇)
Adult strabismus impacts quality of life through diplopia, eye strain, and psychological burden. Access to care may be limited by various factors, yet disparities in adult strabismus care have not been examined nationally. To evaluate potential disparities in access to adult strabismus care across the US by practice type, insurance status, and county-level socioeconomic characteristics. This national secret shopper study used standardized telephone calls to US pediatric ophthalmology practices identified through the American Association for Pediatric Ophthalmology and Strabismus and the American Academy of Ophthalmology that simulated appointment scheduling for an adult patients with strabismus. Of 1064 practices contacted, 1060 were included after excluding 4 clinics with disconnected phone numbers. These data were analyzed from August 2025 to September 2026. Practice type (academic vs other), insurance type (Medicaid vs commercial insurance), and county-level characteristics, including race and ethnicity majority, median household income, Area Deprivation Index (ADI), and Social Vulnerability Index (SVI). Appointment success (ability to schedule appointment during call) and appointment wait time (days between call date and earliest available appointment). Overall, 23.8% (252 of 1060) of practices offered an appointment under at least 1 insurance scenario. Patients using Medicaid had a lower appointment success rate than those with commercial insurance (161 of 648 [24.8%] vs 91 of 194 [46.9%]; difference, -22.1 percentage points; 95% CI, -29.8 to -14.3; P < .001). In multivariable regression, other practice types (adjusted odds ratio [aOR], 1.82; 95% CI, 1.28-2.58; P = .001) and commercial insurance (aOR, 2.36; 95% CI, 1.67-3.33; P = .001) had higher appointment success, while majority racial and ethnic minority counties (aOR, 0.66; 95% CI, 0.45-0.97; P = .04) and lower median household income counties (aOR, 0.64; 95% CI, 0.44-0.93; P = .02) had lower odds. Among practices offering appointments, academic centers had longer wait times than other practices (mean [SD], 95.1 [59.3] days vs 57.0 [54.1] days; 38.1 days difference; 95% CI, 21.2-55.1; P < .001), as did lower-income counties (mean [SD], 78.6 [68.1] days vs 61.3 [52.6] days; -17.4 days difference; 95% CI, -33.3 to -1.4; P = .03). This national secret shopper study identified potential disparities in adult strabismus care access. Commercial insurance and other practice types had higher appointment success, while majority racial and ethnic minority and lower-income counties had reduced access and longer wait times. These findings highlight a potential unmet likely benefit of adult strabismus practitioners and support targeted policy interventions to improve equitable access to care.
中文摘要:成人斜视通过复视、眼疲劳和心理负担影响生活质量。诊疗可及性可能受多种因素限制,但成人斜视诊疗中的差异尚未在全国范围内得到考察。旨在评估美国成人斜视诊疗可及性在执业类型、保险状态和县层面社会经济特征方面可能存在的差异。这项全国性神秘顾客研究通过标准化电话联系美国小儿眼科执业机构,这些机构经美国小儿眼科与斜视协会和美国眼科学会识别,通话模拟为一名成人斜视患者预约。共联系1064家执业机构,排除4家电话无法接通的诊所后纳入1060家。数据分析时间为2025年8月至2026年9月。分析变量包括执业类型(学术型与其他)、保险类型(Medicaid与商业保险)以及县层面特征,包括种族和族裔多数构成、家庭收入中位数、区域剥夺指数(ADI)和社会脆弱性指数(SVI)。结局指标为预约成功(通话期间能够安排预约)和预约等待时间(通话日期与最早可预约日期之间的天数)。总体而言,23.8%(252/1060)的执业机构在至少一种保险情景下提供预约。使用Medicaid的患者预约成功率低于商业保险患者(161/648 [24.8%] 对 91/194 [46.9%];差异为-22.1个百分点;95% CI,-29.8至-14.3;P<.001)。在多变量回归中,其他执业类型(校正比值比[aOR],1.82;95% CI,1.28-2.58;P=.001)和商业保险(aOR,2.36;95% CI,1.67-3.33;P=.001)的预约成功率更高,而种族和族裔少数群体占多数的县(aOR,0.66;95% CI,0.45-0.97;P=.04)和家庭收入中位数较低的县(aOR,0.64;95% CI,0.44-0.93;P=.02)预约成功的几率更低。在提供预约的执业机构中,学术中心的等待时间长于其他执业机构(均值[SD],95.1[59.3]天 对 57.0[54.1]天;差异38.1天;95% CI,21.2-55.1;P<.001),低收入县同样如此(均值[SD],78.6[68.1]天 对 61.3[52.6]天;差异-17.4天;95% CI,-33.3至-1.4;P=.03)。这项全国性神秘顾客研究发现成人斜视诊疗可及性可能存在差异。商业保险和其他执业类型的预约成功率更高,而种族和族裔少数群体占多数及收入较低的县可及性较低且等待时间更长。这些发现凸显成人斜视执业者可能存在尚未满足且很可能有益的服务需求,并支持开展有针对性的政策干预以改善公平获得诊疗。
13白内障 (1篇)
基础研究 (1篇)
Cortical cataracts develop in mice in the absence of Arvcf, a protein that serves as a key component of the adherens junctional complex (AJC) in lens cells. This study aimed to mechanistically probe the proteomic complex associated with Arvcf to identify novel mechanisms underlying cortical cataract formation. Arvcf associated proteins were identified by coimmunoprecipitation of P30 mouse lens lysates using liquid chromatography mass-spectroscopy/mass-spectroscopy, gene ontology analysis, and western blot. Immunofluorescent staining was also performed in Arvcf or ankyrin-B mutant mouse lenses to assess protein expression, association, and junctional localization. In addition to members of the AJC, proteomic analysis revealed that Arvcf associates with several spectrin-associated proteins. Ankyrin-B, NrCAM, and β-spectrin. These findings were verified by quantitative western blots and colocalization analysis. Although spectrin-associated protein expression in Arvcf mutants was unaffected, a significant reduction in their localization specifically at radially orientated cell membranes was observed. Importantly, this reduction correlates with the exact location of cortical opacities and membrane fusion events that abnormally occur between neighboring fiber cells Arvcf-deficient lenses. Finally, Arvcf and N-cadherin localization is altered by the absence of ankyrin-B in lens fiber cells, suggesting that stabilization of the AJC and the spectrin-associated complex of proteins are interdependent. Together, this data supports a novel role for Arvcf linking adherens junctions to the spectrin-associated cytoskeleton. This association is required to stabilize fiber cell membranes, limit cell fusion events, and maintain transparency in the cortical regions of the lens.
中文摘要:缺乏Arvcf的小鼠会形成皮质性白内障,Arvcf是晶状体细胞黏附连接复合体(AJC)的关键组分。本研究旨在从机制上探查与Arvcf相关的蛋白质复合体,以发现皮质性白内障形成的新机制。通过对P30小鼠晶状体裂解物进行免疫共沉淀,并结合液相色谱-质谱/质谱、基因本体分析和蛋白质印迹鉴定Arvcf相关蛋白。还在Arvcf或ankyrin-B突变小鼠晶状体中行免疫荧光染色,评估蛋白表达、关联及连接处定位。蛋白质组分析显示,除AJC成员外,Arvcf还与多种血影蛋白相关蛋白结合,包括ankyrin-B、NrCAM和β-spectrin;这些结果经定量蛋白质印迹和共定位分析验证。Arvcf突变体中血影蛋白相关蛋白的表达未受影响,但其在径向排列细胞膜上的定位显著减少。该减少与Arvcf缺陷晶状体中皮质混浊的精确位置以及相邻纤维细胞间异常发生的膜融合事件相关。ankyrin-B缺失会改变晶状体纤维细胞中Arvcf和N-cadherin的定位,提示AJC与血影蛋白相关蛋白复合体的稳定相互依赖。这些数据支持Arvcf连接黏附连接与血影蛋白相关细胞骨架的新作用;该关联是稳定纤维细胞膜、限制细胞融合并维持晶状体皮质区透明所必需的。
14白内障与屈光 (1篇)
临床研究 (1篇)
To investigate intraocular lens (IOL) power formulas in eyes with prior myopic laser vision correction (M-LVC). Retrospective evaluation of IOL power calculation accuracy. The study included 3,738 eyes from 3,738 patients undergoing routine cataract surgery by 145 surgeons across multiple U.S. centers between October 2, 2017, and August 20, 2025. Veracity database (Carl Zeiss) was used; M-LVC eyes were identified from surgeon-reported history without independent verification. Biometry was obtained with the IOLMaster 700, and subjective refraction was measured 21-90 days postoperatively. Refractive prediction errors were calculated for 14 formulas: early-generation formulas (Haigis-L and Shammas-PL), modern formulas with and without posterior corneal curvature (PCC) input (Barrett True K, Cooke K6 [K6], EVO 2.0, Hoffer QST, PEARL-DGS), Shammas-Cooke (without PCC), and Haigis-TK (with PCC). Main outcome measures were mean absolute error (MAE) and proportions of eyes within ± 0.50 D and ± 1.00 D of target refraction. Formulas were ranked by MAE, and pairwise comparisons were conducted using heteroscedastic testing with Holm's correction. Modern formulas outperformed early-generation formulas, while PCC-adjusted formulas demonstrated lower MAEs than their non-PCC counterparts (p <.0001). Among non-PCC formulas, K6 and EVO 2.0 (both MAE 0.40 D) ranked best, while Shammas-Cooke (0.42 D) outperformed Barrett True K (0.45 D), Haigis-L (0.48 D), Hoffer QST (0.49 D), and Shammas-PL (0.57 D). Among PCC formulas, K6 (0.37 D), PEARL-DGS (0.38 D), EVO 2.0 (0.38 D), and Barrett True K (0.38 D) ranked best. Online modern formulas showed the greatest benefit in extreme eyes. In steep corneas (43 D to <45 D and ≥45 D), K6 increased the proportion within ± 0.50 D by 8.4 and 10.4%, respectively, compared with Barrett True K. In short eyes (AL <23.5 mm), K6 achieved >13% more eyes within ± 0.50 D and reduced MAE by 0.1 D. In eyes with satisfactory postoperative visual acuity, modern formulas outperform early-generation formulas, and PCC-based versions are preferable. With AL <23.5 or K >43 D (22% of these eyes), online modern formulas-particularly K6 and EVO 2.0-provided the greatest accuracy gain vs. Barrett True K. In typical post-M-LVC eyes, such gains are clinically negligible. When full biometry is unavailable, Shammas-Cooke is a reasonable alternative.
中文摘要:评估既往接受近视激光角膜屈光矫正(M-LVC)眼内人工晶状体(IOL)度数计算公式的表现。回顾性评价IOL度数计算的准确性。研究纳入2017年10月2日至2025年8月20日期间美国多家中心145名术者行常规白内障手术的3738例患者共3738只眼。数据取自Veracity数据库(Carl Zeiss);M-LVC眼依据术者报告病史识别,未做独立核实。使用IOLMaster 700行生物测量,术后21至90天测量主觉验光。对14个公式计算屈光预测误差:早期公式(Haigis-L、Shammas-PL);输入或不输入后角膜曲率(PCC)的现代公式(Barrett True K、Cooke K6〔K6〕、EVO 2.0、Hoffer QST、PEARL-DGS);不含PCC的Shammas-Cooke;含PCC的Haigis-TK。主要结局指标为平均绝对误差(MAE)及预测屈光位于±0.50 D和±1.00 D以内的眼比例。按MAE对公式排序,两两比较采用异方差检验并以Holm法校正。现代公式优于早期公式,校正PCC的公式MAE低于未校正PCC的对应版本(p<.0001)。非PCC公式中K6与EVO 2.0(MAE均为0.40 D)排名最佳,Shammas-Cooke(0.42 D)优于Barrett True K(0.45 D)、Haigis-L(0.48 D)、Hoffer QST(0.49 D)和Shammas-PL(0.57 D)。PCC公式中K6(0.37 D)、PEARL-DGS(0.38 D)、EVO 2.0(0.38 D)和Barrett True K(0.38 D)排名最佳。在线现代公式在极端眼中获益最大。陡角膜(43 D至<45 D及≥45 D)中,K6较Barrett True K使±0.50 D以内的眼比例分别提高8.4%和10.4%。短眼(AL<23.5 mm)中,K6使±0.50 D以内的眼比例增加超过13%,MAE降低0.1 D。在术后视力满意的眼中,现代公式优于早期公式,含PCC的版本更可取。当AL<23.5或K>43 D时(占这些眼的22%),在线现代公式,尤其K6和EVO 2.0,较Barrett True K带来最大的准确性提升。在典型M-LVC术后眼中,此类提升的临床意义可忽略。无法获得完整生物测量数据时,Shammas-Cooke是合理替代方案。
15基因治疗 (1篇)
基础研究 (1篇)
Inherited retinal disorders such as Norrie disease lack effective therapies, largely owing to the challenges of delivering genes to retinal tissues via intravitreal injection. The efficacy of gene delivery is constrained by physical impediments, including the inner limiting membrane and the viscoelastic characteristics of the vitreous humor. In this study, we present the development of vitreous humor-mimetic liposomes (VMLs), which have been shown to facilitate efficient retinal gene delivery by enhancing biocompatibility and tissue absorption. The VMLs were engineered by reproducing the lipidomic composition of the native vitreous, as identified through liquid chromatography-mass spectrometry analysis. The subretinal injection of VMLs was conducted to assess the efficiency of gene expression delivery by VMLs. Notably, VML #3 demonstrated a 1.3-fold enhanced GFP transfection compared to conventional nanoparticle, Lipofectamine 2000. Following intravitreal administration, VML #3 facilitated efficient delivery of pGFP-NDP (Norrie disease protein) plasmids and restored retinal vascularization in both Ndp-hemizygous and oxygen-induced retinopathy mouse models. The findings demonstrate the potential of tissue-inspired nanocarriers as effective platforms for enhancing intraocular delivery, suggesting a clinically applicable strategy for the treatment of inherited retinal diseases, including Norrie disease.
中文摘要:Norrie病等遗传性视网膜疾病缺乏有效疗法,主要障碍在于经玻璃体腔注射将基因递送至视网膜组织十分困难。基因递送效率受内界膜以及玻璃体黏弹性特征等物理屏障限制。本研究开发了玻璃体仿生脂质体(VMLs),通过提高生物相容性和组织吸收来促进视网膜基因的高效递送。VMLs依据液相色谱-质谱分析所鉴定的天然玻璃体脂质组学组成进行构建。通过视网膜下注射VMLs评估其递送基因表达的效率。VML #3相较常规纳米颗粒Lipofectamine 2000使GFP转染效率提高1.3倍。经玻璃体腔给药后,VML #3有效递送pGFP-NDP(Norrie病蛋白)质粒,并在Ndp半合子小鼠和氧诱导视网膜病变小鼠模型中恢复视网膜血管化。结果表明,组织启发型纳米载体可作为增强眼内递送的有效平台,为包括Norrie病在内的遗传性视网膜疾病治疗提供了具有临床转化潜力的策略。